Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 328 Diseases and Injuries for 195 Countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 by GBD 2016 Disease and Injury Incidence and Prevalence Collaborators
Western University
Scholarship@Western
Paediatrics Publications Paediatrics Department
9-16-2017
Global, Regional, and National Incidence,
Prevalence, and Years Lived with Disability for 328
Diseases and Injuries for 195 Countries,
1990-2016: a systematic analysis for the Global
Burden of Disease Study 2016
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators
Follow this and additional works at: https://ir.lib.uwo.ca/paedpub
Part of the Pediatrics Commons
Citation of this paper:
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, "Global, Regional, and National Incidence, Prevalence, and
Years Lived with Disability for 328 Diseases and Injuries for 195 Countries, 1990-2016: a systematic analysis for the Global Burden of
Disease Study 2016" (2017). Paediatrics Publications. 194.
https://ir.lib.uwo.ca/paedpub/194
Global Health Metrics
www.thelancet.com   Vol 390   September 16, 2017 1211
Global, regional, and national incidence, prevalence, and 
years lived with disability for 328 diseases and injuries for 
195 countries, 1990–2016: a systematic analysis for the 
Global Burden of Disease Study 2016
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators*
Summary
Background As mortality rates decline, life expectancy increases, and populations age, non-fatal outcomes of diseases 
and injuries are becoming a larger component of the global burden of disease. The Global Burden of Diseases, 
Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of prevalence, incidence, 
and years lived with disability (YLDs) for 328 causes in 195 countries and territories from 1990 to 2016.
Methods We estimated prevalence and incidence for 328 diseases and injuries and 2982 sequelae, their non-fatal 
consequences. We used DisMod-MR 2.1, a Bayesian meta-regression tool, as the main method of estimation, ensuring 
consistency between incidence, prevalence, remission, and cause of death rates for each condition. For some causes, 
we used alternative modelling strategies if incidence or prevalence needed to be derived from other data. YLDs were 
estimated as the product of prevalence and a disability weight for all mutually exclusive sequelae, corrected for 
comorbidity and aggregated to cause level. We updated the Socio-demographic Index (SDI), a summary indicator of 
income per capita, years of schooling, and total fertility rate. GBD 2016 complies with the Guidelines for Accurate and 
Transparent Health Estimates Reporting (GATHER).
Findings Globally, low back pain, migraine, age-related and other hearing loss, iron-deficiency anaemia, and major 
depressive disorder were the five leading causes of YLDs in 2016, contributing 57·6 million (95% uncertainty interval 
[UI] 40·8–75·9 million [7·2%, 6·0–8·3]), 45·1 million (29·0–62·8 million [5·6%, 4·0–7·2]), 36·3 million 
(25·3–50·9 million [4·5%, 3·8–5·3]), 34·7 million (23·0–49·6 million [4·3%, 3·5–5·2]), and 34·1 million 
(23·5–46·0 million [4·2%, 3·2–5·3]) of total YLDs, respectively. Age-standardised rates of YLDs for all causes combined 
decreased between 1990 and 2016 by 2·7% (95% UI 2·3–3·1). Despite mostly stagnant age-standardised rates, the 
absolute number of YLDs from non-communicable diseases has been growing rapidly across all SDI quintiles, partly 
because of population growth, but also the ageing of populations. The largest absolute increases in total numbers of 
YLDs globally were between the ages of 40 and 69 years. Age-standardised YLD rates for all conditions combined 
were 10·4% (95% UI 9·0–11·8) higher in women than in men. Iron-deficiency anaemia, migraine, Alzheimer’s disease 
and other dementias, major depressive disorder, anxiety, and all musculoskeletal disorders apart from gout were the 
main conditions contributing to higher YLD rates in women. Men had higher age-standardised rates of substance use 
disorders, diabetes, cardiovascular diseases, cancers, and all injuries apart from sexual violence. Globally, we noted 
much less geographical variation in disability than has been documented for premature mortality. In 2016, there was a 
less than two times difference in age-standardised YLD rates for all causes between the location with the lowest rate 
(China, 9201 YLDs per 100 000, 95% UI 6862–11943) and highest rate (Yemen, 14 774 YLDs per 100 000, 11 018–19 228).
Interpretation The decrease in death rates since 1990 for most causes has not been matched by a similar decline in 
age-standardised YLD rates. For many large causes, YLD rates have either been stagnant or have increased for some 
causes, such as diabetes. As populations are ageing, and the prevalence of disabling disease generally increases 
steeply with age, health systems will face increasing demand for services that are generally costlier than the 
interventions that have led to declines in mortality in childhood or for the major causes of mortality in adults. Up-to-
date information about the trends of disease and how this varies between countries is essential to plan for an adequate 
health-system response.
Funding Bill & Melinda Gates Foundation, and the National Institute on Aging and the National Institute of Mental 
Health of the National Institutes of Health.
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Introduction
Assessment of death rates by cause has been an essential 
component of tracking progress in global health. The 
Millennium Development Goals (MDGs) emphasised 
child, maternal, and infectious disease mortality and 
spurred investments that contributed to a rapid decline 
in mortality from these sources, although these have 
not been universally achieved at the same level.1,2 
Progress in reducing the disabling outcomes of disease 
has been much slower.3 The Global Burden of Diseases, 
Injuries, and Risk Factors Study 2015 (GBD 2015) 
estimated a modest 2·1% reduction in the age-
standardised rate of years lived with disability (YLDs) 
for all causes compared with a 22·7% reduction in age-
standardised rates of years of life lost (YLLs) for all 
causes between 2005 and 2015.3 The slower progress in 
addressing non-fatal compared with fatal health 
outcomes and ageing of populations make YLDs an 
increasingly important component of global disability-
adjusted life-years (DALYs). In some high-income 
countries with advanced ageing, YLDs already make up 
more than half of the total burden in DALYs.4 The GBD 
Study is the only global effort to quantify non-fatal 
outcomes using a metric that allows comparisons 
between fatal and non-fatal outcomes of a comprehensive 
list of diseases and injuries.
Research in Context
Evidence before this study
The Global Burden of Diseases, Injuries, and Risk Factors Study 
(GBD) produces the only assessment of prevalence, incidence, 
and years lived with disability (YLDs) for a comprehensive list of 
diseases and injuries, and for all countries from 1990 to the 
present. The World Health Organization has published YLD 
estimates for the years 2000–15 largely based on GBD 2015 
results apart from ad hoc changes applied to selected disability 
weights and the prevalence of a small subset of causes. GBD 
2016 is a reassessment of the burden of disease due to 
non-fatal diseases and injuries and updates the GBD 2015 
study results.
Added value of this study
This study adds new knowledge about YLD rates globally and 
improves upon prior iterations of the GBD study in seven ways. 
First, new data were incorporated based on 56 356 unique data 
sources; these were composed mainly of peer-reviewed scientific 
literature identified by systematic reviews, reports from 
statistical agencies or ministries of health, household surveys, 
administrative data systems, claims data, and hospital data. In 
2016, we had 14 521 sources from the scientific literature 
compared with 10 478 such sources used in GBD 2015. Our 
network of collaborators provided 2598 data sources for GBD 
2016 compared with 968 available for GBD 2015;  furthermore, 
3430 sources of survey data were used in GBD 2016. These 
counts reflect our updated counting criteria for GBD 2016. Large 
amounts of new data for the main causes of YLDs were identified 
through our collaboration with the Indian Council of Medical 
Research and the Public Health Foundation of India. For 
particular diseases, the volume of available data increased 
substantially. Examples include Rapid Assessment of Avoidable 
Blindness surveys and the detailed studies reported in the Global 
Atlas of Helminth Infection for schistosomiasis and lymphatic 
filariasis. Second, we substantially changed the modelling 
approach for some diseases, such as cancers and tuberculosis. For 
cancer we improved our analysis of mortality-to-incidence ratios, 
resulting in considerably higher ratios in lower 
Socio-demographic Index (SDI) locations and thus lower YLD 
estimates. We also applied mortality-to-incidence ratios in the 
analysis of tuberculosis to better predict the gap between true 
incidence and notified cases—ie, undetected cases. Third, 
estimation at the subnational level was newly developed for 
Indonesia, and estimates for England were disaggregated into 
those for 150 local government areas. Fourth, we have 
disaggregated several causes to separately estimate 
drug-sensitive, multidrug-resistant, and extensively 
drug-resistant tuberculosis; latent tuberculosis infection; 
alcoholic cardiomyopathy; urogenital, musculoskeletal, and 
digestive congenital anomalies; and self-harm by firearm, to 
provide more detail within the GBD cause hierarchy. Additionally, 
Guinea worm disease was estimated due to the fact that there is 
policy interest in eradication, which is feasible in the near future. 
Sexual violence was added as a non-fatal cause of YLDs because 
of its relevance to several of the new sustainable development 
goal (SDG) targets. Fifth, we were able to incorporate inpatient 
hospital data by cause for 222 more locations and a final total of 
3557 location-years. A separate analysis of total hospital 
admissions per capita by country, year, age, and sex allowed the 
use of hospital data sources that previously had been rejected 
because of incomplete knowledge about catchment populations. 
We extended our analyses of US medical claims data to impute a 
ratio of any health service contact for a diagnosis to inpatient 
episodes for chronic diseases that we applied to hospital 
inpatient data from elsewhere to predict prevalence. Sixth, we 
have extended our analyses of GBD results by SDI with new ways 
of presenting and visualising changes over time and the 
relationship with development. Seventh, we extended the 
terminal age group used in our analyses of older than 80 years 
into 80–84, 85–89, 90–94, and older than 95 years.
Implications of all the available evidence
 As countries confront the effects of the epidemiological 
transition, there will be an increased need for up-to-date 
assessment of non-fatal health outcomes and exploration of 
the implications of growing numbers of individuals in need of 
chronic care as populations age. The GBD study provides 
opportunities to identify important non-fatal health trends 
across various locations and levels of development, and to 
assess the strength of available estimates.
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There are several challenges in standardising the 
estimation of YLDs. For example, case definitions vary; 
there are diverse data sources and study methods; 
accessible data sources are sparse for many diseases, 
with large parts of the world lacking adequate data;  and 
data for severity of outcomes are limited and lack a 
standardised approach. This annual update of the GBD 
study provides an opportunity to incorporate new data 
and improved methods within a standardised framework 
to enhance the precision and accuracy of estimation.
The extensive GBD network of more than 
2518 collaborators from 133 countries and three non-
sovereign locations have provided invaluable critiques of 
methods and helped to identify new data sources. Most of 
the debates arising from GBD 2015 have come as direct 
communications from the collaborative network or have 
been published by collaborators and other researchers. 
For example, collaborators have addressed omissions in 
the GBD cause list,5–10 challenged the GBD hierarchy of 
causes,11 or explored the continual debate regarding 
disability weights.12 There is also a growing scientific 
literature on secondary analyses of GBD results—eg, with 
a focus on chronic kidney disease,13 oral diseases,14 or 
cardiovascular disease among the poorest billion.15
The primary objective of the non-fatal component of 
GBD 2016 was to estimate prevalence, incidence, and 
YLDs for 328 GBD causes from 1990 to 2016. For each 
cycle of GBD, the entire time series is re-estimated to 
incorporate new data and methods; thus, these results 
supersede previous GBD results. We explore the patterns 
of non-fatal disease over time and in comparison to 
expected levels based on an index of sociodemographic 
development.
Methods
Overview
The GBD study provides a standardised analytical 
approach for estimating incidence, prevalence, and YLDs 
by age, sex, cause, year, and location. We aim to use all 
accessible information on disease occurrence, natural 
history, and severity that passes minimum inclusion 
criteria set disease-by-disease (appendix 1, p 33). Our 
approach is to optimise the comparability of data 
collected by varying methods or different case definitions; 
find a consistent set of estimates between data for 
prevalence, incidence, and causes of death; and predict 
estimates for locations with sparse or absent data by 
borrowing information from other locations and using 
covariates.
In this study, we use different methods to reflect the 
available data and specific epidemiology of each dis-
ease. Our main approach is to combine all sources of 
information for a disease using the Bayesian meta-
regression tool DisMod-MR 2.1.16 Subsequently, we 
use data for severity, the occurrence of particular con-
sequences of diseases, or sequelae, to establish the 
proportion of prevalent cases experiencing each sequela. 
Several broad classes of alternative approaches are used 
within the GBD study. First, for injuries, non-fatal 
estimates must account for the cause of injury (eg, a fall), 
the nature of injury (eg, a fracture or head injury), the 
amount of disability arising in the short term, and 
permanent disability for a subset of cases. Second, cancers 
were estimated by assessing the association between 
mortality and incidence, taking into account the effect on 
survival of access to, and quality of, treatment for the 
cancer site. Third, we combined the natural history model 
strategy for HIV/AIDS with the DisMod-MR 2.1 modelling 
approach for tuberculosis as HIV infection affects 
outcomes in patients who also have tuberculosis. Fourth, 
models for malaria, hepatitis, and varicella relied on data 
of the presence of circulating antibodies or parasites in the 
blood to predict the incidence of clinical episodes for which 
we estimate disability. Fifth, neonatal disorders were esti-
mated from birth prevalence data and cohort studies on 
the risk of death in the first month and the probability of 
long-term disabling outcomes. Sixth, incidence of rabies, 
whooping cough, diphtheria, and tetanus was estimated 
from cause-specific mortality rates and data on the case 
fatality of acute episodes (appendix 1, p 33).
Below we describe these modelling efforts organised into 
eight sections; the supplementary methods (appendix 1, 
p 1) presents a single source for additional detail of inputs, 
analytical processes, outputs, and methods specific to each 
cause. This study complies with the Guidelines for Accurate 
and Transparent Health Estimates Reporting (GATHER) 
recommendations (appendix 1, p 723).17
1. Geographic units and time periods
The GBD 2016 study was based on a geographic hierarchy 
that includes 195 countries and territories grouped 
within 21 regions and seven GBD super-regions 
(appendix 1, p 726). For this publication, we present 
subnational estimates in figures and only for Brazil, 
China, India, and the USA. Details of subnational 
estimates will be reported in separate publications.
Cause-specific estimation in GBD 2016 was done for 
the years 1990, 1995, 2000, 2006, 2010, and 2016 and 
interpolated to get a full time series. In view of policy 
priorities, a subset of results focus on change over the 
time period 2006–16. Results from GBD 2016 by year and 
location can be explored further in dynamic data 
visualisations.
2. GBD cause list
In the GBD Study, causes and their sequelae are 
collectively exhaustive and mutually exclusive and are 
organised in a hierarchy with five levels. Level 1 contains 
three broad cause groups: communicable, maternal, 
neonatal, and nutritional diseases; non-communicable 
diseases; and injuries. These are broken down into 
21 Level 2 causes with further disaggregation into 
163 Level 3 causes and 271 Level 4 causes. Sequelae of 
these causes are represented at Level 5 of the hierarchy.
See Online for appendix 1
For data visualisations of GBD 
2016 results see https://vizhub.
healthdata.org/gbd-compare/
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Prevalence in thousands 
(95% UI)
Incidence in thousands 
(95% UI)
YLDs in thousands (95% UI)
2016 counts 2016 counts 2016 counts Percentage change in 
counts between 
2006 and 2016
Percentage change in 
age-standardised 
rates between 
2006 and 2016
All causes 7 122 683 
(7 115 742 to 7 129 084)
44 245 182 
(42 139 690 to 46 565 214)*
805 393 
(601 661 to 1 045 626)
16·4 
(16·0 to 16·9)†
–0·9 
(–1·2 to –0·5)†
Communicable, maternal, neonatal, 
and nutritional disorders
4 943 086 
(4 920 138 to 4 967 418)
25 266 823 
(23 366 307 to 27 404 017)*
101 472 
(72 326 to 136 902)
4·9 
(2·7 to 7·3)†
–5·1 
(–7·2 to –2·9)†
HIV/AIDS and tuberculosis 2 051 462 
(1 904 878 to 2 137 104)
10 884 
(9882 to 12 069)*
6871 
(4846 to 9324)
–3·6 
(–15·5 to 7·1)
–16·9 
(–27·3 to –7·3)†
Tuberculosis 1 918 597 
(1 797 774 to 2 043 357)
9019 
(8052 to 10 157)*
2839 
(1886 to 3843)
6·3 
(4·3 to 8·3)†
–10·6 
(–12·0 to –9·1)†
Drug-susceptible tuberculosis 9036 
(8134 to 10 108)
8705 
(7755 to 9818)
2735 
(1815 to 3 696)
6·4 
(4·3 to 8·6)†
–10·5 
(–12·0 to –8·9)†
Multidrug-resistant tuberculosis 
without extensive drug resistance
313 
(279 to 353)
296 
(261 to 336)
98 
(66 to 136)
–1·0 
(–10·1 to 8·9)
–16·9 
(–24·5 to –8·7)†
Extensively drug-resistant tuberculosis 19 
(17 to 22)
18 
(16 to 21)
6 
(4 to 9)
181·8 
(147·5 to 218·2)†
135·8 
(107·4 to 166·0)†
Latent tuberculosis infection 1 909 229 
(1 788 354 to 2 034 184)
.. ·· .. ··
HIV/AIDS 36 369 
(34 215 to 39 122)
1865 
(1690 to 2129)‡
4032 
(2785 to 5587)
–9·5 
(–24·9 to 7·8)
–20·9 
(–34·7 to –4·9)†
Drug-susceptible HIV/AIDS - 
Tuberculosis
1076 
(760 to 1467)
1365 
(981 to 1847)
415 
(250 to 634)
–20·8 
(–24·7 to –17·4)†
–30·0 
(–33·4 to –27·0)†
Multidrug-resistant  HIV/AIDS - 
Tuberculosis without extensive drug 
resistance
28 
(18 to 41)
36 
(24 to 52)
11 
(7 to 19)
–27·8 
(–39·8 to –15·0)†
–36·2 
(–46·7 to –24·9)†
Extensively drug-resistant HIV/AIDS  - 
Tuberculosis
1 
(1 to 2)
1 
(1 to 2)
0 
(0 to 1)
147·8 
(107·8 to 195·2)†
119·0 
(84·1 to 161·0)†
HIV/AIDS resulting in other diseases 35 264 
(33 138 to 38 026)
1865 
(1690 to 2129)
3605 
(2467 to 5059)
–8·0 
(–25·3 to 12·6)
–19·7 
(–35·1 to –0·7)†
Diarrhoea, lower respiratory infections, 
and other common infectious diseases
434 596 
(422 500 to 442 782)
23 240 453 
(21 377 295 to 25 359 204)*
20 656 
(14 317 to 28 476)
7·2 
(6·4 to 7·9)†
–3·4 
(–4·0 to –2·7)†
Diarrhoeal diseases 66 972 
(63 500 to 70 778)
4 480 401 
(4 246 997 to 4 737 769)
7506 
(5176 to 10 240)
7·5 
(6·5 to 8·5)†
–3·6
(–4·4 to –2·7)†
Intestinal infectious diseases 810 
(730 to 906)
15 532 
(13 599 to 17 777)*
125 
(84 to 175)
–16·2 
(–22·8 to –8·9)†
–22·1 
(–28·2 to –15·4)†
Typhoid fever 746 
(641 to 863)
11 774 
(10 227 to 13 622)
114 
(75 to 159)
–16·2 
(–23·4 to –8·4)†
–22·0 
(–28·5 to –14·6)†
Paratyphoid fever 165 
(145 to 187)
3758 
(3328 to 4257)
10 
(7 to 15)
–10·9 
(–17·7 to –3·6)†
–18·6 
(–24·8 to –12·1)†
Other intestinal infectious diseases ·· ·· 1 
(1 to 2)
–41·0 
(–48·3 to –32·8)†
–45·1 
(–51·9 to –37·7)†
Lower respiratory infections 8 030 
(7 582 to 8 548)
336 462 
(313 085 to 361 622)
482 
(320 to 678)
22·3 
(20·0 to 24·9)†
7·1 
(5·3 to 9·1)†
Upper respiratory infections 235 768 
(211 381 to 262 904)
17 778 134 
(15 853 332 to 19 905 351)
5864 
(3475 to 9057)
9·3 
(8·3 to 10·6)†
–1·2 
(–1·9 to –0·5)†
Otitis media 106 062 
(95 502 to 117 009)
451 730 
(365 179 to 564 104)
3137 
(1948 to 4665)
2·0 
(–0·5 to 4·5)
–5·8 
(–8·1 to –3·6)†
Meningitis 14 423 
(12 441 to 16 722)
2821 
(2464 to 3310)
1483 
(1039 to 1962)
10·8 
(8·3 to 15·3)†
0·5 
(–2·0 to 5·6)
Pneumococcal meningitis 6180 
(5170 to 7365)
612 
(498 to 756)
634 
(445 to 840)
7·6 
(3·9 to 11·8)†
–2·8 
(–6·2 to 1·1)
H influenzae type B meningitis 2012 
(1592 to 2545)
397 
(291 to 534)
248 
(171 to 330)
–13·8
(–18·5 to –9·5)†
–21·1 
(–25·5 to –17·0)†
Meningococcal infection 1661 
(1207 to 2270)
561 
(442 to 707)
168 
(113 to 236)
19·5 
(14·1 to 57·7)†
8·8 
(3·1 to 54·0)†
(Table continues on next page)
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Prevalence in thousands 
(95% UI)
Incidence in thousands 
(95% UI)
YLDs in thousands (95% UI)
2016 counts 2016 counts 2016 counts Percentage change in 
counts between 
2006 and 2016
Percentage change in 
age-standardised 
rates between 
2006 and 2016
(Continued from previous page)
Other meningitis 4571 
(3446 to 5833)
1250 
(1056 to 1487)
432 
(296 to 585)
34·8 
(30·3 to 39·7)†
21·7 
(17·6 to 26·1)†
Encephalitis 14 908 
(9877 to 21 755)
6534 
(5957 to 7165)
1651 
(1181 to 2145)
6·0 
(3·1 to 8·7)†
–6·5 
(–9·1 to –4·2)†
Diphtheria 0 
(0 to 0)
4 
(4 to 6)
0 
(0 to 0)
–58·0 
(–69·3 to –44·4)†
–61·0 
(–71·5 to –47·9)†
Whooping cough 1593 
(1242 to 2001)
11 627 
(9069 to 14 610)
79 
(47 to 124)
–22·5 
(–25·0 to –19·9)†
–25·1 
(–27·6 to –22·6)†
Tetanus 160 
(157 to 163)
90 
(51 to 121)
4 
(2 to 6)
–13·0 
(–25·8 to 0·5)
–21·3 
(–32·8 to –9·3)†
Measles 245 
(89 to 532)
8955 
(3251 to 19 426)
22 
(7 to 51)
–62·4 
(–66·9 to –57·6)†
–64·0 
(–68·3 to –59·4)†
Varicella and herpes zoster 7602 
(6996 to 8221)
148 162 
(144 145 to 152 728)
304 
(187 to 468)
21·4 
(18·5 to 24·4)†
1·6 
(–0·3 to 3·7)
Neglected tropical diseases and malaria 1 821 783 
(1 778 850 to 1 853 280)
440 947 
(378 282 to 512 509)*
13 665 
(9345 to 19 194)
–10·6 
(–15·1 to –6·0)†
–20·0 
(–24·2 to –15·8)†
Malaria 128 948 
(113 638 to 145 601)
213 098 
(172 037 to 265 778)
1741 
(1289 to 2326)
–11·1 
(–15·9 to –6·1)†
–17·2 
(–21·9 to –12·5)†
Chagas disease 7201 
(6065 to 8514)
180 
(150 to 214)
63 
(41 to 90)
9·2 
(5·6 to 12·7)†
–10·8 
(–13·6 to –8·0)†
Leishmaniasis 4835 
(4147 to 5523)
799 
(618 to 1021)
275 
(178 to 401)
26·9 
(15·7 to 40·3)†
10·9 
(0·7 to 23·9)†
Visceral leishmaniasis 30 
(28 to 32)
120 
(112 to 129)
2 
(1 to 3)
–54·2 
(–59·2 to –48·6)†
–59·0 
(–63·4 to –54·2)†
Cutaneous and mucocutaneous 
leishmaniasis
4320 
(3650 to 5238)
678 
(497 to 902)
273 
(177 to 399)
28·6 
(16·8 to 42·9)†
12·5 
(1·7 to 26·1)†
African trypanosomiasis 7 
(4 to 12)
5 
(4 to 6)
2 
(1 to 4)
–72·5 
(–79·1 to –63·6)†
–75·3 
(–81·3 to –67·4)†
Schistosomiasis 189 774 
(179 771 to 200 083)
71 385 
(67 342 to 76 073)
1496 
(755 to 2815)
–24·5 
(–26·0 to –22·5)†
–33·2 
(–34·6 to –31·4)†
Cysticercosis 2676 
(2232 to 3149)
·· 421 
(274 to 581)
–4·6 
(–11·0 to 1·4)
–19·9 
(–25·3 to –15·1)†
Cystic echinococcosis 974 
(674 to 1426)
204 
(151 to 304)
90 
(52 to 146)
–38·3 
(–59·3 to –1·7)†
–45·6 
(–64·1 to –14·2)†
Lymphatic filariasis 29 382 
(24 770 to 36 117)
7604 
(6561 to 8750)
1189 
(588 to 2115)
–37·3 
(–52·4 to –26·0)†
–45·3 
(–58·4 to –35·5)†
Onchocerciasis 14 650 
(9474 to 24 168)
3839 
(1747 to 7518)
962 
(452 to 1672)
–24·0 
(–41·6 to –6·5)†
–32·6 
(–48·5 to –17·5)†
Trachoma 3338 
(2 439 to 4492)
·· 245 
(162 to 354)
–0·5 
(–6·5 to 5·2)
–23·8 
(–28·5 to –19·3)†
Dengue 6046 
(3292 to 10 244)
101 064 
(61 458 to 153 334)
982 
(433 to 1829)
74·7 
(42·5 to 293·7)†
58·4 
(29·3 to 256·7)†
Yellow fever 3 
(1 to 8)
112 
(32 to 283)
0 
(0 to 0)
–18·1 
(–30·1 to –3·5)†
–24·2 
(–35·0 to –10·9)†
Rabies 0 
(0 to 1)
13 
(7 to 19)
0 
(0 to 0)
–46·7 
(–56·0 to –33·4)†
–52·8 
(–61·1 to –40·9)†
Intestinal nematode infections 1 507 853 
(1 450 985 to 1 542 581)
·· 2946 
(1713 to 4804)
–14·4 
(–18·0 to –10·3)†
–22·7 
(–26·0 to –18·9)†
Ascariasis 799 683 
(737 609 to 872 087)
·· 924 
(498 to 1 550)
–26·7 
(–33·0 to –19·8)†
–33·7 
(–39·5 to –27·5)†
Trichuriasis 435 095 
(410 564 to 464 463)
·· 337 
(186 to 574)
–20·0 
(–27·9 to –11·6)†
–27·8 
(–34·9 to –20·2)†
Hookworm disease 450 683 
(424 863 to 479 224)
·· 1685 
(1002 to 2649)
–4·2 
(–9·5 to 1·3)
–13·5 
(–18·3 to –8·5)†
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Food-borne trematodiases 74 725 
(70 800 to 78 800)
34 989 
(23 062 to 45 803)
1771 
(924 to 3158)
6·7 
(1·3 to 15·7)†
–7·0 
(–11·4 to 0·5)
Leprosy 523 
(499 to 547)
55 
(53 to 58)
32 
(21 to 44)
1·2 
(–1·3 to 3·6)
–18·1 
(–20·0 to –16·2)†
Ebola virus disease 1 
(0 to 4)
0 
(0 to 0)
0 
(0 to 1)
·· ··
Zika virus disease 129 
(97 to 179)
7598 
(5696 to 10 664)
4 
(3 to 6)
·· ··
Guinea worm disease 0 
(0 to 0)
0 
(0 to 0)
0 
(0 to 0)
–99·5 
(–99·7 to –99·4)†
–99·6 
(–99·7 to –99·5)†
Other neglected tropical diseases 49 493 
(47 574 to 51 781)
.. 1 445 
(943 to 2094)
6·0 
(3·6 to 8·2)†
–0·6 
(–2·9 to 1·4)
Maternal disorders 8730 
(8105 to 9254)
118 296 
(104 358 to 137 177)*
852 
(589 to 1181)
–5·8 
(–18·4 to 10·1)
–14·6 
(–25·8 to –0·2)†
Maternal haemorrhage 1403 
(1155 to 1706)
9626 
(7835 to 11 884)
60 
(39 to 87)
3·3 
(–19·8 to 32·5)
–5·7 
(–26·6 to 21·4)
Maternal sepsis and other pregnancy 
related infections
1662 
(1256 to 2201)
10 377 
(8385 to 13 151)
46 
(23 to 83)
2·7 
(–46·0 to 98·1)
–5·6 
(–50·1 to 83·4)
Maternal hypertensive disorders 4449 
(2947 to 6101)
20 811 
(18 216 to 23 245)
216 
(120 to 349)
7·8 
(–32·0 to 71·7)
–0·9 
(–37·4 to 57·6)
Maternal obstructed labour and uterine 
rupture
1041 
(868 to 1229)
7238 
(5821 to 9042)
336 
(218 to 472)
–13·7 
(–20·1 to –7·4)†
–22·6 
(–28·2 to –17·0)†
Maternal abortion, miscarriage, 
and ectopic pregnancy
576 
(371 to 820)
70 245 
(56 320 to 88 126)
63 
(35 to 102)
–4·4 
(–40·1 to 49·9)
–12·8 
(–45·4 to 37·1)
Other maternal disorders ·· ·· 131 
(90 to 181)
–10·4 
(–22·4 to 4·8)
–18·6 
(–29·3 to –4·8)†
Neonatal disorders 80 244 
(73 591 to 86 593)
·· 13 737 
(9642 to 19 774)
21·4
(9·0 to 36·3)†
11·4 
(0·0 to 25·1)†
Neonatal preterm birth complications 66 092 
(55 818 to 78 007)
·· 8328 
(5727 to 11 880)
18·4 
(–0·6 to 41·3)
8·5 
(–9·0 to 29·6)
Neonatal encephalopathy due to birth 
asphyxia and trauma
12 134 
(7668 to 19 247)
·· 1596 
(594 to 3694)
30·9 
(21·6 to 46·0)†
18·9 
(11·0 to 31·4)†
Neonatal sepsis and other neonatal 
infections
6653 
(2712 to 15 058)
·· 2647 
(893 to 6765)
29·7 
(22·6 to 39·5)†
19·5
(13·1 to 28·3)†
Haemolytic disease and other neonatal 
jaundice
2093 
(1861 to 2337)
·· 654 
(498 to 822)
19·9 
(16·0 to 23·5)†
9·5
(6·0 to 12·9)†
Other neonatal disorders ·· ·· 512 
(351 to 767)
7·0 
(–3·7 to 19·2)
2·7 
(–7·6 to 14·4)
Nutritional deficiencies 1 673 391 
(1 633 390 to 1 689 822)
598 813 
(516 074 to 717 722)*
41 431 
(27 722 to 58 560)
6·4 
(5·2 to 7·7)†
–2·6 
(–3·7 to –1·5)†
Protein-energy malnutrition 63 135 
(62 102 to 64 196)
43 590 
(42 935 to 44 253)
3205 
(2067 to 4487)
8·3 
(3·4 to 13·3)†
3·9 
(–0·8 to 8·7)
Iodine deficiency 119 214 
(105 724 to 133 961)
3043 
(2708 to 3411)
3138 
(2126 to 4398)
–6·1 
(–7·6 to –4·4)†
–16·9 
(–18·4 to –15·4)†
Vitamin A deficiency 508 801 
(445 148 to 601 630)
552 180 
(469 062 to 671 144)
252 
(159 to 388)
12·0 
(8·7 to 15·5)†
2·6 
(–0·3 to 5·6)
Iron-deficiency anaemia 1 244 781 
(1 205 796 to 1 284 426)
·· 34 727 
(22 960 to 49 579)
7·5 
(6·2 to 8·9)†
–1·8 
(–3·0 to –0·5)†
Other nutritional deficiencies ·· ·· 109 
(70 to 152)
8·5 
(3·4 to 13·8)†
3·8 
(–1·0 to 8·9)
Other communicable, maternal, 
neonatal, and nutritional diseases
1 728 266 
(1 680 548 to 1 764 134)
857 430 
(713 393 to 1 035 256)
4166 
(2686 to 6243)
10·9 
(8·4 to 13·1)†
–0·6 
(–2·7 to 1·3)
Sexually transmitted diseases 
excluding HIV
1 175 931 
(1 131 754 to 1 217 694)
552 776 
(499 026 to 612 824)
2546 
(1628 to 3983)
15·7 
(13·9 to 17·7)†
1·9 
(0·3 to 3·7)†
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Syphilis 56 092 
(44 184 to 70 172)
38 838 
(29 431 to 50 913)
188 
(133 to 249)
29·2 
(25·5 to 32·6)†
3·5 
(1·1 to 6·0)†
Chlamydial infection 93 574 
(75 600 to 114 406)
73 667 
(59 690 to 90 358)
516 
(324 to 804)
10·2 
(8·1 to 12·1)†
–1·3 
(–3·1 to 0·3)
Gonococcal infection 57 124 
(46 375 to 70 820)
190 766 
(147 718 to 242 152)
548 
(341 to 851)
23·5 
(19·4 to 27·6)†
10·5 
(6·7 to 14·2)†
Trichomoniasis 171 779 
(148 048 to 196 705)
148 908 
(126 821 to 171 971)
198 
(76 to 421)
15·9 
(14·8 to 17·1)†
1·8 
(0·9 to 2·7)†
Genital herpes 859 580 
(748 108 to 991 917)
57 156 
(49 205 to 67 554)
221 
(71 to 507)
17·8 
(15·5 to 19·7)†
–0·2 
(–1·6 to 1·5)
Other sexually transmitted diseases 36 588 
(31 753 to 40 490)
43 441 
(37 364 to 50 632)
875 
(576 to 1284)
11·5†
(9·3 to 13·8)
–0·9 
(–3·0 to 1·2)
Hepatitis 640 226 
(566 219 to 731 671)
304 644 
(182 678 to 477 007)
280 
(175 to 413)
–20·9 
(–33·6 to –5·7)†
–29·2†
(–40·2 to –16·3)
Acute hepatitis A 12 270 
(3 159 to 25 111)
159 516 
(41 071 to 326 448)
72 
(39 to 119)
–29·0 
(–60·7 to 27·6)
–35·1 
(–63·2 to 14·6)
Hepatitis B 468 435 
(396 824 to 554 418)
118 976 
(92 788 to 152 775)
165 
(99 to 261)
–16·3 
(–28·6 to –2·3)†
–26·7
(–36·7 to –14·9)†
Hepatitis C 158 055 
(141 445 to 175 144)
7094 
(6474 to 7724)
6 
(3 to 12)
5·1 
(–0·4 to 11·4)
–5·3 
(–10·4 to 0·8)
Acute hepatitis E 1466 
(1308 to 1645)
19 058 
(17 003 to 21 385)
36 
(23 to 54)
–25·7 
(–32·1 to –19·0)†
–30·8 
(–36·6 to –24·7)†
Other infectious diseases 44 426 
(42 785 to 46 296)
9 
(6 to 13)
1 340 
(879 to 1946)
11·5 
(9·5 to 13·7)†
3·5 
(1·6 to 5·7)†
Non-communicable diseases 6 681 939 
(6 668 902 to 6 695 003)
18 358 708 
(17 561 181 to 19 263 162)*
648 563 
(481 335 to 836 494)
17·9 
(17·5 to 18·4)†
–0·4 
(–0·7 to –0·1)†
Neoplasms 42 986 
(42 692 to 43 241)
17 228 
(16 713 to 17 802)
5180 
(3830 to 6697)
30·5 
(28·1 to 33·9)†
1·2 
(–0·6 to 3·8)
Lip and oral cavity cancer 1387 
(1 346 to 1 425)
382 
(371 to 392)
142 
(103 to 186)
32·7 
(27·8 to 37·4)†
3·6 
(–0·3 to 7·0)
Nasopharynx cancer 332 
(314 to 352)
96 
(91 to 101)
40 
(28 to 53)
8·4 
(0·5 to 15·9)†
–11·2 
(–17·5 to –5·3)†
Other pharynx cancer 478 
(452 to 494)
170 
(159 to 176)
58 
(42 to 76)
36·7 
(26·9 to 43·2)†
5·8 
(–1·7 to 10·8)
Oesophageal cancer 556 
(539 to 577)
443 
(433 to 456)
112 
(79 to 144)
9·1 
(5·4 to 13·7)†
–16·2 
(–19·0 to –12·8)†
Stomach cancer 2199 
(2144 to 2255)
1157 
(1134 to 1180)
300 
(218 to 384)
17·9 
(14·6 to 21·5)†
–9·1 
(–11·7 to –6·4)†
Colon and rectum cancer 6323 
(6112 to 6632)
1716 
(1658 to 1795)
599 
(442 to 780)
34·0 
(28·4 to 41·1)†
1·7 
(–2·4 to 7·1)
Liver cancer 1027 
(974 to 1076)
1008 
(953 to 1042)
228 
(163 to 298)
42·9 
(36·6 to 49·9)†
11·4 
(6·7 to 16·8)†
Liver cancer due to hepatitis B 599 
(516 to 675)
436 
(380 to 488)
98 
(68 to 131)
41·0 
(33·4 to 50·8)†
11·3 
(5·3 to 19·0)†
Liver cancer due to hepatitis C 261 
(236 to 286)
189 
(170 to 207)
43 
(31 to 58)
41·7 
(35·4 to 47·7)†
8·0 
(3·3 to 12·6)†
Liver cancer due to alcohol use 186 
(157 to 216)
148 
(125 to 171)
34 
(23 to 46)
48·4 
(37·0 to 62·2)†
13·9 
(5·1 to 24·6)†
Liver cancer due to other causes 326 
(288 to 371)
235 
(210 to 264)
54 
(38 to 71)
44·0 
(35·2 to 52·5)†
13·2 
(6·4 to 19·8)†
Gallbladder and biliary tract cancer 169 
(152 to 179)
184 
(168 to 193)
41 
(29 to 54)
21·3 
(16·2 to 26·8)†
–7·9 
(–11·8 to –3·7)†
Pancreatic cancer 364 
(349 to 375)
418 
(406 to 425)
86 
(60 to 111)
33·8 
(29·2 to 37·5)†
1·8 
(–1·8 to 4·7)
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Larynx cancer 638 
(627 to 653)
187 
(184 to 191)
75 
(55 to 98)
22·8 
(19·3 to 26·5)†
–5·6 
(–8·3 to –2·8)†
Tracheal, bronchus, and lung cancer 2836 
(2750 to 2920)
2008 
(1958 to 2055)
474 
(345 to 598)
30·2 
(26·1 to 33·9)†
0·1 
(–3·0 to 3·0)
Malignant skin melanoma 1347 
(1156 to 1506)
282 
(243 to 314)
90 
(63 to 123)
37·9 
(31·7 to 42·7)†
8·8 
(3·8 to 12·6)†
Non-melanoma skin cancer 853 
(682 to 1066)
1521 
(1109 to 2008)
31 
(17 to 52)
5·8 
(–3·3 to 19·7)
–21·4 
(–28·0 to –10·8)†
Non-melanoma skin cancer 
(squamous-cell carcinoma)
690 
(415 to 996)
635 
(386 to 922)
30 
(16 to 51)
5·2 
(–4·1 to 19·5)
–21·8 
(–28·6 to –11·1)†
Non-melanoma skin cancer (basal-cell 
carcinoma)
103 
(65 to 167)
886 
(574 to 1 262)
1 
(0 to 2)
23·8 
(16·1 to 31·7)†
–5·6 
(–11·5 to 0·4)
Breast cancer 8151 
(7808 to 8610)
1702 
(1629 to 1801)
739 
(535 to 982)
26·9 
(20·6 to 34·5)†
–1·4 
(–6·2 to 4·1)
Cervical cancer 1939 
(1544 to 2082)
511 
(414 to 542)
186 
(128 to 247)
9·4 
(2·7 to 18·3)†
–11·3 
(–16·7 to –4·3)†
Uterine cancer 1959 
(1882 to 2076)
417 
(401 to 442)
150 
(107 to 201)
39·8 
(32·9 to 50·0)†
7·2 
(2·1 to 15·0)†
Ovarian cancer 786 
(743 to 809)
254 
(242 to 260)
116 
(84 to 150)
24·1 
(16·9 to 29·4)†
–2·7 
(–8·3 to 1·3)
Prostate cancer 5697 
(5098 to 6714)
1436 
(1293 to 1619)
533 
(384 to 707)
39·0 
(32·3 to 48·1)†
4·4 
(–0·7 to 11·4)
Testicular cancer 340 
(328 to 355)
67 
(64 to 70)
24 
(17 to 32)
29·8 
(24·0 to 35·9)†
12·8 
(7·8 to 18·2)†
Kidney cancer 1289 
(1226 to 1329)
342 
(331 to 350)
114 
(83 to 150)
27·7 
(23·5 to 31·1)†
0·0 
(–3·3 to 2·6)
Bladder cancer 1767 
(1721 to 1813)
437 
(427 to 448)
165 
(121 to 217)
31·1 
(26·9 to 35·1)†
–0·6 
(–3·7 to 2·5)
Brain and nervous system cancer 781 
(693 to 818)
330 
(299 to 349)
106 
(75 to 139)
37·9 
(33·1 to 43·3)†
12·7 
(8·8 to 17·2)†
Thyroid cancer 1234 
(1187 to 1313)
238 
(229 to 253)
80 
(56 to 110)
48·4 
(41·5 to 58·2)†
17·9 
(12·6 to 25·7)†
Mesothelioma 53 
(49 to 56)
35 
(32 to 36)
11 
(8 to 15)
27·7 
(21·6 to 32·5)†
–1·0 
(–5·8 to 2·6)
Hodgkin’s lymphoma 291 
(264 to 322)
73 
(66 to 82)
29 
(21 to 39)
10·2 
(7·3 to 13·2)†
–6·8 
(–9·3 to –4·1)†
Non-Hodgkin lymphoma 1670 
(1545 to 1746)
461 
(428 to 482)
147 
(107 to 193)
45·2 
(38·0 to 49·0)†
13·8 
(8·1 to 16·8)†
Multiple myeloma 358 
(305 to 398)
138 
(121 to 156)
70 
(49 to 91)
42·8 
(36·8 to 49·4)†
8·6 
(4·1 to 13·7)†
Leukaemia 1675 
(1511 to 1765)
467 
(423 to 488)
214 
(153 to 284)
25·3 
(18·7 to 32·2)†
2·1 
(–3·1 to 7·5)
Acute lymphoid leukaemia 292 
(256 to 310)
76 
(66 to 80)
36 
(25 to 49)
31·1 
(12·6 to 41·6)†
16·6 
(0·7 to 25·8)†
Chronic lymphoid leukaemia 460 
(430 to 496)
105 
(98 to 113)
57 
(41 to 74)
37·4 
(31·6 to 44·6)†
4·3 
(0·0 to 9·5)†
Acute myeloid leukaemia 160 
(142 to 169)
103 
(91 to 108)
29 
(20 to 39)
32·8 
(24·5 to 37·6)†
8·8 
(2·2 to 12·6)†
Chronic myeloid leukaemia 92 
(84 to 99)
32 
(29 to 34)
12 
(8 to 16)
6·5 
(1·9 to 11·0)†
–15·4 
(–18·9 to –12·2)†
Other leukaemia 672 
(565 to 722)
150 
(127 to 161)
81 
(57 to 107)
16·3 
(8·5 to 25·5)†
–3·7 
(–9·9 to 3·7)
Other neoplasms 2632 
(2377 to 2720)
750 
(682 to 772)
221 
(160 to 292)
51·8 
(44·9 to 56·7)†
21·7 
(16·1 to 25·7)†
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Cardiovascular diseases 469 454 
(462 582 to 474 872)
54 120
(51 965 to 56 447)*
33 482 
(24 477 to 43 376)
29·4 
(26·7 to 31·9)†
1·0 
(–1·1 to 2·9)
Rheumatic heart disease 29 677 
(26 737 to 32 927)
1196 
(1095 to 1308)
1456 
(931 to 2116)
17·3 
(13·9 to 20·6)†
3·4 
(0·4 to 6·4)†
Ischaemic heart disease 153 533 
(145 992 to 160 779)
20 731 
(19 530 to 22 072)
6916 
(4812 to 9385)
29·3 
(28·5 to 30·1)†
0·5 
(–0·1 to 1·1)
Cerebrovascular disease 79 574 
(77 057 to 82 118)
13 677 
(12 714 to 14 692)§ 
14 452 
(10 150 to 18 414)
33·5 
(27·3 to 39·2)†
2·7 
(–2·0 to 7·1)
Ischaemic stroke 67 595 
(60 812 to 74 572)
9556 
(8655 to 10 513)§
11 802 
(8246 to 15 151)
35·2 
(27·8 to 42·2)†
3·7 
(–2·1 to 9·0)
Haemorrhagic stroke 15 310 
(13 857 to 16 954)
4120 
(3764 to 4508)§
2650 
(1896 to 3381)
26·6 
(20·1 to 32·9)†
–1·6 
(–6·6 to 3·4)
Hypertensive heart disease 17 190 
(14 948 to 19 774)
·· 1380 
(959 to 1 894)
31·6 
(29·7 to 33·5)†
0·4 
(–0·8 to 1·6)
Cardiomyopathy and myocarditis 6118 
(5779 to 6416)
2483 
(2217 to 2784)*
559 
(384 to 786)
18·7 
(16·8 to 20·7)†
–4·0 
(–5·4 to –2·6)†
Myocarditis 1786 
(1607 to 1977)
2483 
(2217 to 2784)
133 
(89 to 188)
13·1 
(11·1 to 15·1)†
–1·4 
(–2·9 to 0·0)†
Alcoholic cardiomyopathy 1165 
(994 to 1359)
·· 97 
(66 to 138)
20·6 
(15·6 to 25·7)†
–5·4 
(–9·0 to –1·7)†
Other cardiomyopathy 4005 
(3534 to 4525)
·· 329 
(226 to 462)
20·6 
(18·3 to 22·9)†
–4·5 
(–6·1 to –2·9)†
Atrial fibrillation and flutter 46 311 
(41 441 to 52 014)
3841 
(3379 to 4388)
3614 
(2439 to 5024)
32·0 
(30·9 to 33·0)†
0·3 
(–0·4 to 1·0)
Peripheral vascular disease 120 145 
(105 640 to 137 704)
11 020 
(9557 to 12 778)
520 
(244 to 941)
25·5 
(23·8 to 27·3)†
–5·9 
(–6·8 to –5·0)†
Endocarditis 500 
(448 to 568)
1172 
(1068 to 1280)
40 
(27 to 55)
23·0 
(20·5 to 25·6)†
–3·7 
(–5·6 to –1·9)†
Other cardiovascular and circulatory 
diseases
87 122 
(76 311 to 98 866)
·· 4546 
(3102 to 6404)
20·6†
(18·7 to 22·6)
–2·2†
(–3·4 to –1·0)
Chronic respiratory diseases 571 426 
(560 139 to 582 621)
94 696 
(90 108 to 99 441)*
30 954 
(25 068 to 37 362)
24·0 
(22·3 to 26·1)†
3·0 
(1·8 to 4·2)†
Chronic obstructive pulmonary disease 251 631 
(241 958 to 261 129)
18 721 
(18 004 to 19 456)
16 288 
(14 342 to 17 878)
28·8 
(26·2 to 31·4)†
1·4 
(–0·6 to 3·5)
Pneumoconiosis 1111 
(1043 to 1184)
99 
(93 to 105)
162 
(111 to 224)
32·0 
(29·0 to 35·1)†
1·5 
(–0·8 to 3·9)
Silicosis 421 
(380 to 464)
44 
(41 to 49)
60 
(41 to 84)
31·8 
(26·1 to 37·1)†
1·0 
(–3·2 to 4·8)
Asbestosis 152 
(138 to 170)
12 
(11 to 13)
23 
(16 to 32)
26·9 
(24·3 to 29·6)†
–1·3 
(–3·3 to 0·9)
Coal workers pneumoconiosis 294 
(256 to 340)
21 
(19 to 24)
42 
(28 to 60)
34·5 
(27·0 to 42·4)†
2·6 
(–3·0 to 8·6)
Other pneumoconiosis 243 
(210 to 277)
21 
(18 to 24)
36 
(24 to 50)
32·5 
(27·6 to 37·8)†
2·8 
(–1·0 to 7·0)
Asthma 339 440 
(319 582 to 360 796)
75 496 
(71 071 to 80 177)
13 221 
(8726 to 18 839)
17·2 
(16·0 to 18·4)†
3·6 
(2·5 to 4·6)†
Interstitial lung disease and pulmonary 
sarcoidosis
3978 
(3632 to 4352)
379 
(348 to 412)
416 
(282 to 596)
28·9 
(26·7 to 31·2)†
1·7 
(0·3 to 3·1)†
Other chronic respiratory diseases ·· ·· 866 
(752 to 955)
49·7 
(46·2 to 53·0)†
34·2 
(31·1 to 37·3)†
Cirrhosis and other chronic liver diseases 45 783 
(43 781 to 47 831)
1638 
(1575 to 1708)
1574 
(1094 to 2165)
21·0 
(19·4 to 22·6)†
1·8 
(0·5 to 3·0)†
Cirrhosis and other chronic liver diseases 
due to hepatitis B
12 482 
(11 611 to 13 474)
457 
(421 to 500)
394 
(274 to 545)
26·6 
(24·1 to 29·4)†
2·9 
(1·0 to 4·9)†
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Cirrhosis and other chronic liver diseases 
due to hepatitis C
10 903 
(9925 to 11 984)
387 
(353 to 426)
314 
(215 to 433)
26·4 
(23·6 to 29·2)†
2·2 
(0·1 to 4·3)†
Cirrhosis and other chronic liver diseases 
due to alcohol use
11 392 
(10 521 to 12 386)
404 
(373 to 439)
314 
(220 to 431)
25·8 
(23·1 to 28·6)†
0·2 
(–1·7 to 2·4)
Cirrhosis and other chronic liver diseases 
due to other causes
11 007 
(10 105 to 11 958)
391 
(363 to 421)
552 
(376 to 772)
12·3 
(10·0 to 14·6)†
1·7 
(–0·4 to 3·7)
Digestive diseases 262 283 
(257 495 to 266 222)
211 761 
(201 555 to 223 065)*
7287 
(5169 to 9878)
27·4 
(24·7 to 30·3)†
5·9 
(4·0 to 8·0)†
Peptic ulcer disease 74 335 
(69 108 to 80 393)
10 329 
(9 391 to 11 368)
1364 
(891 to 2024)
38·7 
(34·1 to 43·4)†
14·1 
(10·5 to 17·7)†
Gastritis and duodenitis 123 619 
(112 199 to 135 163)
77 140 
(70 074 to 85 452)
1672 
(1094 to 2419)
38·6 
(34·5 to 42·9)†
14·0 
(10·9 to 17·2)†
Appendicitis 857 
(796 to 922)
22 580 
(20 993 to 24 258)
263 
(176 to 360)
9·8 
(6·5 to 13·2)†
0·1 
(–2·8 to 2·9)
Paralytic ileus and intestinal obstruction 170 
(155 to 186)
4651 
(4265 to 5080)
54 
(36 to 74)
25·2 
(23·1 to 27·2)†
4·9 
(3·6 to 6·3)†
Inguinal, femoral, and abdominal hernia 51 239 
(46 088 to 56 543)
36 240 
(31 967 to 40 531)
2152 
(1471 to 2993)
15·3 
(12·9 to 17·6)†
–3·1 
(–4·8 to –1·7)†
Inflammatory bowel disease 6007 
(5622 to 6446)
3518 
(3275 to 3779)
863 
(596 to 1185)
26·8 
(24·0 to 29·6)†
3·8 
(1·8 to 5·9)†
Vascular intestinal disorders 104 
(93 to 115)
583 
(527 to 644)
32 
(21 to 43)
25·7 
(21·5 to 30·0)†
0·2 
(–3·3 to 3·5)
Gallbladder and biliary diseases 17 269 
(15 618 to 19 012)
51 509 
(46 439 to 56 953)
231 
(158 to 325)
29·2 
(25·4 to 32·7)†
4·9 
(2·4 to 7·4)†
Pancreatitis 584 
(532 to 639)
5210 
(4769 to 5703)
73 
(49 to 102)
29·3 
(25·1 to 33·7)†
5·8 
(2·4 to 9·1)†
Other digestive diseases ·· ·· 584 
(413 to 784)
32·4 
(29·4 to 35·6)†
10·1 
(8·2 to 12·2)†
Neurological disorders 2 595 647 
(2 542 097 to 2 651 997)
1 183 726 
(1 021 730 to 1 362 193)
69 426 
(47 199 to 92 890)
16·3 
(14·5 to 18·3)†
0·4 
(–1·0 to 2·0)
Alzheimer’s disease and other dementias 43 836 
(37 756 to 51 028)
7779 
(6620 to 9135)
6415 
(4506 to 8491)
38·2 
(36·4 to 39·9)†
0·7 
(–0·3 to 1·6)
Parkinson’s disease 6063 
(4972 to 7325)
696 
(564 to 850)
706 
(457 to 974)
36·3 
(33·6 to 38·6)†
3·3 
(1·6 to 4·8)†
Epilepsy 23 962 
(20 402 to 27 737)
2 761 
(2 308 to 3 268)
7547 
(5111 to 10 458)
8·8 
(–2·1 to 22·0)
–2·6 
(–12·3 to 9·2)
Multiple sclerosis 2221 
(2034 to 2437)
69 
(63 to 76)
584 
(411 to 764)
24·5 
(21·9 to 26·9)†
3·0 
(0·8 to 5·1)†
Motor neuron disease 331 
(300 to 367)
58 
(52 to 63)
70 
(49 to 93)
21·2 
(19·5 to 23·1)†
1·1 
(0·1 to 2·1)†
Migraine 1 044 772 
(999 535 to 1 087 969)
110 316 
(105 270 to 115 834)
45 122 
(29 046 to 62 827)
14·3 
(13·7 to 14·9)†
0·1 
(–0·2 to 0·5)
Tension-type headache 1 890 670 
(1 707 786 to 2 097 762)
1 061 998 
(899 411 to 1 241 310)
7195 
(4615 to 10 500)
15·4 
(13·7 to 17·0)†
0·4 
(–0·4 to 1·4)
Other neurological disorders 24 
(16 to 33)
48 
(32 to 66)
1786 
(1212 to 2436)
30·1 
(18·7 to 43·7)†
17·4 
(7·4 to 30·2)†
Mental and substance use disorders 1 111 147 
(1 095 612 to 1 128 948)
410 091 
(385 617 to 437 586)*
150 476 
(109 498 to 194 542)
12·9
(12·4 to 13·5)†
–1·4 
(–1·8 to –1·0)†
Schizophrenia 20 883 
(18 497 to 23 422)
1139 
(1006 to 1287)
13 414 
(9859 to 16 714)
16·7
(15·5 to 18·0)†
–0·9 
(–1·7 to –0·2)†
Alcohol use disorders 100 389 
(89 592 to 111 659)
50 432 
(44 249 to 56 797)
10 031 
(6 883 to 13 787)
9·7 
(7·7 to 11·8)†
–4·8 
(–6·7 to –3·1)†
Drug use disorders 61 968 
(60 342 to 63 579)
7460 
(6810 to 8140)
14 607 
(10 464 to 19 045)
15·5
(13·7 to 17·3)†
1·4 
(–0·2 to 3·0)
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Opioid use disorders 26 834 
(23 563 to 30 952)
2795 
(2443 to 3226)
11 132 
(7725 to 14 577)
18·0 
(15·8 to 20·1)†
2·7 
(0·7 to 4·6)†
Cocaine use disorders 5840 
(5322 to 6473)
347 
(304 to 391)
797 
(501 to 1141)
11·8
(10·0 to 13·6)†
–1·4 
(–2·9 to 0·2)
Amphetamine use disorders 4955 
(3693 to 6490)
440 
(330 to 577)
658 
(386 to 1038)
3·7 
(0·4 to 6·8)†
–4·0 
(–7·3 to –0·9)†
Cannabis use disorders 22 094 
(18 965 to 25 856)
3183 
(2706 to 3776)
647 
(401 to 946)
3·7 
(1·2 to 6·0)†
–4·2 
(–5·9 to –2·4)†
Other drug use disorders 3944 
(3537 to 4362)
695 
(624 to 770)
1373 
(919 to 1912)
10·6 
(8·2 to 13·1)†
–1·5 
(–3·6 to 0·7)
Depressive disorders 268 172 
(260 480 to 274 698)
274 704 
(251 855 to 300 436)
44 208 
(30 573 to 59 878)
13·2 
(12·2 to 14·4)†
–3·6 
(–4·3 to –2·9)†
Major depressive disorder 167 836 
(153 908 to 183 754)
257 768 
(234 546 to 284 665)
34 105 
(23 470 to 46 039)
11·2 
(10·1 to 12·3)†
–4·9 
(–5·6 to –4·1)†
Dysthymia 105 580 
(92 588 to 120 440)
16 935 
(14 981 to 19 313)
10 104 
(6 861 to 14 612)
20·5 
(18·3 to 23·2)†
1·0 
(–0·5 to 2·7)
Bipolar disorder 43 908 
(38 383 to 50 196)
3777 
(3313 to 4331)
8954 
(5588 to 13 186)
14·9 
(13·8 to 16·0)†
0·8 
(0·2 to 1·4)†
Anxiety disorders 274 615 
(255 323 to 294 796)
42 407 
(39 560 to 45 513)
26 417 
(18 440 to 35 634)
13·1 
(11·9 to 14·3)†
–0·7 
(–1·7 to 0·2)
Eating disorders 10 523 
(9368 to 11 716)
5440 
(4039 to 7186)
2148 
(1386 to 3091)
17·3 
(15·5 to 19·0)†
9·1 
(7·9 to 10·4)†
Anorexia nervosa 2606 
(1932 to 3450)
897 
(665 to 1183)
556 
(338 to 830)
12·2 
(9·7 to 14·7)†
6·2 
(4·0 to 8·4)†
Bulimia nervosa 7559 
(5765 to 9931)
4543 
(3169 to 6256)
1592 
(972 to 2392)
19·2 
(16·9 to 21·2)†
10·2 
(8·7 to 11·7)†
Autistic spectrum disorders 62 174 
(59 625 to 64 557)
450 
(307 to 624)
9026 
(6119 to 12 681)
11·4 
(10·8 to 12·0)†
0·3 
(–0·2 to 0·8)
Autism 18 302 
(15 766 to 21 177)
51 
(26 to 86)
4649 
(2977 to 6699)
11·3 
(10·3 to 12·3)†
–0·1 
(–0·9 to 0·8)
Asperger syndrome and other autistic 
spectrum disorders
43 798 
(36 425 to 52 403)
399 
(258 to 572)
4377 
(2864 to 6393)
11·5 
(10·9 to 12·1)†
0·6 
(0·2 to 1·1)†
Attention-deficit or hyperactivity 
disorder
62 624 
(57 564 to 68 596)
2872 
(2562 to 3294)
755 
(452 to 1197)
6·1 
(5·0 to 7·1)†
–0·5 
(–1·4 to 0·4)
Conduct disorder 49 005 
(40 946 to 57 034)
16 887 
(13 566 to 20 196)
5947 
(3 702 to 8 998)
2·2 
(0·9 to 3·4)†
2·3
(1·1 to 3·4)†
Idiopathic developmental intellectual 
disability
114 797 
(69 506 to 161 353)
·· 4611 
(2202 to 7932)
2·5 
(–0·9 to 4·6)
–6·9 
(–10·0 to –4·9)†
Other mental and substance use 
disorders
139 505 
(122 047 to 160 430)
4523 
(4004 to 5122)
10 357 
(7059 to 14 807)
17·8 
(17·2 to 18·5)†
0·1 
(–0·4 to 0·5)
Diabetes, urogenital, blood, and 
endocrine diseases
2 927 330 
(2 909 185 to 2 949 337)
811 323 
(769 165 to 854 588)*
62 287 
(44 312 to 84 848)
21·1 
(19·7 to 22·6)†
–0·3 
(–1·4 to 0·8)
Diabetes mellitus 383 453 
(352 588 to 414 576)
20 828 
(19 160 to 22 734)
28 584 
(19 534 to 39 575)
23·6 
(20·9 to 26·5)†
–1·2 
(–3·3 to 1·2)
Acute glomerulonephritis 104 
(90 to 117)
1530 
(1357 to 1729)
5 
(3 to 8)
4·5 
(2·4 to 6·8)†
–10·6 
(–12·1 to –9·1)†
Chronic kidney disease 275 930 
(252 442 to 300 414)
21 329 
(19 100 to 23 599)
8772 
(6600 to 11 104)
30·4 
(28·2 to 32·7)†
3·8 
(2·2 to 5·3)†
Chronic kidney disease due to diabetes 
mellitus
115 356 
(101 848 to 130 636)
8979 
(7742 to 10 377)
3695 
(2768 to 4722)
33·4 
(30·7 to 36·0)†
4·8 
(3·1 to 6·7)†
Chronic kidney disease due to 
hypertension
50 097 
(44 151 to 55 693)
3626 
(3131 to 4163)
1680 
(1200 to 2159)
36·6 
(33·4 to 40·3)†
4·8 
(2·6 to 7·3)†
Chronic kidney disease due to 
glomerulonephritis
49 615 
(43 695 to 55 597)
3893 
(3261 to 4529)
1479 
(1093 to 1927)
20·6 
(17·6 to 23·8)†
–0·4 
(–2·6 to 2·0)
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Chronic kidney disease due to 
other causes
60 862 
(52 600 to 69 124)
4831 
(4135 to 5526)
1918 
(1411 to 2502)
28·0 
(25·3 to 30·7)†
4·0 
(2·0 to 6·0)†
Urinary diseases and male infertility 146 155 
(135 457 to 155 774)
449 242 
(412 808 to 488 929)*
4140 
(2727 to 5875)
25·6
(24·3 to 27·0)†
–1·4 
(–2·2 to –0·5)†
Interstitial nephritis and urinary tract 
infections
6913 
(6201 to 7660)
360 816 
(325 242 to 399 931)
228 
(142 to 345)
14·1 
(12·0 to 16·1)†
1·0 
(–0·5 to 2·4)
Urolithiasis 2839 
(2556 to 3162)
75 218 
(67 725 to 83 689)
208 
(140 to 286)
21·5 
(18·6 to 24·4)†
0·3 
(–1·9 to 2·4)
Benign prostatic hyperplasia 103 655 
(91 930 to 115 236)
13 208 
(11 393 to 15 199)
3384 
(2178 to 4835)
28·9 
(27·5 to 30·3)†
–1·3 
(–2·2 to –0·3)†
Male infertility 28 044 
(22 703 to 35 076)
·· 165 
(66 to 327)
19·3 
(15·7 to 22·6)†
7·9 
(4·9 to 10·6)†
Other urinary diseases ·· ·· 155 
(103 to 216)
–3·3 
(–4·9 to –1·7)†
–16·4 
(–17·5 to –15·3)†
Gynaecological diseases 837 557 
(822 589 to 852 391)
300 826 
(284 093 to 317 864)*
10 195 
(6918 to 14 656)
11·9 
(10·6 to 13·4)†
–2·2 
(–3·3 to –1·1)†
Uterine fibroids 91 012 
(82 090 to 100 488)
9394 
(8303 to 10 601)
1375 
(812 to 2218)
19·0 
(17·9 to 20·1)†
0·2 
(–0·5 to 1·0)
Polycystic ovarian syndrome 10 642 
(8653 to 12 885)
7651 
(5518 to 10 179)
94 
(43 to 173)
7·8 
(6·4 to 9·4)†
–2·1 
(–3·4 to –0·7)†
Female infertility 31 477 
(19 472 to 49 304)
·· 180 
(66 to 399)
38·5 
(29·4 to 49·5)†
25·3 
(17·7 to 34·8)†
Endometriosis 3554 
(3197 to 3935)
9262 
(7894 to 10 960)
332 
(224 to 459)
7·8 
(5·2 to 10·7)†
–3·9 
(–6·2 to –1·5)†
Genital prolapse 250 418 
(222 236 to 278 690)
16 608 
(14 433 to 19 185)
778 
(382 to 1409)
14·8 
(13·7 to 15·9)†
–9·4 
(–10·2 to –8·6)†
Premenstrual syndrome 454 296 
(432 912 to 474 453)
162 435 
(153 441 to 171 301)
3791 
(2344 to 5813)
9·2 
(7·7 to 10·6)†
–2·0 
(–3·3 to –0·8)†
Other gynaecological diseases 104 692 
(93 190 to 116 476)
95 475 
(82 017 to 109 553)
3645 
(2430 to 5090)
11·2 
(8·8 to 14·2)†
–2·4 
(–4·5 to 0·3)
Haemoglobinopathies and haemolytic 
anaemias
1 804 470 
(1 782 496 to 1 828 051)
·· 6572 
(4372 to 9566)
12·8 
(10·9 to 14·9)†
1·8 
(0·1 to 3·7)†
Thalassaemias 366 
(343 to 394)
·· 23 
(15 to 34)
–4·3 
(–8·1 to –0·4)†
–8·5 
(–12·2 to –4·8)†
Thalassaemias trait 287 107 
(276 495 to 298 645)
·· 3280 
(2157 to 4824)
10·9
(8·0 to 13·9)†
–0·6 
(–3·1 to 2·0)
Sickle cell disorders 3888 
(3572 to 4470)
·· 317 
(222 to 441)
21·4 
(17·1 to 26·0)†
15·6 
(11·5 to 19·9)†
Sickle cell trait 461 124 
(418 742 to 516 943)
·· 1555 
(1014 to 2283)
16·8 
(14·8 to 18·8)†
7·3 
(5·4 to 9·1)†
G6PD deficiency 331 513 
(319 093 to 346 326)
·· 26 
(18 to 36)
14·5 
(11·5 to 17·6)†
3·1 
(0·4 to 5·9)†
G6PD trait 865 927 
(851 718 to 882 248)
·· 1 
(0 to 1)
17·6 
(14·9 to 20·7)†
4·9 
(2·6 to 7·5)†
Other haemoglobinopathies and 
haemolytic anaemias
61 625 
(59 671 to 63 634)
·· 1370 
(912 to 1967)
11·6
(9·4 to 14·3)†
–0·7 
(–2·5 to 1·5)
Endocrine, metabolic, blood, and 
immune disorders
127 493 
(119 899 to 135 715)
17 569 
(15 815 to 19 457)
4020 
(2721 to 5537)
19·1 
(17·4 to 20·8)†
–0·5 
(–1·5 to 0·6)
Musculoskeletal disorders 1 270 630 
(1 248 968 to 1 294 805)
652 005 
(591 746 to 719 811)
137 832 
(100 146 to 179 438)
19·9 
(18·7 to 21·0)†
–1·2 
(–1·9 to –0·5)†
Rheumatoid arthritis 21 337 
(19 466 to 23 612)
1174 
(1066 to 1298)
4989 
(3427 to 6604)
28·8 
(26·7 to 31·0)†
3·7 
(2·1 to 5·2)†
Osteoarthritis 301 567 
(285 064 to 318 844)
14 696 
(13 728 to 15 682)
16 283 
(11 486 to 22 047)
31·5 
(30·7 to 32·2)†
2·4 
(1·9 to 3·0)†
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Low back and neck pain 748 081 
(721 756 to 766 729)
313 434 
(281 503 to 347 952)
86 584 
(61 335 to 113 628)
19·3 
(17·7 to 20·7)†
–1·3 
(–2·4 to –0·5)†
Low back pain 511 048 
(457 208 to 572 056)
250 277 
(220 585 to 283 681)
57 648 
(40 820 to 75 877)
18·0 
(16·0 to 20·1)†
–2·0
(–3·6 to –0·9)†
Neck pain 290 524 
(254 815 to 332 009)
63 157 
(55 205 to 74 075)
28 936 
(19 578 to 40 543)
21·9 
(19·9 to 24·0)†
0·1 
(–1·3 to 1·4)
Gout 33 977 
(30 617 to 37 923)
6435 
(5666 to 7248)
1071 
(742 to 1455)
26·2 
(24·3 to 27·9)†
–0·1 
(–1·3 to 1·1)
Other musculoskeletal disorders 337 859 
(289 444 to 390 647)
316 267 
(266 448 to 375 370)
28 904 
(19 554 to 40 812)
14·4 
(11·5 to 17·2)†
–3·5 
(–5·7 to –1·6)†
Other non-communicable diseases 5 292 032 
(5 257 502 to 5 326 591)
14 922 120 
(14 136 832 to 15 793 314)*
150 066 
(102 792 to 212 136)
16·7 
(16·0 to 17·2)†
–0·6 
(–1·0 to –0·2)†
Congenital anomalies 82 890 
(78 027 to 87 071)
·· 9723 
(6979 to 12 887)
9·1 
(7·5 to 10·6)†
–1·5 
(–3·0 to –0·2)†
Neural tube defects 5782 
(5232 to 6393)
·· 1723 
(1220 to 2299)
14·6 
(12·1 to 17·4)†
3·0 
(0·8 to 5·6)†
Congenital heart anomalies 15 377 
(13 712 to 17 128)
·· 755 
(332 to 1284)
8·5 
(6·3 to 10·4)†
–0·9 
(–2·9 to 0·8)
Orofacial clefts 3590 
(3230 to 3967)
·· 46 
(30 to 67)
3·5 
(0·7 to 6·3)†
–7·3 
(–9·8 to –4·8)†
Down’s syndrome 2031 
(1776 to 2314)
·· 185 
(124 to 258)
8·3 
(5·9 to 10·7)†
–1·1 
(–3·4 to 1·1)
Turner syndrome 2719 
(2378 to 3089)
·· 47 
(22 to 76)
6·9 
(3·2 to 10·4)†
–1·0 
(–4·3 to 2·1)
Klinefelter syndrome 3043 
(2641 to 3482)
·· 17 
(8 to 32)
9·0 
(6·2 to 11·7)†
0·0 
(–2·5 to 2·5)
Other chromosomal abnormalities 4310 
(3734 to 4977)
·· 494 
(345 to 665)
4·3 
(2·2 to 6·4)†
1·5 
(–0·6 to 3·6)
Congenital musculoskeletal and limb 
anomalies
10 812 
(9 960 to 11 711)
·· 1536 
(1056 to 2113)
13·2 
(11·1 to 15·2)†
–0·1 
(–1·9 to 1·7)
Urogenital congenital anomalies 7172 
(6493 to 7894)
·· 189 
(112 to 298)
1·8 
(0·1 to 3·1)†
–3·5 
(–4·8 to –2·4)†
Digestive congenital anomalies 9711 
(8741 to 10 731)
·· 427 
(280 to 610)
9·0 
(6·1 to 11·9)†
–3·2 
(–5·8 to –0·6)†
Other congenital anomalies 34 984 
(24 584 to 49 402)
·· 4302 
(2844 to 6310)
6·8 
(4·4 to 9·6)†
–3·9 
(–6·1 to –1·4)†
Skin and subcutaneous diseases 2 266 315 
(2 242 994 to 2 285 332)
5 074 605 
(4 838 566 to 5 335 844)
54 635 
(36 830 to 79 320)
10·7 
(10·2 to 11·3)†
1·2 
(0·9 to 1·5)†
Dermatitis 306 359 
(290 041 to 324 193)
430 376 
(398 274 to 462 932)
11 210 
(6 714 to 18 218)
11·6 
(10·8 to 12·4)†
1·1 
(0·3 to 1·8)†
Psoriasis 65 135 
(62 708 to 67 812)
8170 
(7861 to 8478)
5643 
(4040 to 7377)
21·7 
(20·8 to 22·6)†
4·2 
(3·6 to 5·0)†
Cellulitis 3018 
(2842 to 3210)
61 333 
(58 280 to 64 556)
170 
(112 to 244)
14·0 
(12·2 to 16·0)†
–0·5 
(–1·9 to 1·0)
Pyoderma 21 020 
(20 491 to 21 564)
474 384 
(461 024 to 488 662)
117 
(47 to 243)
22·8 
(21·9 to 23·6)†
5·2 
(4·4 to 5·8)†
Scabies 146 785 
(127 773 to 170 009)
454 671 
(392 690 to 529 184)
3788 
(2104 to 6029)
3·2 
(1·8 to 4·6)†
–5·4 
(–6·2 to –4·8)†
Fungal skin diseases 626 700 
(568 967 to 690 267)
2 098 743 
(1 884 346 to 2 337 325)
3509 
(1403 to 7271)
18·0 
(17·0 to 19·1)†
2·5 
(2·2 to 2·9)†
Viral skin diseases 193 171 
(184 773 to 201 619)
276 755 
(263 471 to 290 018)
5915 
(3674 to 8828)
9·0 
(8·5 to 9·5)†
–0·1 
(–0·5 to 0·2)
Acne vulgaris 614 771 
(560 634 to 672 878)
429 822 
(361 790 to 521 114)
15 836 
(10 644 to 22 843)
5·1 
(4·3 to 5·8)†
2·1 
(1·5 to 2·6)†
(Table continues on next page)
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Prevalence in thousands 
(95% UI)
Incidence in thousands 
(95% UI)
YLDs in thousands (95% UI)
2016 counts 2016 counts 2016 counts Percentage change in 
counts between 
2006 and 2016
Percentage change in 
age-standardised 
rates between 
2006 and 2016
(Continued from previous page)
Alopecia areata 15 416 
(14 906 to 15 948)
27 247 
(26 347 to 28 203)
504 
(323 to 760)
12·8 
(11·8 to 13·9)†
–1·3 
(–2·2 to –0·5)†
Pruritus 66 780 
(59 262 to 74 868)
53 046 
(47 751 to 59 503)
709 
(330 to 1 299)
18·2 
(16·7 to 19·8)†
1·3 
(0·8 to 1·8)†
Urticaria 67 060 
(59 299 to 77 018)
119 403 
(105 497 to 135 993)
4030 
(2576 to 5745)
9·4 
(8·3 to 10·5)†
–0·3 
(–0·8 to 0·3)
Decubitus ulcer 1836 
(1660 to 2017)
6722 
(6040 to 7456)
290 
(203 to 388)
27·0 
(24·2 to 29·6)†
–0·8 
(–2·8 to 1·0)
Other skin and subcutaneous diseases 532 790 
(519 540 to 545 725)
633 932 
(616 730 to 651 838)
2913 
(1409 to 5325)
25·3 
(24·8 to 25·7)†
4·5 
(4·3 to 4·7)†
Sense organ diseases 1 843 201 
(1 825 393 to 1 861 436)
708 004 
(667 844 to 753 886)*
66 702 
(46 534 to 92 392)
21·7 
(20·7 to 22·5)†
–1·9 
(–2·6 to –1·3)†
Glaucoma 4761 
(3973 to 5573)
·· 461 
(311 to 642)
35·7 
(33·7 to 38·0)†
2·1 
(0·7 to 3·6)†
Cataract 83 628 
(73 800 to 93 905)
·· 5789 
(4 135 to 7 915)
31·0 
(29·4 to 32·6)†
0·0 
(–1·2 to 1·1)
Macular degeneration 6147 
(5111 to 7401)
·· 409 
(278 to 556)
37·5 
(34·7 to 40·4)†
2·7 
(0·7 to 4·7)†
Refraction and accommodation 
disorders
854 299 
(822 109 to 885 545)
·· 14 972 
(9 341 to 23 362)
14·9 
(13·7 to 15·9)†
–4·9 
(–5·8 to –4·3)†
Age-related and other hearing loss 1 271 675 
(1 210 237 to 1 337 731)
·· 36 288 
(25 342 to 50 894)
22·3 
(20·4 to 24·0)†
–1·7 
(–2·9 to –0·6)†
Other vision loss 29 249 
(25 873 to 32 927)
·· 2241 
(1578 to 3016)
26·1 
(23·9 to 28·1)†
0·7 
(–0·8 to 2·0)
Other sense organ diseases 210 697 
(195 303 to 225 565)
708 004 
(667 844 to 753 886)
6542 
(4132 to 9828)
23·8 
(23·1 to 24·4)†
0·9 
(0·6 to 1·3)†
Oral disorders 3 583 600 
(3 475 812 to 3 657 885)
9 139 511 
(8 388 756 to 9 926 992)*
19 006 
(11 587 to 29 630)
22·2†
(21·2 to 23·3)
–0·2 
(–0·7 to 0·2)
Caries of deciduous teeth 486 095 
(398 110 to 573 474)
1 762 264 
(1 264 051 to 2 391 119)
127 
(56 to 249)
6·8 
(4·5 to 8·5)†
0·2 
(–1·9 to 1·8)
Caries of permanent teeth 2 435 850 
(2 288 064 to 2 586 461)
7 263 992 
(6 715 107 to 7 835 458)
1708 
(760 to 3325)
8·7 
(8·0 to 9·4)†
–4·2 
(–4·8 to –3·6)†
Periodontal disease 750 847 
(633 975 to 874 077)
89 840 
(74 128 to 106 716)
4898 
(1947 to 10 209)
25·8 
(24·7 to 26·8)†
2·3 
(1·8 to 2·9)†
Edentulism and severe tooth loss 302 342 
(263 801 to 339 035)
23 414 
(19 894 to 27 222)
8338 
(5467 to 11 760)
27·2 
(26·0 to 28·4)†
–0·9 
(–1·6 to –0·3)†
Other oral disorders 134 457 
(128 968 to 140 248)
·· 3935 
(2427 to 5908)
15·2
(14·6 to 15·8)†
0·0 
(–0·3 to 0·3)
Injuries 1 492 784 
(1 413 602 to 1 584 568)
619 651 
(592 467 to 648 150)*
55 358 
(37 181 to 78 689)
22·1 
(21·0 to 23·2)†
2·0 
(1·2 to 2·6)†
Transport injuries 241 194 
(225 137 to 258 446)
75 419 
(68 548 to 82 688)
12 345 
(8227 to 17 658)
25·6 
(24·5 to 26·6)†
4·1 
(3·3 to 4·8)†
Road injuries 194 515 
(182 106 to 208 390)
65 536 
(58 946 to 72 433)
9983 
(6650 to 14 255)
28·1
(27·2 to 29·0)†
5·5 
(4·9 to 6·1)†
Pedestrian road injuries 43 124 
(38 450 to 48 872)
11 342 
(9709 to 13 303)
2261 
(1511 to 3222)
28·7 
(27·1 to 30·1)†
5·8 
(4·9 to 6·7)†
Cyclist road injuries 38 983 
(33 088 to 45 660)
15 288 
(12 715 to 17 993)
1873 
(1238 to 2710)
31·0 
(30·1 to 31·8)†
8·1 
(7·5 to 8·6)†
Motorcyclist road injuries 46 084 
(39 635 to 55 732)
11 346 
(9534 to 13 518)
2336 
(1555 to 3342)
29·5 
(28·3 to 30·6)†
7·3 
(6·5 to 8·0)†
Motor vehicle road injuries 51 784 
(43 776 to 59 354)
20 993 
(18 156 to 23 790)
2821 
(1895 to 3991)
20·9 
(20·0 to 21·8)†
–1·0 
(–1·8 to –0·2)†
Other road injuries 14 539 
(12 463 to 17 017)
6566 
(5217 to 8267)
693 
(457 to 1 014)
48·2 
(46·5 to 49·7)†
22·9 
(21·9 to 23·8)†
(Table continues on next page)
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Prevalence in thousands 
(95% UI)
Incidence in thousands 
(95% UI)
YLDs in thousands (95% UI)
2016 counts 2016 counts 2016 counts Percentage change in 
counts between 
2006 and 2016
Percentage change in 
age-standardised 
rates between 
2006 and 2016
(Continued from previous page)
Other transport injuries 46 680 
(39 471 to 54 858)
9884 
(8552 to 11 480)
2362 
(1595 to 3372)
15·8 
(14·2 to 17·5)†
–1·5 
(–2·8 to –0·3)†
Unintentional injuries 1 127 878 
(1 053 751 to 1 211 481)
510 685 
(484 967 to 539 046)
37 696 
(25 530 to 53 091)
22·9 
(21·8 to 23·8)†
2·3 
(1·5 to 2·9)†
Falls 474 230 
(419 318 to 528 012)
208 272 
(189 203 to 229 948)
18 946 
(13 288 to 26 043)
26·7 
(25·8 to 27·6)†
3·4 
(2·6 to 4·1)†
Drowning 4684 
(4129 to 5324)
846 
(763 to 938)
233 
(153 to 336)
4·9 
(2·9 to 6·9)†
–12·3 
(–13·7 to –11·0)†
Fire, heat, and hot substances 102 124 
(87 477 to 121 846)
10 997 
(9148 to 12 675)
2455 
(1601 to 3666)
18·6†
(17·0 to 19·9)
1·0 
(–0·1 to 1·8)
Poisonings 3526 
(2984 to 4133)
4697 
(3858 to 5639)
298 
(192 to 437)
25·8 
(24·5 to 27·2)†
8·9 
(7·8 to 10·1)†
Exposure to mechanical forces 197 786 
(168 555 to 241 945)
67 906 
(59 032 to 76 818)
4412 
(2854 to 6440)
24·4 
(23·2 to 25·5)†
3·9 
(3·2 to 4·5)†
Unintentional firearm injuries 7091 
(5867 to 8629)
1429 
(1052 to 1893)
228 
(146 to 341)
23·5†
(22·3 to 24·4)
4·0 
(3·3 to 4·5)†
Unintentional suffocation 9395 
(7248 to 12 049)
1804 
(1347 to 2370)
282 
(174 to 438)
11·8 
(10·3 to 13·5)†
–2·8 
(–3·7 to –1·8)†
Other exposure to mechanical forces 181 300 
(153 213 to 224 295)
64 673 
(56 323 to 73 039)
3 901 
(2 536 to 5 696)
25·5 
(24·2 to 26·6)†
4·5 
(3·7 to 5·1)†
Adverse effects of medical treatment 2924 
(2328 to 3567)
38 245 
(34 405 to 42 385)
390 
(246 to 580)
11·8 
(10·2 to 13·5)†
–4·4 
(–6·0 to –2·8)†
Animal contact 53 654 
(47 673 to 61 282)
65 550 
(56 597 to 74 579)
1667 
(1126 to 2315)
11·0 
(9·7 to 12·2)†
–4·0 
(–4·9 to –3·2)†
Venomous animal contact 24 759 
(20 818 to 29 310)
31 691 
(25 886 to 38 600)
1204 
(813 to 1684)
11·7 
(10·4 to 13·1)†
–2·4 
(–3·5 to –1·3)†
Non-venomous animal contact 28 894 
(24 541 to 34 730)
33 859 
(27 953 to 40 468)
463 
(303 to 708)
9·1 
(7·2 to 10·8)†
–7·9 
(–9·4 to –6·7)†
Foreign body 54 797 
(45 419 to 63 613)
35 172 
(30 752 to 40 749)
2040 
(1308 to 3022)
16·6 
(14·9 to 18·5)†
0·8 
(–0·4 to 2·1)
Pulmonary aspiration and foreign 
body in airway
26 682 
(20 450 to 35 018)
10 801 
(9 348 to 12 717)
1124 
(719 to 1683)
12·4 
(10·8 to 14·1)†
–2·1 
(–3·3 to –0·9)†
Foreign body in eyes 3168 
(1880 to 4640)
15 443 
(11 951 to 20 505)
186 
(100 to 310)
26·8 
(24·1 to 30·1)†
8·2 
(6·3 to 10·3)†
Foreign body in other body part 24 947 
(20 403 to 31 426)
8929 
(7508 to 10 562)
730 
(468 to 1 083)
21·2 
(19·5 to 23·1)†
3·8 
(2·6 to 5·0)†
Environmental heat and cold exposure 74 104 
(63 212 to 86 149)
19 591 
(16 473 to 23 142)
2756 
(1829 to 3963)
18·9 
(17·1 to 20·9)†
0·7 
(–0·8 to 2·1)
Other unintentional injuries 160 048 
(131 378 to 191 818)
59 409 
(51 226 to 68 804)
4500 
(2972 to 6571)
20·5 
(19·6 to 21·3)†
1·5 
(0·7 to 2·3)†
Self-harm and interpersonal violence 230 043 
(210 093 to 252 561)
32 470 
(28 739 to 36 265)*
3884 
(2672 to 5491)
9·3 
(8·3 to 10·4)†
–5·8 
(–6·3 to –5·4)†
Self-harm 11 924 
(10 160 to 13 744)
6893 
(6130 to 7759)
528 
(342 to 764)
10·0 
(8·9 to 11·2)†
–9·4 
(–10·1 to –8·8)†
Self-harm by firearm 380 
(326 to 439)
98 
(61 to 149)
13 
(8 to 20)
3·6 
(1·9 to 5·4)†
–12·5 
(–13·8 to –11·2)†
Self-harm by other specified means 11 544 
(9770 to 13 356)
6795 
(6037 to 7607)
515 
(333 to 744)
10·2 
(9·1 to 11·3)†
–9·3 
(–10·1 to –8·7)†
Interpersonal violence 218 118 
(197 726 to 240 339)
25 577 
(22 086 to 29 230)*
3356 
(2325 to 4709)
9·2 
(8·1 to 10·4)†
–5·2 
(–5·7 to –4·8)†
Assault by firearm 2899 
(2388 to 3485)
710 
(560 to 897)
104 
(66 to 156)
14·9 
(13·9 to 16·0)†
–3·6 
(–4·3 to –2·9)†
Assault by sharp object 15 012 
(12 272 to 17 936)
5603 
(4397 to 6946)
412 
(269 to 601)
10·5 
(9·0 to 12·0)†
–6·6 
(–7·6 to –5·7)†
(Table continues on next page)
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For GBD 2016, we expanded the list of causes of non-fatal 
outcomes from 310 to 328. This involved the refinement of 
certain Level 3 causes into new Level 4 causes, includ-
ing disaggregation of tuberculosis and HIV- tuberculosis 
into drug-susceptible tuberculosis, multidrug- resistant 
tuber culosis, extensively drug-resistant tuber culosis, and 
latent tuberculosis infection. Cardiomyopathy and myo-
carditis were further refined as alcoholic cardiomyopathy, 
myocarditis, and other cardio myopathy. Other leukaemia 
was added as an additional sub-cause at Level 4. Self-harm 
was separated into self-harm by firearm and self-harm by 
other means. The previously named cause grouping 
“collective violence and legal intervention” was divided into 
two Level 4 causes: executions and police conflict. New 
causes of non-fatal outcomes added to the GBD hierarchy 
for 2016 included Zika virus disease; musculoskeletal, 
urogenital, and digestive congenital anomalies; Guinea 
worm disease; and sexual violence. Medication overuse 
headache was removed as a cause and, instead, char-
acterised as a sequela of migraine and tension-type 
headache.
3. Sources of data
The first step in non-fatal estimation was the compilation 
of data sources from systematic data and literature 
searches conducted by cause. This process resulted in 
4043 published studies newly included in GBD 2016, 
leading to a total of 14 521. Our network of collaborators 
for GBD 2016 provided 2598 data sources and studies. 
These were systematically screened, together with sources 
Prevalence in thousands 
(95% UI)
Incidence in thousands 
(95% UI)
YLDs in thousands (95% UI)
2016 counts 2016 counts 2016 counts Percentage change in 
counts between 
2006 and 2016
Percentage change in 
age-standardised 
rates between 
2006 and 2016
(Continued from previous page)
Sexual violence 160 421 
(141 228 to 181 452)
.. 1366 
(917 to 1946)
3·5 
(2·2 to 4·8)†
–5·5 
(–6·2 to –4·9)†
Assault by other means 39 786 
(33 335 to 48 036)
19 263 
(16 510 to 22 244)
1474 
(988 to 2129)
14·3 
(13·4 to 15·1)†
–4·7 
(–5·4 to –4·2)†
Forces of nature, conflict and terrorism, 
and executions and police conflict
54 091 
(34 969 to 76 753)
1077 
(759 to 1328)*
1433 
(510 to 3006)
12·5
(5·0 to 18·2)†
–1·1 
(–7·3 to 3·8)
Exposure to forces of nature 7571 
(4293 to 11 602)
377 
(231 to 534)
260 
(71 to 610)
32·2 
(17·0 to 39·5)†
16·4 
(3·5 to 23·0)†
Conflict and terrorism 40 684 
(24 541 to 61 725)
·· 1100 
(432 to 2206)
10·8 
(3·5 to 18·0)†
–2·4 
(–8·5 to 3·9)
Executions and police conflict 5836 
(1906 to 9042)
700 
(410 to 883)
131 
(28 to 344)
–6·7
(–11·2 to –2·3)†
–20·0 
(–23·6 to –16·3)†
Impairments ·· ·· ·· ·· ··
Anaemia 2 042 728 
(1 979 003 to 2 110 037)
·· 61 649 
(41 483 to 86 424)
9·2 
(6·4 to 11·2)†
–2·2 
(–4·8 to –0·3)†
Developmental intellectual disability 196,243 
(150 264 to 242 144)
·· 19 925 
(14 584 to 26 434)
8·3 
(6·5 to 10·7)†
–1·8 
(–3·4 to 0·4)
Epilepsy 45 926 
(39 942 to 54 564)
·· 15 392 
(11 594 to 20 379)
10·5 
(2·5 to 19·1)†
–0·6 
(–7·7 to 7·0)
Guillain-Barré syndrome 65 
(52 to 82)
·· 19 
(12 to 28)
16·7 
(14·1 to 19·5)†
0·5 
(–0·4 to 1·2)
Hearing loss 1 390 482 
(1 329 902 to 1 455 762)
·· 42 630 
(30 019 to 59 264)
18·8 
(17·0 to 20·4)†
–2·5 
(–3·6 to –1·5)†
Heart failure 63 609 
(56 944 to 71 388)
·· 7783 
(5857 to 9788)
30·2
(28·8 to 31·6)†
–0·6 
(–1·6 to 0·3)
Infertility 117 207 
(94 952 to 145 048)
·· 719 
(310 to 1400)
18·7 
(15·4 to 21·6)†
7·0 
(4·3 to 9·4)†
Pelvic inflammatory disease 4099 
(3533 to 4740)
·· 535 
(360 to 743)
7·8 
(5·5 to 10·1)†
–5·5 
(–7·5 to –3·6)†
Vision loss 1 009 472 
(969 235 to 1 047 829)
·· 28 748 
(20 342 to 40 240)
20·4 
(19·1 to 22·0)†
–1·3 
(–2·4 to 0·8)
We did not calculate incidence for the nine impairments, certain neglected tropical diseases, and causes with only birth prevalence. Blank cells mean that no estimate is available. Cells with zeros indicate an 
estimate smaller than 500 as the table presents prevalence and incidence counts in thousands. To download the data in this table, please visit the Global Health Data Exchange (GHDx) at: http://ghdx.healthdata.
org/node/311084. *Incidence for aggregate causes represents the sum of the incidence of the causes below the aggregate. †Percentage changes that are statistically significant. ‡Incidence of HIV/AIDS represents 
new infections of HIV only and does not include new infections of tuberculosis in HIV positive cases. §Incidence estimates for stroke represent first-ever stroke only. YLDs=years lived with disability. 
Table: Global prevalence, incidence, and YLDs for 2016, percentage change of YLD counts, and percentage change of age-standardised YLD rates between 2006 and 2016 for all causes 
and nine impairments
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suggested by country-level experts, surveys located in 
multinational survey data catalogues, and Ministry of 
Health and Central Statistical Office websites. We 
analysed 18 792 sources of epidemiological surveillance 
data (country-years of disease reporting), up from 14 081 
in 2015. All counts reflect our updated counting criteria 
for GBD 2016. The supplementary methods provides 
details of data adjust ments, correction factors, and 
standardisations employed in incorporating these 
different data types (appendix 1, p 18).
The number of location-years of hospital inpatient data 
by cause increased from 1176 in GBD 2015 to 3557 in 
GBD 2016. This increase can be attributed to the addition 
of new years of data for some locations, as well as newly 
incorporated data for 16 countries where we had 
previously lacked clear information about the population 
covered. To allow their use in GBD, we first collated 
information from surveys and hospital administrative 
records to estimate hospital admission rates per capita 
for all GBD locations by age and sex, from 1990 to 2016, 
using DisMod-MR 2.1 (appendix 1, p 7). We then used 
inpatient data by cause from locations with unclear 
denominators as cause fractions of the all-cause inpatient 
admission rates. Three adjustment factors were derived 
from USA health insurance claims data on more than 80 
million person-years of coverage. The first factor 
corrected for multiple inpatient episodes for the same 
cause in an individual. The second adjustment was to 
include secondary diagnostic fields. The third adjustment 
was to include any mention of a cause in inpatient or 
outpatient episodes of care as opposed to inpatient 
episodes with a primary diagnosis only. This new method 
of predicting prevalence or incidence from inpatient data 
allowed us to use these sources for 16 more causes than 
in 2015. The supplementary methods provides a detailed 
description of our process for inpatient data (appendix 1, 
p 11).
To provide a summary view on data availability, the 
number of causes at the most detailed level for which we 
have any prevalence or incidence data from 1980 to 2016 
by location is presented in the appendix (appendix 1, 
p 722). An online search tool is available to view all data 
sources that were used in the estimation process for each 
cause.
4. Non-fatal disease models
Non-fatal diseases were modelled using DisMod-MR 2.1, 
a statistical method that synthesises sparse and 
heterogeneous epidemiological data for non-fatal out-
comes. Estimation occurred at five levels: global, super-
region, region, country, and subnational locations, with 
results from a higher level providing guidance for the 
analysis at a lower geographical level (appendix 1, p 18).
Custom models were created where DisMod-MR 2.1 
does not capture the complexity of the disease, or if 
incidence and prevalence needed to be calculated from 
other data. Further details of these custom models can 
be found in the supplementary methods (appendix 1, 
p 18). Prevalence was estimated for nine impairments, 
disorders that are sequelae of multiple diseases and for 
which there were better data available to estimate the 
overall occurrence than for each underlying cause: 
anaemia, intellectual disability, epilepsy, hearing loss, 
vision loss, heart failure, infertility, pelvic inflammatory 
disease, and Guillain-Barré syndrome.
The methods for estimating YLDs from a number of 
diseases changed substantially for GBD 2016. We 
improved our estimation of mortality-to-incidence ratios 
for cancers to better reflect lower survival probabilities in 
low-income and middle-income locations based on each 
location’s Socio-demographic Index (SDI) value. As a 
consequence, our prevalence and YLD estimates were 
lower in those locations but did not change much for 
higher-SDI locations. We made major changes to our 
modelling of tuberculosis. First, we made explicit 
estimates of latent tuberculosis infection from tuberculin 
skin testing data and the risk of developing active 
tuberculosis by induration size. Second, we predicted 
mortality-to-incidence ratios in locations with high data-
quality ratings (4-star or 5-star using a system developed 
for the GBD 2016 causes of death estimation)18 and SDI 
as a covariate. We anchored the lower end of the SDI 
scale with a datapoint from an untreated cohort of 
pulmonary tuberculosis cases in the 1960s, half of whom 
had died after five years.18,19 Third, we estimated incidence 
from these mortality-to-incidence ratios in all locations 
except those with higher reported notifications. Fourth, 
we modelled these incidence estimates as well as the 
prevalence data from surveys in low-income and middle-
income countries and cause-specific mortality rates 
among the proportion of the population with latent 
infection in DisMod-MR 2.1. Fifth, we estimated the 
proportions of tuberculosis cases with multidrug-
resistant tuberculosis or extensively drug-resistant tuber-
culosis from notification and survey data and included 
an increased risk of multidrug-resistant tuberculosis in 
HIV/AIDS-infected patients with tuber culosis from a 
meta-analysis.20
In our measles estimation strategy, we included the 
coverage of measles-containing vaccine second-dose 
(MCV2) rather than just the coverage of the primary 
vaccine as a covariate. As relatively few countries in sub-
Saharan Africa have introduced MCV2, the estimated 
incidence for those locations is notably higher compared 
with previous estimates.
5. Severity distributions and disability weights
For 214 causes at Level 4 of the GBD hierarchy, sequelae 
were defined in terms of severity, usually graded as mild, 
moderate, or severe outcomes. We followed the same 
approach as in GBD 2015. For Zika virus disease, we 
included sequelae for those with symptomatic acute 
infection, a small proportion with Guillain-Barré 
syndrome, and the number of neonates with congenital 
For the online tool used for 
estimation see http://ghdx.
healthdata.org/gbd-2016
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Zika virus disease as reported to the Pan American 
Health Organization (PAHO). For sexual violence, we 
estimated YLDs associated with concurrent physical 
injuries and the short-term psychological outcomes 
following sexual violence.
A more substantial change in estimating severity was 
applied to stroke. A systematic review was done to collect 
data on modified Rankin scores, a measure of neurological 
disability.21 Levels of Rankin score were analysed in 
DisMod-MR 2.1 and mapped to the existing GBD health 
state lay descriptions for mild, moderate, and severe motor 
impairment from stroke, and, separately, the proportion of 
stroke patients with moderate-to-severe motor impairment 
who also experienced cognitive impairment. For GBD 2016 
we used the same disability weights as in GBD 2013 and 
GBD 2015; the supplementary methods provides a 
complete listing of lay descriptions of all 235 health states 
used in GBD 2016 (appendix 1, p 799).
6. Comorbidity
We estimated comorbidity by simulating 40 000 individuals 
in every location-age-sex-year combination as exposed to 
the independent probability, based on the prevalence of 
the sequelae included in GBD 2016. In simulants with 
two or more sequelae, we assumed a multiplicative 
function to combine disability weights and then 
distributed the reduced combined weight proportionately 
among all comorbid sequelae. Averaging these adjusted 
values across all simulants with a particular sequela gave 
the adjusted value of YLDs. There was no change in the 
approach compared with GBD 2015.
7. YLD computation
All computations in GBD were done 1000 times, every 
time drawing from the distribution of the sampling 
error of data inputs, the uncertainty of data corrections 
for measurement errors, the uncertainty in coefficients 
from model fit (eg, in DisMod-MR 2.1), and the 
uncertainty of severity distributions and disability 
weights. Uncertainty bounds for a quantity of interest 
were defined by the 25th and 975th value of the ordered 
1000 estimate values. If there was a change in disease 
estimates between locations or over time that was in the 
same direction in more than 950 of the 1000 samples we 
report it as significant. Age-standardised prevalence 
YLD rates were calculated based on the GBD reference 
population.22
The GBD cause hierarchy is comprehensive and 
includes 35 residual disease categories to capture YLDs 
from conditions for which we do not currently make 
separate estimates. For 22 of these residual categories, 
we made explicit epidemiological estimates of prevalence 
and incidence, and define sequelae based on the most 
common diseases in the Level 2 or 3 cause group and 
severity distributions from the Medical Expenditure 
Panel Survey (MEPS).23 For 13 residual categories, we 
had no epidemiological data and estimated YLDs from 
the ratio of YLDs to YLLs from explicitly modelled 
diseases in the cause category, assuming that relative to 
each death, the number of YLDs was similar to that of 
other diseases at the same level of the GBD hierarchy 
(appendix 1, p 29).
8. SDI and epidemiological transition
SDI is a summary measure that places all GBD locations 
on a spectrum of socioeconomic development.24 The SDI 
was developed for GBD 2015 to provide a comparable 
metric of overall development. This was achieved by 
using an equal weighting of lag-distributed income per 
capita, average years of education in the population over 
age 15 years, and total fertility rate.22 For GBD 2016, we 
modified the estimation of SDI by taking into 
consideration that SDI scales were subject to change 
based on increasing geographic units and an extended 
time period of analysis, affecting the interpretability 
across GBD iterations. We redefined the values of zero 
and one for each component of the index: zero now 
represents the level below which we have not observed 
GDP per capita or educational attainment or above which 
we have not observed the total fertility rate in known 
datasets. Maximum scores for educational attainment 
and Lagged Distributed Income represent a plateau in 
the relationship between each of the two components 
and life expectancy or under-5 mortality rates, suggesting 
no additional benefit. Analogously, the maximum score 
for total fertility rate represents the minimum level at 
which the relationship with the selected health outcomes 
plateaued. An SDI value was generated for each location 
and year as the geometric mean of each component 
score. Five SDI quintiles, high, high-middle, middle, 
low-middle, and low, were selected based on 2016 values 
of SDI; additional details are available in the 
supplementary methods (appendix 1).22
A Gaussian process regression was used to evaluate 
the average relationship for each age-sex-cause group, 
for cause-specific YLD rates on SDI at Levels 1, 2, and 3 
of the GBD cause hierarchy using data from 1990 
to 2016. These rates were used as the expected values for 
cause-specific YLD rates at a given level of SDI. 
Additional detail on this analysis is available in the 
supplementary methods (appendix 1, p 30) and in 
previous GBD publications.18
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or the 
writing of the report. All authors had full access to 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Global prevalence and incidence
Global prevalence, incidence, and YLDs for 328 causes 
and nine impairments, as well as percent change of YLDs 
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and percent change of age-standardised YLD rates 
from 2006 to 2016 are listed in the table. Cause-specific 
estimates for each year of the GBD estimation period 
1990–2016 by location, age, and sex are available through 
an online results tool.
Prevalence
In 2016, the ten causes with the greatest prevalence were 
caries of permanent teeth (2·44 billion, 95% UI 
2·29 billion to 2·59 billion), latent tuberculosis infection 
(1·91 billion, 1·79 billion to 2·03 billion), tension-type 
headache (1·89 billion, 1·71 billion to 2·10 billion), age-
related and other hearing loss (1·27 billion, 1·21 billion to 
1·34 billion), iron-deficiency anaemia (1·24 billion cases, 
1·21 billion to 1·28 billion), migraine (1·04 billion, 
1·00 billion to 1·09 billion), glucose-6-phosphate 
dehydrogenase deficiency (G6PD) trait (866 million, 
852 million to 882 million), genital herpes (860 million, 
748 million to 992 million), refraction and accommodation 
disorders (854 million, 822 million to 886 million), and 
ascariasis (800 million, 738 million to 872 million; table). 
The vast majority of cases for two of these causes are 
asymptomatic sequelae that have no YLDs associated 
with them: genital herpes with no active lesions, and 
G6PD trait that does not result in anaemia. Similarly, 
latent tuberculosis infection is a highly prevalent cause 
but without any associated disability. The leading ten 
causes of prevalence accounted for 17·5% 
(95% uncertainty interval [UI] 15·8–19·3) of YLDs 
globally in 2016.
Incidence
In 2016, the ten causes with the highest incidence were 
upper respiratory infections (17·78 billion, 15·85 billion 
to 19·90 billion), caries of permanent teeth (7·26 billion, 
6·72 billion to 7·84 billion), diarrhoeal diseases 
(4·48 billion, 4·25 billion to 4·74 billion), fungal skin 
diseases (2·10 billion, 1·88 billion to 2·34 billion), caries 
of deciduous teeth (1·76 billion, 1·26 billion to 
2·39 billion), tension-type headache (1·06 billion, 
899 million to 1·24 billion), other sense organ diseases 
(708 million, 668 million to 754 million), other skin and 
subcutaneous diseases (634 million, 617 million to 
652 million), vitamin A deficiency (552 million, 
469 million to 671 million), and pyoderma (474 million, 
461 million to 489 million; table). These ten causes of 
incidence accounted for 4·4% (3·7–5·6) of all YLDs 
globally in 2016.
Overall global numbers of YLDs and trends 2006–2016
Globally, communicable, maternal, neonatal, and 
nutritional deficiency diseases accounted for 12·6% 
(95% UI 11·3–14·0) of YLDs in 2016 (101·5 million, 
72·3 million to 136·9 million), while NCDs accounted 
for 80·6% (78·2–82·5) or 648·6 million (481·3 million 
to 836·5 million) of YLDs and injuries accounted 
for 6·9% (5·6–8·4) or 55·4 million (37·2 million to 
78·7 million) of YLDs (table). In 2016, the 
age-standardised YLD rate for all causes was lowest in 
China at 9201 YLDs per 100 000 (95% UI 6862–11 943 
per 100 000); Yemen had the highest age-standardised 
YLD rate at 14 774 YLDs per 100 000 (11 018–19 228 
per 100 000). 
Figure 1C shows the change in global YLDs over time 
in three ways: mean percentage change in number of 
YLDs, mean percentage change in all-age rates, and 
mean percentage change in age-standardised YLD 
rates from 1990 to 2006 and from 2006 to 2016. The 
mean percentage change in the number of YLDs 
reflects the combined effects of population growth, 
population ageing, and epidemiological change. 
Population ageing and epidemiological change explain 
the mean percentage change in all-age rates. The mean 
percent change in age-standardised YLD rates reflects 
epidemiological change that is not due to ageing or 
population growth. All top-30 YLD causes increased in 
the number of YLDs between 1990 and 2016. Alcohol 
use disorder, major depressive disorder, and refraction 
and accommodation errors had the largest declines in 
age-standardised YLD rates from 2006 to 2016 but the 
change did not exceed 5%. Preterm birth complications 
had the largest increase in age-standardised YLD 
rates, 8·5%. Among the top 30 causes of YLDs, the 
difference between the change in all-age and age-
standardised rates between 2006 and 2016 was 10% or 
greater for age-related and other hearing loss, dia-
betes, chronic obstructive pulmonary disease (COPD), 
osteoarthritis, ischaemic stroke, edentulism, and 
ischaemic heart disease, indicating that these diseases 
largely affect the elderly and therefore become 
more prominent causes of YLDs in an ageing global 
population.
Low back pain and migraine were the leading causes 
of YLDs in high-income, high-middle-income, and 
middle-SDI quintile countries, but iron-deficiency 
anaemia was the leading cause in low-middle-SDI and 
low-SDI quintiles in 2016 (appendix 2, p 14). Low back 
pain, migraine, and age-related and other hearing loss 
were in the top five causes of YLDs in all SDI quintiles. 
Major depressive disorders appeared in the top five in 
all quintiles but the middle, where it was displaced by 
diabetes. Neck pain was a top five cause of YLDs in 
high-income, high-middle-income, and middle-SDI 
quintiles. In 2016, 28 of the 30 leading causes of age-
standardised YLD rates for high-SDI countries were 
NCDs, versus 23 out of 30 in low-SDI countries. 
Between 2006 and 2016, there were large drops in age-
standardised rates of YLDs for malaria, HIV/AIDS, 
onchocerciasis, and schistosomiasis in the low-SDI 
quintile.
Leading causes of YLDs by age-standardised rates
For men, the most common leading detailed cause of 
YLDs in 2016 was low back pain, resulting in the 
For the online results tool used 
for estimation see http://ghdx.
healthdata.org/gbd-2016
See Online for appendix 2
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(Figure 1 continues on next page)
Non–communicable InjuriesCommunicable, maternal, neonatal, and nutritional
Leading causes 1990 Leading causes 2006 Leading causes 2016Mean
% change in
number of
prevalent
cases
(1990–2006)
Mean
% change
in all-age
prevalence
rate
(1990–2006)
Mean %
change in age-
standardised
prevalence
rate
(1990–2006)
Mean
% change in
number of
prevalent
cases
(2006–16)
Mean
% change
in all-age
prevalence
rate
(2006–16)
Mean %
change in age-
standardised
prevalence
rate
(2006–16)
Mean
% change in
number of
incidence
cases
(1990–2006)
Mean
% change
in all-age
incidence
rate
(1990–2006)
Mean %
change in age-
standardised
incidence
rate
(1990–2006)
Mean
% change in
number of
incidence
cases
(2006–16)
Mean
% change
in all-age
incidence
rate
(2006–16)
Mean %
change in age-
standardised
incidence
rate
(2006–16)
1 Permanent caries 1 Permanent caries 23·5 –1·1 –4·7 1 Permanent caries 9·4 –2·7 –3·4
2 Latent tuberculosis infection 2 Tension headache 23·9 –0·8 –5·1 2 Latent tuberculosis infection 12·6 0·1 –1·7
3 Tension headache 3 Latent tuberculosis infection 22·3 –2·0 –5·9 3 Tension headache 10·5 –1·7 –2·3
4 Ascariasis 4 Iron-deficiency anaemia 23·3 –1·3 2·1 4 Age-related hearing loss 26·0 12·1 0·3
5 Age-related hearing loss 44·0 15·3 0·8 5 Iron-deficiency anaemia 9·5 –2·6 –0·9
6 Migraine 6 Migraine 30·6 4·6 –1·3 6 Migraine 13·3 0·8 –0·5
7 Age-related hearing loss 7 Ascariasis –22·6 –38·0 –38·1 7 G6PD trait 12·5 0·1 0·3
8 G6PD trait 8 G6PD trait 28·3 2·7 2·9 8 Genital herpes 5·5 –0·4
9 Refraction and accommodation 30·3 4·4 –4·4 9 Refraction and accommodation 17·3 4·3 –3·8
10 Refraction and accommodation 10 Genital herpes 42·6 14·2 2·8 10 Ascariasis –5·2 –15·6 –14·9
11 Trichuriasis 11 Periodontal diseases 45·4 16·4 1·3 11 Periodontal diseases 25·9 12·0 2·2
12 Acne vulgaris 24·6 –0·2 2·6 12 Fungal skin diseases 18·2 5·2 2·4
13 Hookworm disease 13 Fungal skin diseases 31·4 5·2 3·2 13 Acne vulgaris 5·1 –6·5 2·0
14 Acne vulgaris –8·0 –26·3 –22·1 14 Other skin diseases 25·5 11·6 4·4
15 Deciduous caries –8·8 –27·0 –27·7 15 Low back pain 18·0 5·0 –2·1
16 Periodontal diseases 16 Deciduous caries –0·6 –20·4 –3·3 16 Vitamin A deficiency –2·7 –13·4 –10·7
17 Fungal skin diseases –17·4 –33·8 –34·1 17 Deciduous caries 7·3 –4·6 0·7
18 Hepatitis B 18 Low back pain 24·8 –0·1 –10·3 18 Falls 27·6 13·5 4·7
19 Low back pain 19 Other skin diseases 42·1 13·8 5·5 19 Hepatitis B 10·9 –1·3 –2·2
20 Premenstrual syndrome 20·6 –2·4 20 Sickle cell trait 17·5 4·5 6·2
21 Other skin diseases 21 Premenstrual syndrome 31·8 5·5 –0·9 21 Premenstrual syndrome 9·3 –2·8 –2·1
22 Sickle cell trait 22 Sickle cell trait 34·6 7·7 9·5 22 Hookworm disease –10·8
23 Falls 23 Falls 27·5 2·1 –7·2 23 Trichuriasis 0·4 –10·7 –9·6
24 Asthma 24 Diabetes 74·3 39·6 21·9 24 Diabetes 22·0 8·5 –1·9
25 Dermatitis 25 Other musculoskeletal disorders 42·7 14·3 4·5 25 Asthma 17·5 4·5 3·5
26 G6PD deficiency 26 G6PD deficiency 32·6 6·2 7·5 26 Other musculoskeletal disorders 14·6 1·9 –3·6
27 Thalassaemia trait 27 Asthma 16·3 –6·8 –7·2 27 G6PD deficiency 13·1 0·6 1·8
28 Other musculoskeletal disorders 28 Dermatitis 21·2 –3·0 –0·6 28 Dermatitis 12·2 –0·2 0·7
29 Schistosomiasis 29 Schistosomiasis 32·4 6·0 –1·9 29 Edentulism 27·3 13·2 –0·9
30 Anxiety disorders 30 Thalassaemia trait 19·4 –4·4 –3·8 30 Osteoarthritis 30·0 15·6 0·9
31 Anxiety disorders33 Diabetes 32 Thalassaemia trait
33 Edentulism35 Edentulism 33 Anxiety disorders
34 Osteoarthritis37 Osteoarthritis 39 Schistosomiasis
A
B
1 Upper respiratory infections 1 Upper respiratory infections 16·6 –6·6 –4·5 1 Upper respiratory infections 9·3 –2·8 –1·4
2 Permanent caries 2 Permanent caries 25·2 0·2 –4·6 2 Permanent caries 11·3 –1·0 –2·7
3 Diarrhoeal diseases 3 Diarrhoeal diseases 11·8 –10·5 –6·6 3 Diarrhoeal diseases 8·1 –3·8 –3·5
4 Deciduous caries 4 Fungal skin diseases 32·4 6·0 2·3 4 Fungal skin diseases 19·3 6·1 1·7
5 Fungal skin diseases 5 Deciduous caries –0·3 –20·1 –3·3 5 Deciduous caries 8·2 –3·8 1·3
6 Tension headache 6 Tension headache 19·7 –4·1 –6·9 6 Tension headache 8·1 –3·9 –3·3
7 Vitamin A deficiency 7 Other sense organ diseases 26·9 1·6 1·3 7 Other sense organ diseases 15·9 3·1 0·8
8 Hepatitis A 8 Vitamin A deficiency –8·6 –26·8 –22·7 8 Other skin diseases 26·9 12·9 4·9
9 Other sense organ diseases 9 Other skin diseases 44·1 15·4 6·5 9 Vitamin A deficiency –6·0 –16·4 –13·6
10 Scabies 10 Scabies 9·2 –12·5 –8·6 10 Pyoderma 22·9 9·3 3·8
11 Otitis media 11 Otitis media 9·9 –12·0 1·6 11 Scabies 2·7 –8·6 –5·8
12 Other skin diseases 12 Acne vulgaris 24·7 –0·2 4·3 12 Otitis media 8·0 –3·9 1·4
13 Acne vulgaris 13 Pyoderma 35·5 8·5 2·7 13 Dermatitis 14·0 1·4 –0·3
14 Dermatitis 14 Dermatitis 30·7 4·7 –0·4 14 Acne vulgaris 4·5 –7·1 2·8
15 Pyoderma 15 Hepatitis A –34·0 –47·2 –35·4 15 Interstitial nephritis and UTI 14·3 1·6 1·1
16 Interstitial nephritis and UTI 16 Interstitial nephritis and UTI 27·6 2·1 0·1 16 Lower respiratory infections 22·3 8·8 6·1
17 Lower respiratory infections 17 Lower respiratory infections 12·9 –9·6 –4·9 17 Other musculoskeletal disorders 16·7 3·8 –3·1
18 Viral skin diseases 18 Other musculoskeletal disorders 42·9 14·4 3·5 18 Viral skin diseases 9·5 –2·6 –0·2
19 Other musculoskeletal disorders 19 Viral skin diseases 20·9 –3·2 –0·3 19 Major depression 11·1 –1·2 –5·1
20 Hepatitis B 20 Malaria 31·3 5·1 15·7 20 Low back pain 17·9 4·8 –2·2
21 Malaria 21 Major depression 31·5 5·3 –1·9 21 Malaria –12·7 –22·4 –18·3
22 Major depression 22 Low back pain 23·7 –0·9 –10·9 22 Falls 22·8 9·3 5·0
23 Low back pain 23 Falls 21·1 –3·1 –5·1 23 Gonorrhoea 21·2 7·8 9·6
24 Falls 24 Gonorrhoea 40·6 12·6 8·3 24 Premenstrual syndrome 6·5 –5·2 –2·3
25 Varicella 25 Hepatitis B –18·3 –34·6 –29·5 25 Hepatitis A –50·5 –56·0 –51·8
26 Premenstrual syndrome 26 Premenstrual syndrome 29·0 3·3 –1·3 26 Trichomoniasis 15·1 2·4 1·7
27 Gonorrhoea 27 Varicella 10·1 –11·9 –0·7 27 Varicella 8·4 –3·6 0·0
28 Trichomoniasis 28 Trichomoniasis 34·3 7·5 2·0 28 Urticaria 9·2 –2·8 –0·3
29 Urticaria 29 Urticaria 16·6 –6·7 –0·3 29 Hepatitis B –23·1 –31·6 –29·8
30 Complication abortions 30 Migraine 25·9 0·8 –0·1 30 Migraine 10·7 –1·6 0·0
33 Complication abortions31 Migraine 39 Complication abortions
14 Vitamin A deficiency
15 Hookworm disease
17 Trichuriasis
20 Hepatitis B
Global Health Metrics
www.thelancet.com   Vol 390   September 16, 2017 1231
highest age-standardised rates of YLDs in 133 of 
195 countries and territories, including every country 
in the high-income regions, central and eastern 
Europe, central Asia, Andean and Tropical Latin 
America, and eastern and central sub-Saharan Africa, 
as well as most countries in southeast Asia, north 
Africa and the Middle East, and western sub-Saharan 
Africa. Diabetes, the second most common leading 
cause of YLD rates for men, ranked first in 38 countries 
in Central Latin America, the Caribbean, Oceania, and 
North Africa and the Middle East. Iron-deficiency 
anaemia was the leading cause in India, Bhutan, 
Sudan, Yemen, and Mali. HIV/AIDS was the leading 
cause in South Africa, Lesotho, Swaziland, Namibia, 
and Botswana.
In 2016, low back pain was the leading cause of age-
standardised YLD rates for women in 104 of the 195 
countries and territories (figure 2B). It was the main 
cause of YLDs in almost all high-income, central Europe, 
eastern Europe, North Africa and the Middle East, and 
Andean and Tropical Latin American countries. Iron-
deficiency anaemia was the leading cause for women 
(35 countries), followed by migraine and diabetes 
in 24 and 17 countries, respectively. HIV/AIDS was the 
lead ing cause in southern sub-Saharan Africa, Zambia, 
and Malawi.
YLDs over time for countries classified into SDI quintiles 
in 2016
Trends for the number of YLDs (in millions) and age-
standardised YLD rates from 1990 to 2016 at Level 1 of the 
GBD cause hierarchy are shown by SDI quintile in 
figure 3. Generally, there was little or no change in the 
age-standardised rates of YLDs for NCDs, com municable, 
maternal, neonatal, and nutritional causes, or injuries, 
apart from a decrease in communicable, maternal, 
neonatal, and nutritional YLD rates be tween 2000 
and 2016 in the low-SDI quintile. The large increase in 
total YLD numbers for NCDs reflects the combined 
effect of population growth, ageing, and epidemiological 
Figure 1: Leading 30 Level 4 causes of global prevalence (A), incidence (B), and YLDs (C), for 1990, 2006, and 2016, with mean percentage change of counts, and all-age and age-standardised 
rates
Causes are connected by arrows between time periods; solid lines are increases and dashed lines are decreases. For the time period 1990–2006 and for 2006–16, three measures of change are 
shown: percentage change of counts, percentage change in the all-age rate, and percentage change in the age-standardised rate. Statistically significant changes are shown in bold. Solid lines are 
increases in rank and dashed lines are decreases in rank. YLDs=years lived with disability. G6PD=glucose-6-phosphate dehydrogenase deficiency. UTI=urinary tract infection. COPD=chronic 
obstructive pulmonary disease. 
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1 Low back pain 1 Low back pain 24·8 0·0 –10·3 1 Low back pain 18·0 5·0 –2·0
2 Migraine 2 Migraine 32·3 5·9 –0·4 2 Migraine 14·3 1·6 0·1
3 Iron-deficiency anaemia 3 Iron-deficiency anemia 20·0 –3·9 1·8 3 Age-related hearing loss 22·3 8·8 –1·7
4 Major depression 4 Major depression 30·9 4·8 –2·2 4 Iron-deficiency anaemia 7·5 –4·4 –1·8
5 Age-related hearing loss 5 Age-related hearing loss 40·0 12·1 –0·2 5 Major depression 11·2 –1·1 –4·9
6 Anxiety disorders 6 Other musculoskeletal disorders 42·6 14·2 4·6 6 Neck pain 21·9 8·4 0·1
7 Other musculoskeletal disorders 7 Neck pain 41·2 13·1 –0·9 7 Other musculoskeletal disorders 14·4 1·7 –3·5
8 Neck pain 8 Anxiety disorders 30·6 4·6 –0·1 8 Diabetes 23·6 10·0 –1·2
9 Diabetes 9 Diabetes 72·9 38·4 20·2 9 Anxiety disorders 13·1 0·6 –0·7
10 Acne vulgaris 10 Acne vulgaris 24·7 –0·2 2·7 10 Falls 26·7 12·7 3·4
11 Falls 11 Falls 25·1 0·2 –9·2 11 COPD 28·8 14·5 1·4
12 Refraction and accommodation 12 Refraction and accommodation 28·1 2·6 –4·6 12 Osteoarthritis 31·5 16·9 2·4
13 Asthma 13 COPD 38·5 10·9 –2·9 13 Acne vulgaris 5·1 –6·5 2·1
14 COPD 14 Osteoarthritis 55·8 24·8 6·2 14 Refraction and accommodation 14·9 2·2 –4·9
15 Schizophrenia 15 Schizophrenia 36·0 8·9 –0·4 15 Schizophrenia 16·7 3·8 –0·9
16 Dermatitis 16 Asthma 16·1 –7·1 –7·0 16 Asthma 17·2 4·2 3·6
17 Osteoarthritis 17 Dermatitis 19·2 –4·6 –0·3 17 Ischaemic stroke 35·2 20·3 3·7
18 Opioid use disorders 18 Opioid use disorders 24·6 –0·2 –4·6 18 Dermatitis 11·6 –0·7 1·1
19 Alcohol use disorders 19 Alcohol use disorders 31·4 5·2 –1·2 19 Opioid use disorders 18·0 4·9 2·7
20 Other mental and substance 20 Other mental and substance 36·1 9·0 0·0 20 Other mental and substance 17·8 4·8 0·1
21 Diarrhoeal diseases 21 Ischaemic stroke 44·1 15·4 –1·8 21 Dysthymia 20·5 7·2 1·0
22 Dysthymia 22 Dysthymia 37·9 10·4 0·4 22 Alcohol use disorders 9·7 –2·4 –4·8
23 Ischaemic stroke 23 Bipolar disorder 32·7 6·3 0·1 23 Bipolar disorder 14·9 2·2 0·8
24 Epilepsy 24 Neonatal preterm birth 34·2 7·4 11·9 24 Edentulism 27·2 13·2 –0·9
25 Bipolar disorder 25 Diarrhoeal diseases 9·8 –12·1 –7·3 25 Neonatal preterm birth 18·4 5·3 8·5
26 Neonatal preterm birth 26 Epilepsy 17·5 –5·9 –4·7 26 Epilepsy 8·8 –3·3 –2·6
27 Conduct disorder 27 Edentulism 42·4 14·0 –2·3 27 Diarrhoeal diseases 7·5 –4·4 –3·6
28 Tension headache 28 Tension headache 32·7 6·2 –0·7 28 Tension headache 15·4 2·6 0·4
29 Edentulism 29 Conduct disorder 14·7 –8·1 –0·1 29 Ischaemic heart disease 29·3 15·0 0·5
30 Upper respiratory infections 30 Viral skin diseases 19·4 –4·4 –0·3 30 Other sense organ diseases 23·8 10·1 0·9
31 Upper respiratory infections31 Viral skin diseases 32 Conduct disorder
32 Ischaemic heart disease33 Ischaemic heart disease 33 Viral skin diseases
33 Other sense organ diseases34 Other sense organ diseases 34 Upper respiratory infections
 Communicable, maternal, 
 neonatal, and nutritional
 Non–communicable
 Injuries
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Figure 2: Leading Level 4 causes of age-standardised YLD rates by country for males (A) and females (B) in 2016
ATG=Antigua and Barbuda. COPD=chronic obstructive pulmonary disease. FSM=Federated States of Micronesia. LCA=Saint Lucia. Marshall Isl=Marshall Islands. Solomon Isl=Solomon Islands. TLS=Timor-
Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines. YLDs=years lived with disability.
Persian Gulf
A
B
Caribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern 
Mediterranean
Malta
Singapore Balkan Peninsula Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
Persian GulfCaribbean LCA
Dominica
ATG
TTO
Grenada
VCT
TLS
Maldives
Barbados
Seychelles
Mauritius
Comoros
West Africa Eastern 
Mediterranean
Singapore
Malta
Balkan Peninsula Tonga
Samoa
FSM
Fiji
Solomon Isl
Marshall Isl
Vanuatu
Kiribati
HIV/AIDS other
Onchocerciasis
Iron-deficiency anaemia
Ischaemic stroke
COPD
Opioid use disorders
Diabetes
Low back pain
Neck pain
Other musculoskeletal
Age-related hearing loss
Conflict & terror
HIV/AIDS other
Onchocerciasis
Iron-deficency anaemia
Migraine
Major depressive disorder
Diabetes
Low back pain
Neck pain
Other musculoskeletal
Falls
Global Health Metrics
www.thelancet.com   Vol 390   September 16, 2017 1233
change. NCDs contributed the most YLDs at each SDI 
quintile, followed by communicable, maternal, neonatal, 
and nutritional causes and injuries, with exceptions for 
high and high-middle quintiles, where injuries 
contributed more YLDs than com municable, maternal, 
neonatal, and nutritional causes in 2016. This was 
particularly the case at the highest level of SDI, where 
YLDs from communicable, mat ernal, neonatal, and 
nutritional causes and injuries represented only a small 
fraction of overall YLDs.
YLD pattern by age and sex
Between 1990 and 2016 the number of YLDs for 
21 Level 2 causes increased, particularly in the 40–69 
year age range (figure 4). In childhood, other NCDs 
(skin diseases being the largest contributor in this 
category), nutritional deficiencies, infectious diseases, 
and mental and sub stance use disorders were the main 
causes of YLDs. After childhood, NCDs were the 
dominant source of YLDs. Mental and substance use 
disorders were the largest contributors to disability in 
young adults, while at older ages, other NCDs (with 
hearing loss and vision loss being the largest con-
tributors to this category), musculo skeletal dis orders, 
and cardiovascular diseases were the most important 
causes. YLDs from injuries were largest between ages 20 
and 69 years.
YLD rates were higher in males than in females at ages 
under 10 years and between ages 75 and 94 years 
(figure 5). At all other ages, all-cause YLD rates were 
higher in females. Boys had higher YLD rates for mental 
disorders (particularly conduct disorder and autism), 
while girls had higher YLD rates for other non-
communicable diseases (most of this difference is 
explained by higher YLD rates from dermatitis). At ages 
over 10 years, musculoskeletal disorders contributed 
most to higher YLD rates in females. The next two cause 
groups with higher YLD rates in females were neuro-
logical disorders (particularly migraine and, at older 
ages, Alzheimer’s disease and other dementias) and 
nutritional deficiencies (mostly iron-deficiency anaemia). 
The sex differences in mental and substance use 
disorders were small, with slightly elevated rates in 
younger males, and somewhat higher rates in older 
Figure 3: Trends of age-standardised YLD rates per 100 000 and total YLDs from 1990 to 2016, by GBD Level 1 causes, by SDI quintile
SDI=Socio-demographic Index. YLDs=years lived with disability. Shaded areas show 95% uncertainty intervals.
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females. The small overall sex difference masks much 
higher YLD rates from depressive disorder and anxiety in 
females and higher YLD rates from injuries, substance 
use disorders, and autism spectrum disorders in males. 
Adult males older than 55 years had higher YLD rates 
from diabetes, urogenital, blood, and endocrine disorders 
(diabetes and benign prostatic hyperplasia being the 
main drivers of differences), injuries, chronic respiratory 
diseases, and cancers.
Rates of YLDs and change in rates of YLDs by cause
Figure 6 shows the annualised rates of change in age-
standardised YLD rates between 2006 and 2016, with 
Level 3 causes against age-standardised YLD rates 
presented on a log-scale from right to left. 15 causes 
significantly increased by more than 1%: six cancers 
(brain and nervous system, liver, non-Hodgkin 
lymphoma, testicular, thyroid, and other neoplasms), 
dengue, gastritis and duodenitis, leishmaniasis, neonatal 
encephalopathy due to birth asphyxia and trauma, 
neonatal sepsis and other neonatal infections, other 
chronic respiratory diseases, other neurological 
disorders, peptic ulcer disease, and Zika virus disease. Of 
31 causes with declines of greater than 1·0% per year, 
25 were communicable, maternal, neonatal, and 
nutritional causes and five were NCD causes. Road 
injuries was the only cause out of 30 causes with age-
standardised rates of YLDs greater than 100 per 
100 000 that significantly increased by more than 0·5% 
annually. There were no large causes with a greater than 
0·5% decrease in age-standardised YLD rates.
Leading causes of YLDs and deviations from expected 
levels based on SDI
Age-standardised YLD rates for the top ten most detailed 
causes are plotted by region and year against SDI in the 
supplementary results (appendix 2, p 4). The black solid 
line represents the expected value based on SDI. Two of 
the top ten causes, iron-deficiency anaemia and age-
related and other hearing loss show a large decline in 
expected values with increasing SDI, while the regional 
estimates are relatively close to the expected line. The 
interpretation is that much of the variation in YLD rates 
for these two causes is linked to SDI. The expected lines 
for the other top ten conditions show a less clear pattern 
with SDI while regional estimates are dispersed widely 
around the line. These graphs show that most of the 
variation in YLD rates for these leading causes of YLDs 
depends on factors other than socio demographic 
development, unlike the much clearer relation ship 
between SDI and rates of YLLs for the leading causes 
of death.18
Low back pain and migraine ranked in the top ten of 
YLDs in all 195 countries and territories in 2016. Adult-
onset hearing loss was in the top ten in 193 countries and 
territories. Major depressive disorder ranked in the top ten 
in all but four countries. Anxiety disorders, iron-deficiency 
anaemia, neck pain, diabetes, and other musculoskeletal 
disorders ranked in the top ten of more than half of the 
countries and territories (figure 7).
Apart from showing the top ten causes of YLDs by 
country, figure 7 also shows for each top ten cause the 
variation from expected values based on SDI. The cells in 
Figure 4: Global YLDs for 21 Level 2 causes by 23 GBD age groups for both sexes combined in 1990 and 2016
Composition of Level 2 causes of disability globally for males and females combined by age group showing difference in composition between 1990 and 2016. Number of total YLDs due to Level 2 
causes is indicated by height of bar; causes are colour coded to highlight the relative number of total YLDs due to a specific cause.YLDs=years lived with disability. 
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dark red have at least twice the expected values and those 
in dark blue at least 50% lower values. In the high-income 
super-region, the USA had much higher than expected 
YLDs from opioid dependence. YLDs due to Alzheimer’s 
disease and other dementia were more than double what 
was expected in Italy and Japan. Greece had much higher 
than expected rates of COPD. YLDs from other 
musculoskeletal disorders were more than twice the 
expected values in Australia, Canada, Chile, Greenland, 
and the USA. Many eastern and central European 
countries had much higher than expected YLDs from falls, 
alcohol use disorders, and ischaemic stroke. Four coun-
tries in central Asia had more than twice the expected rates 
of iron-deficiency anaemia. In Latin America, YLDs from 
diabetes were more than twice the expected rate in 
Barbados, Jamaica, Mexico, Puerto Rico, Saint Vincent 
and the Grenadines, Trinidad and Tobago, and the Virgin 
Islands. Venezuela had less than half the expected rate of 
YLDs from low back pain but more than double the 
expected rate of YLDs from diarrhoea. Haiti had higher 
than expected YLDs from asthma. YLDs from iron-
deficiency anaemia were more than double the expected 
rate in five Caribbean nations. China had more than twice 
the expected YLD rate of ischaemic stroke, while North 
Korea had more than double the expected YLD rate for 
neck pain. In the southeast Asia region, YLD rates of iron-
deficiency anaemia were more than twice the expected 
values in Maldives and Mauritius. Mauritius also had 
more than twice the expected YLD rates for diabetes and 
COPD. Thailand and the Seychelles had more than twice 
the expected rate of COPD. Timor-Leste was the only 
country in the region where lymphatic filariasis and long-
term disability from conflict ranked among the top ten 
causes of YLDs. Diabetes ranked highly in all island 
nations of Oceania with much higher YLDs than expected 
based on SDI. In North Africa and the Middle East, more 
than twice the expected YLD rates from opioid dependence 
were found in Afghanistan, Bahrain, Iran, Iraq, Jordan, 
Kuwait, Lebanon, Libya, Palestine, Oman, Qatar, and the 
United Arab Emirates. Afghanistan and Bahrain had more 
than twice the expected YLD rates of diabetes. Long-term 
disability from injuries sustained during conflict ranked 
in the top ten for Afghanistan, Lebanon, Syria, and Iraq.
Iron-deficiency anaemia was much higher than expected 
in India and Bhutan. India had considerably higher than 
expected YLDs from COPD. Bangladesh was the only 
country in 2016 with YLDs from the residual category of 
other congenital anomalies in the top ten. Bhutan had 
more than double the expected YLDs from diarrhoea. 
HIV/AIDS was the leading cause of YLDs in southern sub-
Saharan Africa. Malaria ranked in the top ten for YLDs in 
14 sub-Saharan African countries. Three neglected tropical 
diseases, schistosomiasis, lymphatic filariasis, and oncho-
cerciasis, ranked in the top ten of YLDs in six, three, and 
seven sub-Saharan African countries, respectively. In 
Madagascar, protein-energy malnutrition ranked in the 
top ten. Epilepsy was a top ten cause of YLDs in Senegal 
and São Tomé and Príncipe. Much lower than expected 
Figure 5: Sex difference in global YLD rates per 100 000 for 21 Level 2 causes by age, 2016
YLDs=years lived with disability.
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Figure 6: Relationship of global age-standardised YLD rates per 100 000 in 2016 and the annualised rate of change in age-standardised YLD rates for each Level 3 cause, 2006-2016
For both sexes combined. Age-standardized YLD rates are represented on a logarithmic scale on the x-axis. Causes for which the annualised rate of change is not significant are listed in italics. Level 3 
causes related to shocks (forces of nature, conflict and terrorism, and executions and police conflict) are excluded. Not shown in figure (YLD, ARC): Diphtheria: (0.0003, -0.09), Measles: (0.3, -0.1), 
Afr Tryp: (0.03, -0.1), Echino: (1, -0.06), LF: (15.8, -0.06), Dengue: (13.2, 0.05), Rabies: (0.0009, -0.08), Ebola: (0.002, 0.3), Zika: (0.06, 0.6), GWD: (0.00001, -0.6). A Fib=Atrial fibrillation and flutter. 
ADHD=Attention-deficit/hyperactivity disorder. AGN=Acute glomerulonephritis. ALS=Motor neuron disease. ASD=Autistic spectrum disorders. Afr Tryp=African trypanosomiasis. Alcohol=Alcohol use 
disorders. Alzheimer’s=Alzheimer’s disease and other dementias. Animal=Animal contact. Anxiety=Anxiety disorders. Appendicit=Appendicitis. Asthma=Asthma. Back + neck=Low back and neck pain. 
Bipolar=Bipolar disorder. Bladder C=Bladder cancer. Brain C=Brain and nervous system cancer. Breast C=Breast cancer. CKD=Chronic kidney disease. CMP=Cardiomyopathy and myocarditis.
COPD=Chronic obstructive pulmonary disease. Cervix C=Cervical cancer. Chagas=Chagas disease. Cirr Alc=Cirrhosis and other chronic liver diseases due to alcohol use. Cirr HepB=Cirrhosis and other 
chronic liver diseases due to hepatitis B. Cirr HepC=Cirrhosis and other chronic liver diseases due to hepatitis C. Colorect C=Colon and rectum cancer. Comp Abort=Maternal abortion, miscarriage, 
and ectopic pregnancy. Conduct=Conduct disorder. Congenital=Congenital birth defects. Cysticer=Cysticercosis. Dengue=Dengue. Depression=Depressive disorders. Diabetes=Diabetes mellitus. 
Diarrhoea=Diarrhoeal diseases. Diphtheria=Diphtheria. Drown=Drowning. Drugs=Drug use disorders. Eating=Eating disorders. Ebola=Ebola virus disease. Echino=Cystic echinococcosis. 
Encepha=Encephalitis. Endocar=Endocarditis. Endocrine=Endocrine, metabolic, blood, and immune disorders. Epilepsy=Epilepsy. F Body=Foreign body. FB Trema=Food-borne trematodiases. 
Falls=Falls. Fire=Fire, heat, and hot substances. GWD=Guinea worm disease. Gall Bile=Gallbladder and biliary diseases. Gallblad C=Gallbladder and biliary tract cancer. Gastritis=Gastritis and duodenitis. 
Gout=Gout. Gyne=Gynaecological diseases. HIV=HIV/AIDS. HTN HD=Hypertensive heart disease. Haemog=Haemoglobinopathies and haemolytic anaemias. Heat + cold=Environmental heat and cold 
exposure. Hep=Hepatitis. Hernia=Inguinal, femoral, and abdominal hernia. Hodgkin’s=Hodgkin’s lymphoma. IBD=Inflammatory bowel disease. ID=Idiopathic developmental intellectual disability. 
IHD=Ischaemic heart disease. ILD=Interstitial lung disease and pulmonary sarcoidosis. Ileus=Paralytic ileus and intestinal obstruction. Intest Inf=Intestinal infectious diseases. Iodine=Iodine deficiency. 
Iron=Iron-deficiency anaemia. Kidney C=Kidney cancer. LF=Lymphatic filariasis. LRI=Lower respiratory infections. Larynx C=Larynx cancer. Leish=Leishmaniasis. Leprosy=Leprosy. 
Leukaemia=Leukaemia. Lip Oral C=Lip and oral cavity cancer. Liver C=Liver cancer. Lung C=Tracheal, bronchus, and lung cancer. Lymphoma=Non-Hodgkin lymphoma. MS=Multiple sclerosis. 
Malaria=Malaria. Mat HTN=Maternal hypertensive disorders. Mat Haem=Maternal haemorrhage. Mat Sepsis=Maternal sepsis and other maternal infections. Measles=Measles. Mech=Exposure to 
mechanical forces. Med Treat=Adverse effects of medical treatment. Melanoma=Malignant skin melanoma. Meningitis=Meningitis. Mesothel=Mesothelioma. Migraine=Migraine. Myeloma=Multiple 
myeloma. NN Enceph=Neonatal encephalopathy due to birth asphyxia and trauma. NN Haemol=Haemolytic disease and other neonatal jaundice. NN Preterm=Neonatal preterm birth complications. 
NN Sepsis=Neonatal sepsis and other neonatal infections. Naesoph C=Naesopharynx cancer. Nematode=Intestinal nematode infections. Obst Labour=Maternal obstructed labour and uterine rupture. 
Oesophag C=Oesophageal cancer. Oncho=Onchocerciasis. Oral=Oral disorders. Osteoarth=Osteoarthritis. Oth Cardio=Other cardiovascular and circulatory diseases. Oth Cirr=Cirrhosis and other chronic 
liver diseases due to other causes. Oth Digest=Other digestive diseases. Oth Inf=Other infectious diseases. Oth MSK=Other musculoskeletal disorders. Oth Mat=Other maternal disorders. Oth 
Ment=Other mental and substance use disorders. Oth NN=Other neonatal disorders. Oth NTD=Other neglected tropical diseases. Oth Neopla=Other neoplasms. Oth Neuro=Other neurological 
disorders. Oth Nutr=Other nutritional deficiencies. Oth Phar C=Other pharynx cancer. Oth Resp=Other chronic respiratory diseases. Oth Trans=Other transport injuries. Oth Unint=Other unintentional 
injuries. Otitis=Otitis media. Ovary C=Ovarian cancer. PAD=Peripheral artery disease. PEM=Protein-energy malnutrition. PUD=Peptic ulcer disease. Pancreas C=Pancreatic cancer. 
Pancreatit=Pancreatitis. Parkinson’s=Parkinson’s disease. Pneumocon=Pneumoconiosis. Poison=Poisonings. Prostate C=Prostate cancer. RHD=Rheumatic heart disease. Rabies=Rabies. Rheu 
Arth=Rheumatoid arthritis. Road Inj=Road injuries. STD=Sexually transmitted diseases excluding HIV. Schisto=Schistosomiasis. Schiz=Schizophrenia. Self Harm=Self-harm. Sense=Sense organ 
diseases. Skin=Skin and subcutaneous diseases. Skin C=Non-melanoma skin cancer. Stomach C=Stomach cancer. Stroke=Cerebrovascular disease. TB=Tuberculosis. Tens Head=Tension-type headache. 
Testis C=Testicular cancer. Tetanus=Tetanus. Thyroid C=Thyroid cancer.  Trachoma=Trachoma. URI=Upper respiratory infections. Urinary=Urinary diseases and male infertility. Uterus C=Uterine cancer. 
Varicella=Varicella and herpes zoster. Vasc Intest=Vascular intestinal disorders. Violence=Interpersonal violence. Vit A=Vitamin A deficiency. Whooping=Whooping cough. Yellow Fev=Yellow fever. 
YLD=years lived with disability. Zika=Zika virus disease.
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(1·22)
Migraine
(1·11)
Neck pain
(1·14)
Hearing
(1·22)
MDD
(1·21)
Falls
(1·19)
Anxiety
(1·10)
Diabetes
(0·82)
Edentul
(1·37)
Oth MSK
(1·10)
Cyprus
Back pain
(1·16)
Migraine
(1·20)
Neck pain
(1·18)
Anxiety
(1·19)
Hearing
(0·99)
Diabetes
(1·03)
Falls
(0·89)
MDD
(0·82)
Oth MSK
(1·11)
Acne
(1·09)
Denmark
Back pain
(1·85)
Migraine
(1·06)
Neck pain
(1·21)
Falls
(0·94)
Anxiety
(1·14)
MDD
(0·77)
Hearing
(0·76)
Oth MSK
(1·39)
Diabetes
(0·79)
Osteoarth
(0·92)
Finland
Back pain
(1·18)
Migraine
(1·09)
Neck pain
(1·39)
Falls
(1·33)
MDD
(1·30)
Diabetes
(1·13)
Hearing
(0·96)
Anxiety
(0·84)
Edentul
(1·40)
Isch Stroke
(1·23)
France
Back pain
(1·17)
Migraine
(1·10)
MDD
(1·29)
Hearing
(1·28)
Falls
(1·18)
Anxiety
(1·25)
Neck pain
(0·96)
Oth MSK
(1·22)
Diabetes
(0·71)
Oth Cardio
(1·93)
Germany
Back pain
(1·39)
Hearing
(1·62)
Migraine
(1·04)
Neck pain
(1·32)
Anxiety
(1·27)
Falls
(1·08)
MDD
(1·04)
Diabetes
(1·15)
Oth MSK
(1·23)
Osteoarth
(1·09)
Greece
Back pain
(1·25)
Migraine
(1·12)
Hearing
(1·51)
Neck pain
(1·43)
MDD
(1·21)
Anxiety
(1·20)
Falls
(1·01)
COPD
(2·89)
Edentul
(1·59)
Oth MSK
(1·08)
Iceland
Back pain
(1·13)
Migraine
(1·10)
Neck pain
(1·07)
Anxiety
(1·13)
Hearing
(0·92)
Falls
(0·79)
MDD
(0·82)
Oth MSK
(1·12)
Asthma
(1·26)
Dermatitis
(1·55)
Ireland
Back pain
(0·98)
Migraine
(1·12)
Neck pain
(1·12)
MDD
(1·11)
Anxiety
(1·22)
Falls
(0·97)
Hearing
(0·88)
Asthma
(1·59)
Diabetes
(0·75)
Oth MSK
(1·12)
Israel
Back pain
(1·11)
Migraine
(1·07)
Neck pain
(1·09)
MDD
(0·95)
Hearing
(0·90)
Diabetes
(0·88)
Anxiety
(0·81)
Falls
(0·88)
Oth MSK
(0·92)
Acne
(1·06)
Italy
Back pain
(1·25)
Migraine
(1·22)
Hearing
(1·57)
Neck pain
(1·37)
Falls
(1·14)
Anxiety
(1·21)
MDD
(1·01)
Diabetes
(1·07)
Oth MSK
(1·36)
Alzheimer’s
(2·49)
Luxembourg
Back pain
(1·08)
Migraine
(1·23)
Neck pain
(1·13)
Anxiety
(1·15)
MDD
(0·95)
Falls
(0·86)
Hearing
(0·90)
Diabetes
(0·84)
Asthma
(1·54)
Oth Cardio
(1·80)
Malta
Back pain
(1·27)
Migraine
(1·15)
Neck pain
(1·30)
Hearing
(1·21)
Falls
(1·11)
Anxiety
(1·17)
MDD
(0·83)
Diabetes
(0·99)
Oth MSK
(1·15)
Asthma
(1·29)
Netherlands
Back pain
(1·21)
Migraine
(1·14)
Neck pain
(1·36)
Anxiety
(1·49)
Hearing
(1·07)
MDD
(1·02)
Diabetes
(1·07)
Falls
(0·76)
Edentul
(1·66)
Oth MSK
(1·45)
Norway
Back pain
(0·92)
Migraine
(0·99)
Neck pain
(1·21)
Anxiety
(1·35)
MDD
(1·01)
Falls
(0·94)
Hearing
(0·83)
Diabetes
(0·92)
Oth MSK
(1·00)
Asthma
(1·14)
Portugal
Back pain
(1·43)
Migraine
(1·19)
MDD
(1·40)
Neck pain
(1·50)
Hearing
(1·44)
Anxiety
(1·20)
Diabetes
(1·22)
Falls
(1·11)
Oth MSK
(1·22)
Asthma
(1·48)
Spain
Back pain
(1·06)
Migraine
(1·21)
Hearing
(1·39)
Neck pain
(1·15)
MDD
(1·04)
Anxiety
(1·21)
Falls
(1·04)
Diabetes
(0·86)
Oth MSK
(1·18)
Osteoarth
(1·05)
Sweden
Back pain
(1·23)
Neck pain
(1·79)
MDD
(1·39)
Migraine
(0·91)
Diabetes
(1·29)
Hearing
(1·04)
Falls
(1·09)
Anxiety
(1·12)
Dermatitis
(1·80)
Oth MSK
(1·18)
Switzerland
Back pain
(1·32)
Migraine
(1·14)
Neck pain
(1·23)
Hearing
(1·05)
Falls
(1·04)
Anxiety
(1·16)
MDD
(0·98)
Oth MSK
(1·29)
Edentul
(1·40)
Diabetes
(0·68)
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UK
Back pain
(1·36)
Migraine
(1·05)
Hearing
(1·21)
MDD
(1·13)
Neck pain
(1·06)
Falls
(1·00)
Anxiety
(1·05)
Oth MSK
(1·40)
Asthma
(1·47)
Diabetes
(0·74)
England
Back pain
(1·41)
Migraine
(1·03)
Hearing
(1·24)
MDD
(1·12)
Neck pain
(1·00)
Falls
(0·99)
Anxiety
(1·03)
Oth MSK
(1·41)
Asthma
(1·44)
Diabetes
(0·74)
Northern Ireland
Back pain
(1·08)
Migraine
(1·12)
Neck pain
(1·19)
Anxiety
(1·35)
MDD
(1·12)
Hearing
(1·06)
Falls
(0·95)
Asthma
(1·55)
Oth MSK
(1·22)
Diabetes
(0·73)
Scotland
Back pain
(1·16)
Migraine
(1·18)
Neck pain
(1·50)
MDD
(1·19)
Falls
(1·17)
Hearing
(1·02)
Anxiety
(1·12)
Oth MSK
(1·35)
Asthma
(1·65)
Diabetes
(0·75)
Wales
Back pain
(1·15)
Migraine
(1·11)
Neck pain
(1·47)
MDD
(1·11)
Hearing
(1·03)
Falls
(1·09)
Anxiety
(1·08)
Oth MSK
(1·36)
Asthma
(1·55)
Diabetes
(0·82)
Southern Latin America
Back pain
(1·26)
Migraine
(0·98)
Oth MSK
(2·05)
Anxiety
(1·38)
MDD
(0·98)
Hearing
(0·95)
Neck pain
(0·91)
Diabetes
(0·88)
Acne
(1·13)
Asthma
(1·20)
Argen
na
Back pain
(1·22)
Migraine
(0·97)
Oth MSK
(1·97)
Anxiety
(1·37)
MDD
(0·93)
Hearing
(0·93)
Neck pain
(0·90)
Diabetes
(0·93)
Acne
(1·15)
Asthma
(1·18)
Chile
Back pain
(1·34)
Migraine
(0·98)
Oth MSK
(2·26)
Anxiety
(1·39)
MDD
(1·12)
Hearing
(0·96)
Neck pain
(0·93)
Diabetes
(0·77)
Acne
(1·12)
Asthma
(1·22)
Uruguay
Back pain
(1·24)
Migraine
(0·99)
Oth MSK
(1·95)
Anxiety
(1·40)
Hearing
(1·19)
MDD
(0·96)
Neck pain
(1·03)
Diabetes
(0·82)
Asthma
(1·28)
Acne
(1·06)
Central Europe, eastern Europe, and central Asia Back pain
(1·21)
Falls
(1·99)
Migraine
(1·06)
Hearing
(1·34)
MDD
(0·97)
Neck pain
(0·90)
Isch stroke
(2·09)
Diabetes
(0·89)
Osteoarth
(1·36)
Alcohol
(2·13)
Eastern Europe
Back pain
(1·23)
Falls
(1·89)
Migraine
(1·10)
Hearing
(1·41)
MDD
(1·17)
Isch stroke
(2·57)
Alcohol
(2·99)
Neck pain
(0·93)
Osteoarth
(1·47)
Diabetes
(0·90)
Belarus
Back pain
(1·34)
Falls
(2·37)
Migraine
(1·15)
Hearing
(1·43)
MDD
(1·28)
Neck pain
(0·95)
Alcohol
(2·73)
Isch stroke
(2·25)
Osteoarth
(1·48)
Diabetes
(0·82)
Estonia
Back pain
(1·26)
Falls
(1·80)
Migraine
(1·10)
Hearing
(1·54)
MDD
(1·26)
Diabetes
(1·16)
Neck pain
(0·90)
Isch stroke
(1·88)
Osteoarth
(1·47)
Alcohol
(2·62)
Latvia
Back pain
(1·36)
Falls
(1·98)
Migraine
(1·12)
Hearing
(1·63)
Isch stroke
(2·93)
MDD
(1·09)
Diabetes
(1·17)
Neck pain
(0·95)
Osteoarth
(1·60)
Alcohol
(2·36)
Lithuania
Back pain
(1·32)
Falls
(2·18)
Hearing
(1·56)
Migraine
(1·06)
MDD
(1·41)
Isch stroke
(2·24)
Neck pain
(0·92)
Osteoarth
(1·50)
Alcohol
(2·36)
Diabetes
(0·81)
Moldova
Back pain
(1·66)
Migraine
(1·26)
Hearing
(1·44)
Falls
(2·28)
MDD
(1·04)
Neck pain
(1·08)
Alcohol
(2·47)
Diabetes
(1·02)
Osteoarth
(1·64)
Anxiety
(0·70)
Russia
Back pain
(1·12)
Falls
(1·87)
Migraine
(1·07)
Hearing
(1·36)
MDD
(1·10)
Isch stroke
(2·67)
Alcohol
(3·11)
Neck pain
(0·92)
Osteoarth
(1·46)
Diabetes
(0·92)
Ukraine
Back pain
(1·61)
Migraine
(1·18)
Falls
(2·06)
Hearing
(1·62)
MDD
(1·38)
Neck pain
(1·02)
Isch stroke
(2·75)
Alcohol
(2·78)
Osteoarth
(1·59)
Diabetes
(0·88)
Central Europe
Back pain
(1·36)
Falls
(2·43)
Migraine
(1·07)
Hearing
(1·46)
Neck pain
(0·93)
Diabetes
(1·05)
MDD
(0·78)
Osteoarth
(1·43)
Isch stroke
(1·72)
Anxiety
(0·80)
Albania
Back pain
(1·70)
Migraine
(1·11)
Falls
(2·44)
Hearing
(1·47)
Neck pain
(1·00)
Anxiety
(0·83)
MDD
(0·64)
Osteoarth
(1·42)
Refraction
(1·34)
Diabetes
(0·62)
Bosnia and 
Herzegovina
Back pain
(1·66)
Falls
(2·78)
Migraine
(1·14)
Hearing
(1·72)
Diabetes
(1·51)
Neck pain
(1·13)
Isch stroke
(2·90)
Osteoarth
(1·72)
MDD
(0·75)
Anxiety
(0·84)
Bulgaria
Back pain
(1·36)
Falls
(2·31)
Hearing
(1·64)
Migraine
(1·07)
Neck pain
(0·99)
Diabetes
(1·20)
Isch stroke
(2·32)
MDD
(0·85)
Osteoarth
(1·57)
Anxiety
(0·83)
Croa
a
Back pain
(1·43)
Falls
(2·33)
Hearing
(1·58)
Migraine
(1·06)
MDD
(0·99)
Neck pain
(0·95)
Diabetes
(1·11)
Osteoarth
(1·50)
Isch stroke
(1·85)
Anxiety
(0·81)
Czech Republic
Back pain
(1·38)
Falls
(2·72)
Migraine
(1·05)
Hearing
(1·39)
Diabetes
(1·41)
Neck pain
(0·90)
MDD
(0·89)
Osteoarth
(1·36)
Isch stroke
(1·47)
Anxiety
(0·79)
Hungary
Back pain
(1·50)
Falls
(2·69)
Migraine
(1·08)
Hearing
(1·49)
Diabetes
(1·21)
MDD
(0·97)
Neck pain
(0·95)
Isch stroke
(1·98)
Osteoarth
(1·49)
Anxiety
(0·81)
Macedonia
Back pain
(1·27)
Falls
(2·09)
Migraine
(1·10)
Hearing
(1·34)
Diabetes
(1·32)
Neck pain
(0·94)
MDD
(0·70)
Anxiety
(0·81)
Isch stroke
(2·01)
Osteoarth
(1·38)
Montenegro
Back pain
(1·34)
Falls
(2·00)
Migraine
(1·06)
Hearing
(1·37)
Diabetes
(1·11)
Neck pain
(0·90)
MDD
(0·79)
Osteoarth
(1·35)
Anxiety
(0·79)
IHD
(1·92)
Poland
Back pain
(1·23)
Falls
(2·36)
Migraine
(1·08)
Hearing
(1·39)
Neck pain
(0·89)
Diabetes
(0·96)
Refraction
(2·55)
Osteoarth
(1·34)
Anxiety
(0·80)
MDD
(0·66)
Romania
Back pain
(1·41)
Falls
(2·49)
Migraine
(1·07)
Hearing
(1·53)
Neck pain
(0·96)
Isch stroke
(2·08)
Osteoarth
(1·53)
MDD
(0·79)
Anxiety
(0·79)
Iron
(3·14)
Serbia
Back pain
(1·61)
Falls
(2·53)
Migraine
(1·09)
Hearing
(1·66)
Diabetes
(1·44)
Neck pain
(1·04)
MDD
(0·88)
Isch stroke
(2·78)
Osteoarth
(1·77)
Anxiety
(0·82)
Slovakia
Back pain
(1·37)
Falls
(2·20)
Migraine
(1·08)
Hearing
(1·24)
Neck pain
(0·87)
MDD
(0·73)
Diabetes
(0·86)
Osteoarth
(1·25)
Anxiety
(0·80)
Isch stroke
(1·36)
Slovenia
Back pain
(1·44)
Falls
(3·36)
Migraine
(1·05)
Hearing
(1·39)
MDD
(1·02)
Neck pain
(0·92)
Diabetes
(1·01)
Osteoarth
(1·43)
Anxiety
(0·79)
Edentul
(1·60)
Central Asia
Back pain
(0·95)
Migraine
(0·98)
Iron
(3·02)
Hearing
(0·97)
Falls
(1·43)
MDD
(0·76)
Neck pain
(0·79)
Anxiety
(0·59)
Diabetes
(0·62)
Refraction
(1·21)
Armenia
Back pain
(1·20)
Migraine
(1·04)
Hearing
(1·39)
Falls
(1·53)
Neck pain
(0·96)
Diabetes
(1·11)
MDD
(0·78)
Osteoarth
(1·42)
Refraction
(1·62)
Anxiety
(0·63)
Azerbaijan
Back pain
(0·97)
Migraine
(1·01)
Hearing
(1·00)
Falls
(1·27)
Iron
(2·35)
Neck pain
(0·84)
MDD
(0·62)
Diabetes
(0·81)
Alcohol
(1·67)
Anxiety
(0·60)
Georgia
Back pain
(1·18)
Migraine
(1·01)
Hearing
(1·55)
Falls
(1·67)
Neck pain
(1·01)
MDD
(0·81)
Diabetes
(0·96)
Iron
(1·93)
Osteoarth
(1·46)
Refraction
(1·73)
Kazakhstan
Back pain
(0·98)
Migraine
(0·96)
Iron
(3·80)
Falls
(1·53)
MDD
(0·98)
Hearing
(0·98)
Neck pain
(0·80)
Alcohol
(1·61)
Anxiety
(0·58)
Osteoarth
(1·02)
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Kyrgyzstan
Back pain
(1.11)
Iron
(2.00)
Migraine
(1.04)
Hearing
(0.97)
MDD
(0.82)
Falls
(1.76)
Neck pain
(0.86)
Alcohol
(1.66)
Anxiety
(0.61)
Refraction
(1.05)
Mongolia
Back pain
(0.98)
Migraine
(1.02)
Falls
(2.13)
Iron
(2.00)
MDD
(1.00)
Hearing
(0.88)
Alcohol
(2.26)
Neck pain
(0.82)
Anxiety
(0.59)
Refraction
(1.04)
Tajikistan
Back pain
(1.11)
Migraine
(1.07)
Iron
(1.06)
Hearing
(0.89)
Falls
(2.07)
MDD
(0.60)
Neck pain
(0.85)
Anxiety
(0.63)
Acne
(0.87)
Refraction
(0.95)
Turkmenistan
Back pain
(0.81)
Migraine
(0.97)
Falls
(1.10)
Hearing
(0.80)
MDD
(0.67)
Iron
(1.95)
Neck pain
(0.70)
Anxiety
(0.58)
Diabetes
(0.55)
Acne
(0.79)
Uzbekistan
Back pain
(0.96)
Iron
(3.49)
Migraine
(1.00)
Hearing
(0.92)
Falls
(1.49)
MDD
(0.72)
Neck pain
(0.78)
Anxiety
(0.60)
Diabetes
(0.63)
Refraction
(1.10)
Latin America and Caribbean 
Back pain
(0.81)
Migraine
(1.00)
Diabetes
(1.29)
Hearing
(1.02)
MDD
(0.92)
Anxiety
(1.03)
Oth MSK
(1.15)
Neck pain
(0.89)
Falls
(0.94)
Iron
(1.09)
Central Latin America
Migraine
(0.97)
Diabetes
(1.71)
Back pain
(0.60)
Hearing
(0.97)
MDD
(0.79)
Oth MSK
(1.05)
Neck pain
(0.84)
Anxiety
(0.68)
Acne
(0.86)
Refraction
(1.13)
Colombia
Migraine
(1.04)
Back pain
(0.74)
Hearing
(1.06)
Oth MSK
(1.14)
Diabetes
(1.02)
Neck pain
(0.92)
MDD
(0.68)
Asthma
(1.25)
Anxiety
(0.62)
Refraction
(1.28)
Costa Rica
Migraine
(1.02)
Back pain
(0.64)
Hearing
(1.17)
MDD
(0.95)
Diabetes
(1.16)
Oth MSK
(1.22)
Neck pain
(0.93)
Anxiety
(0.70)
Asthma
(1.30)
Osteoarth
(1.11)
El Salvador
Migraine
(1.05)
Back pain
(0.73)
Diabetes
(1.45)
Hearing
(1.14)
MDD
(1.00)
Neck pain
(0.93)
Oth MSK
(0.89)
Anxiety
(0.72)
Asthma
(1.44)
Refraction
(1.27)
Guatemala
Migraine
(1.03)
Back pain
(0.83)
Diabetes
(1.40)
MDD
(1.00)
Hearing
(0.90)
Oth MSK
(0.77)
Anxiety
(0.72)
Neck pain
(0.85)
Acne
(1.01)
Alcohol
(1.68)
Honduras
Migraine
(1.06)
Back pain
(0.76)
Hearing
(0.93)
Diabetes
(1.15)
MDD
(0.83)
Oth MSK
(1.01)
Neck pain
(0.90)
Anxiety
(0.73)
Asthma
(1.42)
Acne
(0.98)
Mexico
Diabetes
(2.20)
Migraine
(0.94)
Back pain
(0.54)
Hearing
(0.95)
MDD
(0.77)
Oth MSK
(1.09)
Neck pain
(0.81)
Anxiety
(0.69)
Acne
(0.86)
Refraction
(1.13)
Nicaragua
Migraine
(1.08)
Back pain
(0.75)
MDD
(0.92)
Hearing
(0.98)
Diabetes
(1.16)
Oth MSK
(0.93)
Neck pain
(0.94)
Anxiety
(0.74)
Refraction
(1.05)
Acne
(0.91)
Panama
Migraine
(0.95)
Back pain
(0.56)
Diabetes
(1.29)
Hearing
(1.00)
MDD
(0.79)
Neck pain
(0.80)
Oth MSK
(1.05)
Anxiety
(0.66)
Asthma
(1.22)
Refraction
(1.30)
Venezuela
Migraine
(0.95)
Diabetes
(1.38)
Back pain
(0.49)
MDD
(0.85)
Hearing
(0.92)
Oth MSK
(1.07)
Neck pain
(0.78)
Anxiety
(0.67)
Acne
(0.84)
Diarrhea
(2.32)
Andean Latin America
Back pain
(0.95)
Migraine
(0.96)
Hearing
(1.04)
Anxiety
(0.98)
MDD
(0.73)
Neck pain
(0.85)
Diabetes
(0.86)
Iron
(1.06)
Dermatitis
(1.57)
Oth MSK
(0.72)
Bolivia
Back pain
(1.05)
Migraine
(0.95)
Iron
(1.49)
Hearing
(1.03)
MDD
(0.93)
Anxiety
(0.99)
Diabetes
(0.99)
Neck pain
(0.86)
Dermatitis
(1.72)
Asthma
(1.38)
Ecuador
Back pain
(0.91)
Migraine
(0.91)
MDD
(0.89)
Hearing
(0.96)
Anxiety
(0.98)
Diabetes
(0.96)
Neck pain
(0.84)
Oth MSK
(0.76)
Dermatitis
(1.41)
Falls
(0.95)
Peru
Back pain
(0.94)
Migraine
(0.99)
Hearing
(1.07)
Anxiety
(0.98)
Iron
(1.30)
Neck pain
(0.86)
MDD
(0.59)
Diabetes
(0.77)
Dermatitis
(1.59)
Asthma
(1.27)
Caribbean
Migraine
(1.00)
Back pain
(0.68)
Diabetes
(1.50)
MDD
(1.10)
Hearing
(1.17)
Iron
(1.93)
Oth MSK
(1.29)
Anxiety
(0.99)
Neck pain
(0.93)
Asthma
(1.59)
Antigua and Barbuda
Migraine
(1.00)
Diabetes
(1.72)
Back pain
(0.56)
Iron
(3.37)
Oth MSK
(1.53)
Hearing
(0.96)
MDD
(0.84)
Anxiety
(1.00)
Neck pain
(0.84)
Asthma
(1.43)
The Bahamas
Migraine
(0.99)
Diabetes
(1.70)
Back pain
(0.57)
Oth MSK
(1.90)
Hearing
(0.99)
MDD
(0.86)
Anxiety
(0.98)
Neck pain
(0.84)
Iron
(2.24)
Asthma
(1.37)
Barbados
Diabetes
(2.43)
Migraine
(0.99)
Back pain
(0.63)
Hearing
(1.38)
Oth MSK
(2.12)
MDD
(0.99)
Neck pain
(0.96)
Anxiety
(0.99)
Osteoarth
(1.44)
Iron
(2.42)
Belize
Migraine
(1.00)
Iron
(1.36)
Diabetes
(1.34)
Back pain
(0.64)
Oth MSK
(1.14)
MDD
(0.90)
Anxiety
(1.00)
Asthma
(1.94)
Hearing
(0.79)
Neck pain
(0.79)
Bermuda
Migraine
(0.96)
Back pain
(0.50)
Oth MSK
(1.75)
Diabetes
(1.27)
MDD
(0.92)
Hearing
(0.89)
Anxiety
(0.96)
Neck pain
(0.76)
Asthma
(1.44)
Iron
(2.55)
Cuba
Migraine
(1.02)
MDD
(1.37)
Hearing
(1.46)
Back pain
(0.60)
Diabetes
(1.38)
Oth MSK
(1.61)
Neck pain
(1.04)
Anxiety
(1.00)
Falls
(1.10)
Iron
(2.21)
Dominica
Diabetes
(1.96)
Migraine
(0.99)
Back pain
(0.62)
Hearing
(1.11)
Oth MSK
(1.47)
MDD
(0.88)
Anxiety
(0.98)
Neck pain
(0.87)
Asthma
(1.53)
Osteoarth
(1.07)
Dominican Republic
Migraine
(0.98)
Back pain
(0.69)
MDD
(0.91)
Hearing
(0.98)
Anxiety
(0.98)
Oth MSK
(1.10)
Diabetes
(0.93)
Neck pain
(0.82)
Asthma
(1.43)
Iron
(1.06)
Grenada
Diabetes
(1.89)
Migraine
(0.99)
Oth MSK
(1.78)
Back pain
(0.62)
MDD
(0.92)
Hearing
(1.00)
Anxiety
(0.99)
Asthma
(1.82)
Neck pain
(0.81)
Iron
(1.25)
Guyana
MDD
(1.64)
Diabetes
(1.99)
Migraine
(1.02)
Iron
(1.75)
Back pain
(0.68)
Hearing
(0.95)
Anxiety
(1.02)
Oth MSK
(1.08)
Asthma
(1.84)
Neck pain
(0.92)
Haiti
Iron
(1.13)
Migraine
(1.16)
Back pain
(0.88)
MDD
(1.08)
Hearing
(1.01)
Oth MSK
(1.25)
Diabetes
(1.46)
Asthma
(2.24)
Anxiety
(1.15)
Neck pain
(1.11)
Jamaica
Diabetes
(2.25)
Migraine
(0.99)
Back pain
(0.67)
Oth MSK
(1.55)
Hearing
(1.15)
Iron
(1.99)
MDD
(0.86)
Anxiety
(0.98)
Neck pain
(0.87)
Asthma
(1.62)
Puerto Rico
Diabetes
(2.30)
Migraine
(0.97)
Back pain
(0.52)
Hearing
(1.17)
MDD
(1.04)
Oth MSK
(1.72)
Neck pain
(0.81)
Anxiety
(0.97)
Osteoarth
(1.26)
Falls
(0.67)
Saint Lucia
Migraine
(1.04)
Diabetes
(1.83)
Back pain
(0.69)
Hearing
(1.18)
Oth MSK
(1.54)
MDD
(1.02)
Anxiety
(1.03)
Neck pain
(0.94)
Iron
(1.62)
Asthma
(1.58)
Saint Vincent and the Grenadines 
Diabetes
(2.40)
Migraine
(1.04)
Back pain
(0.71)
MDD
(1.02)
Hearing
(1.11)
Oth MSK
(1.31)
Anxiety
(1.02)
Iron
(1.41)
Neck pain
(0.96)
Asthma
(1.68)
Suriname
MDD
(1.55)
Diabetes
(1.89)
Migraine
(1.00)
Back pain
(0.64)
Oth MSK
(1.39)
Hearing
(1.01)
Anxiety
(0.99)
Iron
(1.57)
Neck pain
(0.89)
Asthma
(1.70)
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(Figure 7 continues on next page)
Trinidad and Tobago
Diabetes
(3·63)
Migraine
(1·03)
Back pain
(0·61)
MDD
(1·24)
Oth MSK
(1·94)
Hearing
(1·09)
Anxiety
(1·01)
Neck pain
(0·92)
Asthma
(1·46)
Iron
(1·85)
Virgin Islands
Diabetes
(2·24)
Back pain
(0·56)
Migraine
(0·94)
Hearing
(1·29)
Oth MSK
(2·00)
MDD
(1·06)
Neck pain
(0·88)
Anxiety
(0·95)
Osteoarth
(1·44)
Asthma
(1·34)
Tropical Latin America
Back pain
(1·06)
Migraine
(1·05)
Anxiety
(1·48)
MDD
(1·09)
Oth MSK
(1·35)
Hearing
(1·04)
Neck pain
(0·96)
Iron
(1·57)
Falls
(1·22)
Diabetes
(0·87)
Brazil
Back pain
(1·05)
Migraine
(1·04)
Anxiety
(1·47)
MDD
(1·09)
Oth MSK
(1·37)
Hearing
(1·04)
Neck pain
(0·96)
Iron
(1·60)
Falls
(1·21)
Diabetes
(0·86)
Paraguay
Back pain
(0·96)
Migraine
(1·01)
Anxiety
(1·44)
Diabetes
(1·20)
MDD
(0·88)
Hearing
(0·91)
Iron
(1·41)
Oth MSK
(0·94)
Neck pain
(0·79)
Asthma
(1·41)
Southeast Asia, east Asia, and Oceania Back pain
(0·71)
Neck pain
(1·28)
Hearing
(1·19)
Migraine
(0·69)
Diabetes
(1·13)
MDD
(0·78)
Oth MSK
(1·11)
Anxiety
(0·78)
Schiz
(1·62)
Isch stroke
(2·08)
East Asia
Neck pain
(1·50)
Back pain
(0·61)
Hearing
(1·21)
Migraine
(0·64)
MDD
(0·89)
Diabetes
(1·12)
Oth MSK
(1·08)
Isch stroke
(2·57)
Schiz
(1·89)
Osteoarth
(1·46)
China
Neck pain
(1·52)
Back pain
(0·62)
Hearing
(1·20)
MDD
(0·90)
Migraine
(0·64)
Diabetes
(1·11)
Isch stroke
(2·65)
Oth MSK
(1·06)
Schiz
(1·90)
Osteoarth
(1·48)
North Korea
Hearing
(1·61)
Back pain
(1·05)
Neck pain
(2·04)
Iron
(0·81)
Migraine
(0·79)
Oth MSK
(1·07)
Diabetes
(1·20)
MDD
(0·80)
Anxiety
(0·93)
Schiz
(1·91)
Taiwan (Province of China)
Diabetes
(1·90)
Back pain
(0·65)
Hearing
(1·34)
Neck pain
(1·22)
Migraine
(0·67)
Oth MSK
(1·60)
Osteoarth
(1·30)
Anxiety
(0·83)
Schiz
(1·87)
MDD
(0·67)
Southeast Asia
Back pain
(1·00)
Migraine
(0·82)
Hearing
(1·18)
Diabetes
(1·15)
Oth MSK
(1·15)
Anxiety
(0·83)
Neck pain
(0·84)
Iron
(1·15)
COPD
(1·68)
MDD
(0·57)
Cambodia
Back pain
(1·44)
Iron
(1·28)
Migraine
(0·92)
Hearing
(1·14)
Anxiety
(0·92)
Oth MSK
(0·91)
MDD
(0·72)
Diabetes
(0·90)
Acne
(1·08)
Neck pain
(0·93)
Indonesia
Back pain
(0·98)
Migraine
(0·81)
Hearing
(1·06)
Iron
(1·57)
Diabetes
(1·15)
Oth MSK
(1·01)
Anxiety
(0·84)
Neck pain
(0·84)
COPD
(1·50)
Acne
(0·98)
Laos
Back pain
(1·12)
Iron
(0·97)
Migraine
(0·84)
Hearing
(1·03)
Anxiety
(0·98)
Oth MSK
(0·92)
Diabetes
(0·99)
Acne
(1·14)
MDD
(0·58)
Neck pain
(0·80)
Malaysia
Back pain
(0·69)
Diabetes
(1·39)
Migraine
(0·75)
MDD
(0·82)
Anxiety
(0·90)
Oth MSK
(1·09)
Neck pain
(0·67)
Acne
(1·10)
Hearing
(0·61)
Iron
(1·79)
Maldives
Iron
(2·90)
Back pain
(0·83)
Migraine
(0·81)
Hearing
(1·01)
Oth MSK
(1·06)
Anxiety
(0·83)
MDD
(0·70)
Diabetes
(0·84)
Neck pain
(0·72)
Acne
(1·05)
Mauritius
Diabetes
(2·46)
Back pain
(0·92)
Iron
(3·78)
Hearing
(1·33)
Migraine
(0·80)
Oth MSK
(1·47)
MDD
(0·89)
Neck pain
(0·84)
Anxiety
(0·86)
COPD
(2·37)
Myanmar
Back pain
(1·09)
Hearing
(1·63)
Migraine
(0·89)
Iron
(1·06)
Oth MSK
(1·08)
Diabetes
(1·05)
Anxiety
(0·91)
Neck pain
(0·94)
COPD
(1·56)
Acne
(1·02)
Philippines
Back pain
(1·00)
Migraine
(0·78)
Diabetes
(1·29)
Hearing
(1·03)
Oth MSK
(1·09)
Anxiety
(0·82)
COPD
(1·68)
Acne
(1·06)
Neck pain
(0·74)
Asthma
(1·36)
Sri Lanka
Back pain
(0·97)
Hearing
(1·52)
Diabetes
(1·78)
Migraine
(0·80)
MDD
(0·80)
Anxiety
(0·86)
Neck pain
(0·86)
Oth MSK
(0·98)
COPD
(1·90)
Iron
(1·28)
Seychelles
Back pain
(0·86)
Migraine
(0·78)
Hearing
(1·17)
Diabetes
(1·33)
Oth MSK
(1·17)
Anxiety
(0·83)
Neck pain
(0·81)
COPD
(2·10)
MDD
(0·58)
Osteoarth
(1·22)
Thailand
Back pain
(1·03)
Oth MSK
(2·19)
Hearing
(1·61)
Migraine
(0·86)
Neck pain
(0·96)
COPD
(2·58)
Diabetes
(1·05)
MDD
(0·76)
Anxiety
(0·90)
Osteoarth
(1·30)
Timor-Leste
Back pain
(0·96)
Iron
(0·84)
Migraine
(0·78)
Hearing
(1·07)
MDD
(0·72)
LF
(5934·58)
Anxiety
(0·83)
Acne
(1·13)
Conflict
(106·53)
Refraction
(1·07)
Vietnam
Back pain
(1·13)
Migraine
(0·88)
Hearing
(1·24)
Oth MSK
(1·12)
Diabetes
(0·98)
Neck pain
(0·93)
COPD
(1·74)
MDD
(0·65)
Anxiety
(0·69)
Acne
(0·90)
Oceania
Diabetes
(2·44)
Back pain
(1·12)
Iron
(1·01)
Hearing
(1·12)
Migraine
(0·79)
Asthma
(2·13)
Oth MSK
(1·01)
Hookworm
(5·31)
MDD
(0·77)
Anxiety
(0·89)
American Samoa
Diabetes
(2·89)
Back pain
(0·65)
Iron
(2·44)
Migraine
(0·63)
Oth MSK
(1·10)
Asthma
(1·60)
Hearing
(0·76)
Neck pain
(0·75)
Anxiety
(0·74)
Osteoarth
(1·21)
Federated States of Micronesia 
Diabetes
(2·49)
Back pain
(0·85)
Iron
(1·49)
Migraine
(0·70)
Hearing
(1·02)
Oth MSK
(0·95)
MDD
(0·73)
Asthma
(1·83)
Anxiety
(0·83)
Acne
(1·13)
Fiji
Diabetes
(4·40)
Back pain
(0·74)
Migraine
(0·68)
Hearing
(1·03)
Iron
(2·22)
Neck pain
(0·87)
Oth MSK
(1·12)
Asthma
(1·68)
MDD
(0·71)
Anxiety
(0·80)
Guam
Diabetes
(2·43)
Back pain
(0·63)
Hearing
(0·97)
Migraine
(0·63)
MDD
(0·81)
Oth MSK
(1·39)
Neck pain
(0·80)
Iron
(3·16)
Asthma
(1·47)
COPD
(2·47)
Kiribati
Diabetes
(3·99)
Iron
(1·01)
Back pain
(1·08)
Hearing
(1·17)
Migraine
(0·84)
Asthma
(2·16)
Oth MSK
(1·03)
MDD
(0·78)
Anxiety
(0·94)
Neck pain
(1·22)
Marshall Islands
Diabetes
(4·32)
Iron
(1·54)
Back pain
(0·87)
Migraine
(0·70)
Hearing
(0·95)
Oth MSK
(0·98)
Asthma
(1·82)
MDD
(0·68)
Anxiety
(0·81)
Neck pain
(0·90)
Northern Mariana Islands 
Diabetes
(1·62)
Back pain
(0·59)
Migraine
(0·70)
Iron
(2·98)
Oth MSK
(1·13)
Neck pain
(0·68)
MDD
(0·63)
Asthma
(1·39)
Anxiety
(0·74)
Hearing
(0·60)
Papua New Guinea
Iron
(0·82)
Back pain
(1·14)
Diabetes
(2·17)
Hearing
(1·09)
Migraine
(0·82)
Hookworm
(4·10)
Asthma
(2·11)
Oth MSK
(1·10)
MDD
(0·77)
Anxiety
(0·93)
Samoa
Diabetes
(2·41)
Back pain
(0·95)
Hearing
(1·13)
Migraine
(0·68)
Iron
(0·85)
Oth MSK
(0·88)
Anxiety
(0·82)
Asthma
(1·71)
Neck pain
(0·96)
MDD
(0·65)
Solomon Islands
Iron
(0·97)
Diabetes
(2·62)
Back pain
(1·03)
Hearing
(1·07)
Migraine
(0·78)
Oth MSK
(1·09)
Asthma
(2·00)
MDD
(0·74)
Anxiety
(0·90)
Neck pain
(1·08)
Tonga
Diabetes
(2·74)
Back pain
(0·93)
Iron
(1·46)
Hearing
(1·13)
Migraine
(0·68)
Asthma
(2·21)
Oth MSK
(0·91)
Anxiety
(0·82)
Neck pain
(0·92)
MDD
(0·59)
Vanuatu
Iron
(1·41)
Diabetes
(2·19)
Back pain
(1·06)
Hearing
(1·12)
Migraine
(0·77)
Oth MSK
(1·05)
Asthma
(1·99)
MDD
(0·73)
Anxiety
(0·87)
Neck pain
(1·09)
1 2 3 4 5 6 7 8 9 10
Global Health Metrics
www.thelancet.com   Vol 390   September 16, 2017 1241
North Africa and Middle East 
Back pain
(1 04)
Migraine
(1·15)
MDD
(1·26)
Diabetes
(1·46)
Anxiety
(1·19)
Iron
(1·66)
Oth MSK
(1·21)
Neck pain
(1·10)
Hearing
(0·89)
Opioids
(2·12)
North Africa and Middle East 
Back pain
(1·04)
Migraine
(1·15)
MDD
(1·26)
Diabetes
(1·46)
Anxiety
(1·19)
Iron
(1·66)
Oth MSK
(1·21)
Neck pain
(1·10)
Hearing
(0·89)
Opioids
(2·12)
Afghanistan
Migraine
(1·29)
Back pain
(1·05)
Conflict
(49·98)
MDD
(1·24)
Cut leish
(2640·81)
Anxiety
(1·46)
Diabetes
(2·21)
Iron
(0·35)
Hearing
(0·81)
Opioids
(3·52)
Algeria
Back pain
(1·04)
Migraine
(1·18)
Diabetes
(1·63)
MDD
(1·13)
Oth MSK
(1·39)
Anxiety
(1·20)
Neck pain
(1·18)
Hearing
(0·96)
Iron
(1·31)
Opioids
(1·89)
Bahrain
Diabetes
(2·38)
Back pain
(0·89)
Migraine
(1·19)
MDD
(1·34)
Oth MSK
(1·57)
Anxiety
(1·16)
Neck pain
(1·02)
Iron
(2·00)
Opioids
(2·45)
Hearing
(0·66)
Egypt
Back pain
(1·06)
Migraine
(1·16)
Diabetes
(1·75)
MDD
(0·97)
Oth MSK
(1·24)
Anxiety
(1·10)
Neck pain
(1·13)
Hearing
(0·89)
Iron
(1·04)
Asthma
(1·45)
Iran
Back pain
(0·90)
MDD
(1·78)
Migraine
(1·15)
Anxiety
(1·46)
Diabetes
(1·54)
Oth MSK
(1·62)
Neck pain
(1·04)
Opioids
(3·13)
Hearing
(0·82)
Osteoarth
(0·98)
Iraq
Migraine
(1·17)
Back pain
(1·06)
Iron
(0·82)
Diabetes
(1·89)
MDD
(1·11)
Conflict
(132·40)
Opioids
(3·74)
Anxiety
(1·20)
Neck pain
(1·19)
Hearing
(0·74)
Jordan
Migraine
(1·09)
Back pain
(0·82)
Diabetes
(1·46)
MDD
(1·03)
Anxiety
(1·14)
Oth MSK
(1·23)
Neck pain
(0·93)
Iron
(1·35)
Hearing
(0·73)
Opioids
(2·05)
Kuwait
Migraine
(1·20)
Back pain
(0·73)
MDD
(1·16)
Diabetes
(1·27)
Anxiety
(1·18)
Neck pain
(0·92)
Oth MSK
(1·50)
Opioids
(2·41)
Asthma
(1·08)
Hearing
(0·51)
Lebanon
Migraine
(1·15)
Back pain
(0·74)
MDD
(1·19)
Anxiety
(1·31)
Conflict
(3529·68)
Diabetes
(1·32)
Neck pain
(1·02)
Hearing
(0·98)
Asthma
(1·37)
Opioids
(2·09)
Libya
Back pain
(0·81)
Migraine
(1·13)
MDD
(1·17)
Diabetes
(1·46)
Anxiety
(1·17)
Neck pain
(0·95)
Oth MSK
(1·36)
Hearing
(0·74)
Opioids
(2·11)
Asthma
(1·05)
Morocco
Back pain
(1·44)
MDD
(2·14)
Migraine
(1·32)
Diabetes
(1·85)
Anxiety
(1·32)
Oth MSK
(1·34)
Neck pain
(1·45)
Hearing
(1·12)
Iron
(0·97)
Opioids
(1·89)
Palestine
Migraine
(1·19)
MDD
(1·46)
Back pain
(1·04)
Anxiety
(1·26)
Diabetes
(1·40)
Oth MSK
(1·00)
Iron
(0·43)
Hearing
(0·76)
Neck pain
(1·20)
Opioids
(2·34)
Oman
Back pain
(0·88)
Migraine
(1·15)
Diabetes
(1·75)
MDD
(1·12)
Anxiety
(1·13)
Oth MSK
(1·34)
Neck pain
(0·94)
Opioids
(2·50)
Iron
(1·17)
Acne
(0·79)
Qatar
Back pain
(0·82)
Migraine
(1·18)
Diabetes
(1·82)
MDD
(1·25)
Anxiety
(1·14)
Oth MSK
(1·46)
Opioids
(2·97)
Neck pain
(0·88)
Acne
(0·86)
Hearing
(0·47)
Saudi Arabia
Back pain
(0·80)
Migraine
(1·20)
MDD
(1·04)
Anxiety
(1·12)
Neck pain
(0·94)
Diabetes
(1·09)
Oth MSK
(1·39)
Iron
(3·04)
Hearing
(0·63)
Opioids
(1·95)
Sudan
Iron
(2·05)
Back pain
(1·28)
Migraine
(1·25)
MDD
(1·24)
Anxiety
(1·32)
Oth MSK
(1·09)
Neck pain
(1·23)
Hearing
(0·83)
Diabetes
(1·00)
Asthma
(1·68)
Syria
Migraine
(1·15)
Back pain
(0·97)
MDD
(1·08)
Anxiety
(1·22)
Neck pain
(1·05)
Iron
(1·13)
Conflict
(374·03)
Hearing
(0·83)
Diabetes
(0·97)
Oth MSK
(0·83)
Tunisia
Back pain
(1·13)
Migraine
(1·22)
Diabetes
(1·78)
MDD
(1·32)
Oth MSK
(1·64)
Neck pain
(1·35)
Anxiety
(1·25)
Hearing
(1·15)
Opioids
(1·95)
Osteoarth
(1·26)
Turkey
Back pain
(1·06)
Migraine
(1·12)
Diabetes
(1·46)
MDD
(1·08)
Oth MSK
(1·66)
Neck pain
(1·14)
Hearing
(1·02)
Anxiety
(1·02)
Osteoarth
(1·23)
Iron
(1·66)
United Arab Emirates
Back pain
(0·91)
Migraine
(1·14)
Diabetes
(1·73)
Oth MSK
(1·56)
MDD
(0·94)
Anxiety
(1·06)
Opioids
(3·11)
Neck pain
(0·95)
Hearing
(0·57)
Falls
(0·66)
Yemen
Iron
(2·73)
Migraine
(1·23)
Back pain
(1·10)
Hearing
(1·39)
MDD
(1·27)
Anxiety
(1·31)
Oth MSK
(1·09)
Neck pain
(1·21)
Diabetes
(0·94)
Acne
(1·03)
South Asia
Iron
(2·49)
Migraine
(1·25)
Back pain
(0·92)
Oth MSK
(1·56)
Hearing
(1·19)
MDD
(1·05)
COPD
(2·22)
Diabetes
(1·06)
Anxiety
(0·88)
Refraction
(1·16)
South Asia
Iron
(2·49)
Migraine
(1·25)
Back pain
(0·92)
Oth MSK
(1·56)
Hearing
(1·19)
MDD
(1·05)
COPD
(2·22)
Diabetes
(1·06)
Anxiety
(0·88)
Refraction
(1·16)
Bangladesh
Back pain
(1·35)
Migraine
(1·41)
Oth MSK
(1·80)
MDD
(1·34)
Hearing
(1·36)
Iron
(0·72)
Anxiety
(1·09)
Diabetes
(1·03)
Neck pain
(0·82)
Oth cong
(2·81)
Bhutan
Iron
(2·89)
Migraine
(1·27)
Back pain
(1·10)
Oth MSK
(1·41)
Hearing
(1·08)
MDD
(0·94)
Diarrhoea
(2·88)
Diabetes
(1·06)
Anxiety
(0·93)
COPD
(1·37)
India
Iron
(3·00)
Migraine
(1·24)
Oth MSK
(1·60)
Back pain
(0·85)
Hearing
(1·21)
COPD
(2·58)
MDD
(1·05)
Diabetes
(1·03)
Anxiety
(0·84)
Refraction
(1·28)
Nepal
Migraine
(1·50)
Back pain
(1·40)
Iron
(0·73)
Oth MSK
(1·58)
MDD
(1·04)
Hearing
(1·03)
Anxiety
(1·03)
COPD
(1·69)
Diabetes
(1·08)
Acne
(1·01)
Pakistan
Iron
(1·48)
Migraine
(1·23)
Back pain
(0·93)
Diabetes
(1·37)
Hearing
(1·00)
Oth MSK
(1·16)
MDD
(0·87)
Anxiety
(0·95)
COPD
(1·24)
Acne
(0·97)
Sub-Saharan Africa
Iron
(1·02)
Back pain
(1·04)
Migraine
(0·83)
MDD
(1·06)
Hearing
(0·93)
Anxiety
(0·86)
Oth HIV
(13·09)
Acne
(1·07)
Asthma
(1·34)
Dermatitis
(1·28)
Southern sub-Saharan Africa 
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(1·28)
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(1·05)
Neck pain
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(1·16)
Benin
Iron
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(0·76)
Anxiety
(0·80)
Acne
(1·07)
Malaria
(21·13)
Cape Verde
Iron
(1·71)
Back pain
(1·06)
MDD
(1·25)
Migraine
(0·89)
Hearing
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(1·03)
Acne
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(1·00)
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(42·25)
Côte d’Ivoire
Iron
(1·21)
Back pain
(1·17)
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(0·92)
MDD
(0·88)
Hearing
(0·81)
Anxiety
(0·83)
Oth HIV
(9·78)
Schisto
(203·91)
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(1·06)
Asthma
(1·23)
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Iron
(1·42)
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(0·99)
MDD
(1·12)
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(0·90)
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(116·98)
Hearing
(0·74)
Anxiety
(0·83)
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(1·06)
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(1·10)
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(0·97)
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(0·89)
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(0·80)
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(0·78)
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Neck pain
(0·84)
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(1·13)
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(0·95)
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(0·96)
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(0·88)
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Schisto
(60·46)
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(1·15)
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Iron
(1·19)
Back pain
(1·15)
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(0·96)
MDD
(1·01)
Hearing
(0·86)
Anxiety
(0·87)
Oth HIV
(6·31)
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(0·99)
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(1·01)
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(11·64)
Liberia
Oncho
(105·74)
Iron
(0·70)
Back pain
(1·08)
Migraine
(0·95)
MDD
(1·10)
Hearing
(0·85)
Anxiety
(0·87)
Acne
(1·03)
Schisto
(68·82)
Diarrhoea
(0·94)
Mali
Iron
(1·42)
Back pain
(0·83)
Migraine
(0·90)
Malaria
(1·37)
Hearing
(0·78)
MDD
(0·66)
Anxiety
(0·87)
Acne
(0·97)
LF
(4·51)
Neck pain
(0·93)
Mauritania
Iron
(1·43)
Back pain
(1·24)
Migraine
(0·92)
MDD
(0·81)
Hearing
(0·82)
Anxiety
(0·81)
Acne
(1·15)
Asthma
(1·39)
Neck pain
(0·88)
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(0·99)
Niger
Iron
(0·83)
Back pain
(0·92)
Migraine
(0·89)
MDD
(0·78)
Hearing
(0·82)
Malaria
(0·57)
Anxiety
(0·89)
Acne
(0·95)
Diarrhoea
(0·81)
Dermatitis
(0·91)
Nigeria
Iron
(1·40)
Back pain
(1·14)
Migraine
(0·85)
MDD
(1·06)
Hearing
(0·84)
Anxiety
(0·77)
Acne
(1·08)
Malaria
(50·95)
Asthma
(1·29)
Neck pain
(0·79)
São Tomé and Príncipe  
Iron
(0·88)
Back pain
(1·00)
Migraine
(0·90)
MDD
(0·82)
Hearing
(0·80)
Anxiety
(0·81)
LF
(338·74)
Acne
(1·07)
Epilepsy
(1·50)
Neck pain
(0·84)
Senegal
Iron
(1·21)
Back pain
(1·02)
Migraine
(0·94)
MDD
(0·87)
Hearing
(0·81)
Anxiety
(0·86)
Acne
(1·03)
Neck pain
(0·93)
Dermatitis
(1·08)
Epilepsy
(1·41)
Sierra Leone
Iron
(1·00)
Back pain
(1·10)
Migraine
(0·95)
MDD
(1·00)
Malaria
(4·04)
Oncho
(38·86)
Anxiety
(0·87)
Hearing
(0·66)
Acne
(1·02)
Neck pain
(0·95)
Togo
Iron
(0·91)
Back pain
(1·14)
Migraine
(0·95)
MDD
(1·02)
Hearing
(0·80)
Malaria
(9·35)
Anxiety
(0·85)
Acne
(1·05)
Neck pain
(0·93)
Asthma
(1·15)
Eastern sub-Saharan Africa 
Iron
(0·69)
Back pain
(0·94)
MDD
(1·06)
Migraine
(0·79)
Hearing
(0·93)
Anxiety
(0·93)
Acne
(1·11)
Oth HIV
(8·86)
Asthma
(1·33)
Dermatitis
(1·28)
Burundi
Back pain
(0·88)
MDD
(0·95)
Migraine
(0·81)
Hearing
(0·93)
Iron
(0·29)
Anxiety
(0·95)
Dermatitis
(1·19)
Asthma
(1·17)
Diarrhoea
(0·95)
Acne
(0·96)
Comoros
Back pain
(1·04)
Iron
(0·78)
Migraine
(0·83)
Hearing
(0·95)
MDD
(0·90)
Anxiety
(0·93)
Asthma
(1·71)
Acne
(1·11)
Dermatitis
(1·44)
Diarrhoea
(1·05)
Djibouti
Iron
(0·88)
Back pain
(0·99)
MDD
(1·07)
Migraine
(0·84)
Hearing
(1·04)
Anxiety
(0·92)
Diabetes
(0·95)
Acne
(1·02)
Dermatitis
(1·35)
Asthma
(1·25)
Eritrea
Iron
(0·85)
Back pain
(0·79)
MDD
(1·05)
Migraine
(0·82)
Hearing
(0·88)
Anxiety
(0·94)
Acne
(1·07)
Dermatitis
(1·41)
Asthma
(1·29)
Diarrhoea
(0·90)
Ethiopia
Back pain
(0·94)
Iron
(0·47)
MDD
(1·08)
Migraine
(0·80)
Hearing
(0·99)
Anxiety
(1·01)
Acne
(1·10)
Dermatitis
(1·14)
Asthma
(1·04)
Diarrhoea
(0·82)
Kenya
Back pain
(0·95)
Iron
(0·79)
Hearing
(1·07)
Migraine
(0·75)
MDD
(0·90)
Oth HIV
(24·61)
Anxiety
(0·84)
Acne
(1·24)
Dermatitis
(1·53)
Diarrhoea
(1·24)
Madagascar
Back pain
(1·05)
Iron
(0·61)
Hearing
(1·16)
MDD
(1·05)
Migraine
(0·83)
Anxiety
(0·95)
Asthma
(1·57)
Acne
(1·08)
Dermatitis
(1·35)
PEM
(2·90)
Malawi
Iron
(0·84)
Oth HIV
(18·39)
Back pain
(0·93)
Migraine
(0·78)
Hearing
(0·92)
MDD
(0·84)
Anxiety
(0·92)
Dermatitis
(1·37)
Acne
(1·06)
Asthma
(1·24)
Mozambique
Iron
(0·98)
Oth HIV
(12·47)
Back pain
(0·92)
MDD
(1·02)
Migraine
(0·79)
Hearing
(0·96)
Anxiety
(0·95)
Asthma
(1·32)
Acne
(1·04)
Malaria
(1·35)
Rwanda
Back pain
(1·00)
MDD
(1·12)
Migraine
(0·83)
Hearing
(0·92)
Conflict
(52·75)
Asthma
(1·80)
Anxiety
(0·94)
Iron
(0·29)
Acne
(1·07)
Alcohol
(1·76)
Somalia
Iron
(0·73)
Back pain
(0·83)
MDD
(1·02)
Migraine
(0·83)
Hearing
(0·97)
Anxiety
(1·01)
Acne
(1·08)
Dermatitis
(1·17)
Asthma
(1·18)
Diarrhoea
(0·83)
South Sudan
Iron
(0·74)
Oncho
(8·92)
Back pain
(0·78)
MDD
(0·90)
Migraine
(0·79)
Hearing
(0·94)
Diarrhoea
(1·18)
Iodine
(1·51)
Anxiety
(0·96)
Dermatitis
(1·07)
Tanzania
Iron
(0·91)
Back pain
(0·84)
MDD
(0·98)
Migraine
(0·74)
Hearing
(0·79)
Asthma
(1·76)
Anxiety
(0·88)
Oth HIV
(12·46)
Acne
(1·15)
Dermatitis
(1·17)
Uganda
Iron
(0·76)
MDD
(1·37)
Back pain
(0·84)
Migraine
(0·75)
Oth HIV
(11·50)
Anxiety
(0·85)
Acne
(1·10)
Hearing
(0·63)
Asthma
(1·35)
Dermatitis
(1·26)
Zambia
Oth HIV
(35·96)
Iron
(0·81)
Back pain
(0·82)
Migraine
(0·80)
MDD
(0·92)
Hearing
(0·82)
Anxiety
(0·85)
Acne
(1·11)
Dermatitis
(1·55)
Diarrhoea
(1·00)
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YLDs from iron-deficiency anaemia were found in 
Burundi, Ethiopia, and Rwanda. The long-term conse-
quences of injuries sustained during the 1994 genocide in 
Rwanda still ranked among the top ten causes of YLDs 
in 2016.
Discussion
Summary of main findings
The largest Level 2 disease groups contributing to non-
fatal burden in 2016 were mental and substance use 
disorders (18·7%, 95% UI 15·9–21·0), other NCDs 
(18·6%, 15·6–22·5), and musculoskeletal disorders 
(17·1%, 15·3–18·9), together covering more than half of 
global YLDs. Despite mostly stagnant age-standardised 
rates, the number of YLDs from NCDs grew rapidly in all 
the SDI quintiles, due to population growth and ageing. 
Across all causes of YLDs, age-standardised rates of 
YLDs decreased between 1990 and 2016 by 2·7% (95% UI 
2·3–3·1) in contrast to the 39·1% (37·8–40·2) decrease 
in YLL rates over the same time period.18 Thus, the 
relative contribution of YLD to the overall burden of 
disease in DALYs increased from 21·7% (17·2–26·6) 
in 1990 to 33·5% (27·4–39·7) in 2016.
Age-standardised YLD rates for all conditions combined 
were 10·4% (9·0–11·8) higher in women compared to 
men. Iron-deficiency anaemia, migraine, Alzheimer’s 
disease and other dementias, major depressive disorder, 
anxiety, and all musculoskeletal disorders apart from gout 
were the main conditions contributing to higher YLD 
rates in women. Men had higher age-standardised rates of 
substance use disorders, diabetes, cardiovascular diseases, 
cancers, and all injuries apart from sexual violence.
Globally, we found much less geographical variation 
in disability than has been documented for premature 
mortality. In 2016, there was a less than two-fold 
difference in age-standardised YLD rates for all causes 
between the location with the lowest (China, 9201 YLDs 
per 100 000, 95% UI 6862–11 943 per 100 000) and 
highest rates (Yemen, 14 774 YLDs per 100 000, 
11 018–19 228 per 100 000). By contrast, there was a 
greater than tenfold range in age-standardised rates of 
YLLs between countries in GBD 2016.18 Two other 
countries with mainly Chinese populations, Singapore 
and Taiwan (Province of China), were ranked second 
and fourth lowest in terms of age-standardised YLD 
rates, respectively. The low YLD rates in China were 
largely determined by much lower prevalence of 
headaches, musculoskeletal disorders (in particular low 
back pain), major depressive disorder, iron-deficiency 
anaemia, falls, and anxiety. Low rates of reporting 
chronic pain and low prevalence of depressive disorder 
and anxiety in China and among Chinese immigrants 
elsewhere have frequently been reported, but these 
findings may partly be explained by standard diag-
nostic tools inadequately detecting cases in the Chinese 
and cultural differences in the perception and com-
munication of pain.25–29
Trends across the causes of YLD were also different. 
For example, age-standardised YLD rates for NCDs were 
stagnant between 1990 and 2016 and showed little 
variation by SDI quintile; YLD rates for communicable, 
maternal, neonatal, and nutritional diseases were highest 
at lower SDI quintiles but with a steady drop; and injury 
YLD rates showed modest declines since 1990. Over the 
same period, age-standardised YLL rates of 
communicable, maternal, neonatal, and nutritional 
diseases rapidly declined, particularly in lower SDI 
quintiles. The decline in YLL rates from NCDs was 
Figure 7: Leading ten causes of YLDs with ratio of observed YLDs to YLDs expected on the basis of SDI in 2016, by location
Values shown in brackets represent the ratio of observed YLDs to predicted YLDs on the basis of SDI, rounded to two digits. Acne=Acne vulgaris. Alcohol=Alcohol use disorders. Alzheimer’s=Alzheimer’s 
disease and other dementias. Anxiety=Anxiety disorders. Asthma=Asthma. Back pain=Low back pain. COPD=Chronic obstructive pulmonary disease. Conflict=Conflict and terrorism. Cut 
Leish=Cutaneous and mucocutaneous leishmaniasis. Dermatitis=Dermatitis. Diabetes=Diabetes mellitus. Diarrhoea=Diarrhoeal diseases. Edentul=Edentulism and severe tooth loss. Epilepsy=Epilepsy. 
Falls=Falls. Hearing=Age-related and other hearing loss. Hookworm=Hookworm disease. IHD=Ischaemic heart disease. Iodine=Iodine deficiency. Iron=Iron-deficiency anaemia. Isch Stroke=Ischaemic 
stroke. LF=Lymphatic filariasis. MDD=Major depressive disorder. Malaria=Malaria. Migraine=Migraine. Neck Pain=Neck pain. Oncho=Onchocerciasis. Opioids=Opioid use disorders. 
Osteoarth=Osteoarthritis. Oth Cardio=Other cardiovascular and circulatory diseases. Oth Cong=Other congenital anomalies. Oth HIV=HIV/AIDS resulting in other diseases. Oth MSK=Other 
musculoskeletal disorders. PEM=Protein-energy malnutrition. Refraction=Refraction and accommodation disorders. SDI=Socio-demographic Index. Schisto=Schistosomiasis. Schiz=Schizophrenia. 
YLD=Years lived with disability.
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slower than the decline in communicable, maternal, 
neonatal, and nutritional diseases but still substantial. 
The main causes of YLLs and YLDs were also notably 
different. Of the top 30 causes of YLLs, only seven 
appeared in the top 30 causes of YLDs (diabetes, falls, 
COPD, ischaemic stroke, neonatal preterm birth 
complication, diarrhoeal diseases, and ischaemic heart 
disease). At Level 4, 17 of the top 30 causes of YLDs were 
diseases for which we estimated no YLLs as they are not 
considered underlying causes of death.
Cross-cutting themes
The availability and quality of epidemiological data the 
GBD Study draws upon to make non-fatal estimates vary 
enormously among diseases and by location. A multitude 
of study methods and preferred case definitions pose 
challenges to making comparable estimates. A large part 
of the effort in the GBD study in making non-fatal 
estimates is to identify and correct for known sources of 
measurement error. The main classes of data sources 
each have their own limitations. Surveys can be biased by 
low response rates or by exclusion of individuals who do 
not reside in a traditional household, and may be limited 
in the capacity to properly identify cases within the 
limited diagnostic means available during a survey. 
Administrative data on health service encounters include 
only those seeking and receiving health care and are 
likely biased toward more severe disease, but may offer 
more accurate diagnostic variables than available in 
surveys. With the development of electronic medical 
records and advancements in linkage between data 
sources, non-fatal population health assessments can 
benefit tremendously if survey and administrative 
records can be linked. This would help to overcome 
many of the limitations of individual data sources: 
administrative records can provide rich diagnostic 
information, while surveys can provide better infor-
mation on cases that are not in contact with health 
services, exposure to risk factors, and health status 
measures that can provide information on severity. The 
challenges in low-income and middle-income countries 
will be to fund the data systems and infrastructure and 
development of technical expertise, and to provide access 
to generic rather than proprietary software to manage 
electronic medical record data and produce the linkages 
while preserving confidentiality.
In the GBD 2016 companion paper on causes of death18 
we reported a faster decline in age-standardised YLL rates 
for the top ten causes of YLL (ischaemic heart disease, 
cerebrovascular disease, lower respiratory infections, 
diarrhoeal diseases, road injuries, neonatal preterm birth 
complications, malaria, COPD, HIV/AIDS, and neonatal 
encephalopathy) than for the rest of causes, globally and in 
each of the SDI quintiles. We hypothesised that a greater 
investment in large causes has led to greater improve-
ments. We did not observe an equivalent rapid decline in 
the age-standardised YLD rates for these top ten causes of 
YLLs. YLD rates for ischaemic heart disease, stroke, LRI, 
COPD, and road injuries increased by less than 10% over 
the last ten years. YLDs for diarrhoeal diseases declined by 
less than 10%. The only top ten YLL causes with a greater 
decline in YLD rates were HIV/AIDS and malaria, though 
at a lesser pace than the change in YLL rates. Antiretroviral 
treatment greatly reduces the death rate in persons living 
with HIV but also improves the immune status of 
survivors. Thus, while there was a small increase in 
prevalence, the age-standardised YLD rate dropped by 
almost a fifth since 2006 as a larger proportion of cases 
were estimated to be in higher CD4 categories, for which 
we apply a lower disability weight. YLD rates from preterm 
birth compli cations and neonatal encephalopathy 
increased, while YLL rates dropped by almost a quarter. 
Improved survival through neonatal intensive care 
interventions predisposes survivors to the risk of long-
term disabling outcomes. In terms of how we measure the 
burden of disease in DALYs, this means that large gains by 
prevention of YLLs can be accompanied by a smaller 
amount of health loss in terms of YLDs in new survivors. 
Similarly, health interventions that address mortality by 
reducing the case fatality among causes of disease or 
injury may in turn lead to an increase in non-fatal 
outcomes. For example, reducing cardio vascular risks in 
people with diabetes will increase the prevalence of those 
with sequelae such as neuropathy or vision loss. Similarly, 
preventing death from a myo cardial infarction by 
revascularisation improves sur vival and thus exposes 
more people to heart failure as a complication.
The MDGs focused health policy on predominant 
infectious, neonatal, and maternal causes of death. The 
health-related SDGs have expanded into a number of non-
communicable diseases and injuries. However, the focus 
remains on reducing mortality rather than the main 
causes of disability. The only goals that correspond with 
non-fatal outcomes are those related to substance use 
(goal 3.5) and physical and sexual violence (goals 5.2, 11.7, 
16.1, and 16.2). Furthermore, the targets formulated on 
incidence of HIV, tuberculosis, malaria, and hepatitis were 
included because of the large number of deaths associated 
with these infectious diseases rather than presumably out 
of concern for their non-fatal outcomes.1 Diabetes and 
opioid use disorder are the only causes in the top 20 of age-
standardised YLD rates at Level 4, globally, that are 
mentioned in the SDGs. The diabetes target, however, is 
formulated as an indicator of mortality only. The mental, 
musculoskeletal, sense organ, and neurological disorders 
that contribute to more than half of all YLDs are not 
considered. While this may partially be a bias toward 
assessing global health in terms of mortality, it may also 
reflect a perception that there is inadequate knowledge to 
address these major causes of disability. Indeed, the much 
smaller gap in YLD rates compared to the large differences 
in YLL rates between high-SDI and low-SDI countries 
suggests that the capacity to intervene in non-fatal 
outcomes is more limited.
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Several threats exist that could lead to reversals in global 
health gains, such as widespread antimicrobial resis-
tance,30,31 conflict,32 climate change,33,34 and obesity.35 
Of these, obesity has the more immediately apparent 
health consequences and has a large effect on non-fatal 
outcomes such as diabetes, low back pain, and 
osteoarthritis. The increase in diabetes incidence due to 
obesity and the improved survival in people with diabetes, 
largely through prevention of deaths from cardiovascular 
complications, both contribute to increases in prevalence 
and a need for intensive long-term management to prevent 
fatal and disabling complications. Recent conflicts such as 
those  in Libya, South Sudan, Syria, and Yemen are major 
health threats not only in terms of casualties but also 
because they lead to long-term physical and mental 
consequences directly related to the violence as well as the 
broader health consequences of disrupted health services 
and declining economic status.36
Important changes in GBD 2016 compared with 
GBD 2015
The intensive collaborations with countries for which we 
present subnational estimates and the expanding network 
of GBD collaborators have contributed to a 36·2% increase 
in data sources for non-fatal outcome estimates compared 
to GBD 2015, as well as greater scrutiny of our methods 
and results. In particular, the close collaboration with the 
Indian Council for Medical Research and the Public 
Health Foundation of India, and 14 disease expert groups 
convened by these partners, has greatly enhanced the 
quality of the estimates for India. There was a 
49·9% increase in non-fatal data sources in India, and 
disease experts provided access to state-level data for 
causes, while in GBD 2015 we had only access to national 
aggregates.
Increasingly, the GBD Study is making use of admin-
istrative data based on health care encounters. Public 
access to these data sources at the level of detail required 
for GBD analyses remains limited, and enormous scope 
remains to expand access to these valuable sources of 
health information in many more countries. By estimating 
total admission rates from both administrative and survey 
sources, we were able to increase the number of countries 
with available inpatient data from 26 in 2015 to 41 in 2016. 
To predict the level of disease under any type of care for 
other countries with inpatient data available, we applied 
the ratio of people with a diagnosis during inpatient and 
outpatient episodes to that of inpatient diagnoses only in 
US medical claims data. In our analyses for most 
conditions, the administrative data sources were adjusted 
to the level of a reference case set for the disease of interest. 
Thus, we make use of the detailed information on age and 
sex in these data sources while adjusting for a potential 
systematic bias compared to data sources with measure-
ments according to the reference case. For instance, our 
reference case for diabetes prevalence was the proportion 
of a population with fasting plasma glucose greater than 
7 mmol/L or on diabetes treatment in a representative 
survey. The adjustment of administrative data reflects the 
proportion of people with diabetes who may be unaware of 
their condition or who for other reasons have not contacted 
health services in the year of interest.
To estimate indicators of sexual violence for the SDGs, 
we added sexual violence as a subcause of interpersonal 
violence in the GBD hierarchy. The focus of the effort in 
GBD 2016 has been to estimate the prevalence of people 
who report sexual violence by intimate partners and other 
perpetrators in the last 12 months. For non-fatal outcomes, 
we quantified the immediate concurrent physical injuries 
and the more immediate mental health consequences. 
We realise this is a limited scope for estimating all 
relevant health loss from sexual violence. In future 
iterations of GBD we intend to include sexual violence as 
a risk factor for longer-term outcomes such as major 
depressive disorder, anxiety disorder, and substance use 
disorders. Going forward, we aim to become more 
comprehensive in our estimation of violence to include 
the wider health consequences of physical violence to 
children and adults as well as bullying.
Although efforts were undertaken to update data for all 
causes of YLDs in GBD 2016, a number of sources of new 
data were especially influential in improving estimates 
for selected causes. A large number of rapid-assessment 
vision loss surveys37 contributed to an increase in the 
number of sources to measure vision loss and its 
underlying causes from 397 in 2015 to 768 in 2016, with 
data available in 75 low-SDI and middle-SDI countries. 
Likewise, the Global Atlas for Helminth Infections Project 
provided a large amount of new data for schistosomiasis 
and lymphatic filariasis.38
A new approach to fitting ensembles of distributions 
improved the estimation of anaemia by better rep-
resenting the tail end of the distributions of haemoglobin 
that most concerns our estimation of disability than can 
be derived from a single parametric distribution. This is 
important because for many surveys for which we rely on 
academic papers and survey reports we only have data for 
means and standard deviations.
The change in modelling strategy for tuberculosis was 
substantial. The new estimates of the prevalence of latent 
tuberculosis infection is of policy interest, as there are 
intervention strategies that target treatment of latent 
tuberculosis in high-risk individuals.39 It allowed us to 
model active disease among those with latent infection to 
improve the search for a consistent fit between cause of 
death rates, prevalence surveys, and notification of 
incident disease, the three main sources of epidemiological 
data on tuberculosis. Next, we estimated the association 
between SDI and the ratio of mortality to incidence, 
assuming this measure of case fatality is dependent on 
development as a proxy for quality of case finding and 
management. This provided greater alignment of mor-
tality and non-fatal estimates of tuberculosis than we have 
been able to achieve in past GBD studies.
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A substantial new effort on the severity of stroke was 
the analysis of 18 studies providing Rankin score data on 
the severity of disability in stroke survivors. Thus, we 
were able to make estimates by age, sex, year, and location 
to capture greater nuances in outcomes – for example, 
reflecting differences in access to rehabilitative services.
Disease-specific considerations
The GBD study is the only source of comprehensive 
quantification of the disabling outcomes of diseases and 
injuries. For a number of diseases there are efforts to 
estimate global disease prevalence or incidence. Where 
appropriate, in the following sections on major sources of 
YLDs, comparisons with other global estimates are made; 
further detail can also be found in the supplementary 
methods (appendix 1, p 30).
Mental and substance use disorders
GBD 2016 confirms that mental and substance use 
disorders, led by depressive disorders, are a major cause 
of non-fatal burden. With age-standardised prevalence 
and YLD rates for mental and substance use disorders 
showing less than 10% change between 1990 and 2016, 
apart from bulimia YLD rates which increased by 
almost 20%, our findings show no sizeable improvement 
in population mental health over time at the global level. 
Interventions can decrease the severity or increase 
remission for certain disorders and can be effectively 
administered in low-income, middle-income, and high-
income settings.40 However, these have yet to be brought 
up to scale in most countries. Because there are no data 
measuring the severity of mental disorders in a consistent 
manner, we have been unable to capture treatment 
effects that alter severity of disease. By imposing severity 
distributions from two high-income countries only, we 
are probably underestimating the burden of mental 
disorders in countries with less access to quality care.
Musculoskeletal disorders
Low back pain and neck pain are the two largest causes of 
musculoskeletal disability; their measurement is fully 
dependent on self-report measures. In GBD, we adjust for 
variations in recall period, anatomical location, minimum 
duration of episodes, and whether activity-limiting or not. 
Although less than 40% of low back pain can be attributed 
to occupational risks or increased BMI, there are no risks 
in GBD that are linked to neck pain. The lack of predictive 
covariates raises concern that we might be assigning 
measurement error as spatial variation and that the two to 
two-and-a-half-times difference in age-standardised 
prevalence between locations is overestimating true 
differences in disease occurrence of these two conditions.
Diabetes
Several factors have contributed to the increase in the 
prevalence of diabetes. Ageing of populations along with 
greater exposure to lifestyle-related risk factors, most 
importantly high BMI, has increased the incidence of 
diabetes in almost all countries.41 At the same time, 
improvements in treatment of diabetes have increased 
the life expectancy among people with diabetes. The large 
increase in prevalence imposes a substantial economic 
burden on health-care systems. In the USA, diabetes was 
responsible for the largest health-care spending and the 
greatest increase over the past two decades among 
155 health conditions.42 This highlights the importance of 
development and implementation of more effective 
population-level strategies to prevent diabetes.
Dementia
Age-standardised prevalence of dementia varied four-
times  between countries. Dementia surveys generally 
have a two-step approach to identifying cases, with an 
initial screening phase followed by more intensive 
diagnostic procedures in those who screened positive. We 
scrutinised all sources of dementia and identified a wide 
range of screening and diagnostic tools, varying 
thresholds on these methods, and diagnoses made 
according to different classification systems. This made it 
impossible to identify a reference study method or case 
definition. Thus, it is likely that we are overestimating the 
variation in prevalence.
Headaches
We changed our strategy to include medication overuse 
headache as a sequela of migraine and tension-type 
headache. This led to an increase in their prevalence and 
YLD estimates, particularly for migraine as more than 
two-thirds of medication overuse headache occurs in 
people with migraine as the primary headache. Thus, 
migraine has become the second largest cause of disability 
in 2016. As limited surveys are available that report on the 
frequency and duration of headache episodes, we have not 
been able to quantify any effect of treatment.
Malaria
Globally, malaria case incidence trends estimated in 
GBD 2016 followed a very similar pattern to GBD 2015, 
where there was a gradual rise in cases until 2005 
followed by a steady decline. For all years, however, the 
updated estimates are approximately one-quarter lower 
than those from GBD 2015, reflecting mainly lower 
estimates outside Africa and in particular for India. 
Outside Africa, and for lower-burden countries within 
Africa, 2016 estimates were produced using a 
spatiotemporal geostatistical model. Globally, this 
improved approach led to a reduction in estimated cases 
of around 75 million (about 26% reduction) of which 
most (roughly 60 million fewer cases) were in India, with 
other notable reductions in Myanmar (roughly 11 million 
fewer), Indonesia (roughly 3 million fewer), and Pakistan 
(roughly 1 million fewer). In high-burden countries in 
sub-Saharan Africa, where the methodology remained 
similar to GBD 2015, changes were relatively modest and 
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reflected the inclusion of newly available cross-sectional 
parasite rate surveys or updates to data on malaria 
intervention coverage in recent years.
Tuberculosis
For the first time, we have estimated the prevalence of 
latent tuberculosis infection. Globally, this disease affects 
1·91 billion people (95% UI 1·79 billion to 2·03 billion) 
who are at risk of developing active disease when the 
immune system weakens through old age, HIV infection, 
diabetes, malnutrition, or excessive alcohol use. Globally, 
we estimate there were 10·4 million (9·37 million to 
11·7 million) incident cases of tuberculosis in 2016, 
which is the same as the 10·4 million cases estimated by 
WHO for 2015.43 The separate estimation of 331 000 cases 
(95% UI 293 000–373 000) of multidrug-resistant and 
19 800 incident cases (17 300–22 600) of exten-
sively drug-resistant tuberculosis with or without HIV 
infections has great policy relevance, as the resources 
required for treatment of resistant cases are many times 
greater given that treatment needs to be applied for a 
longer period and with more expensive drugs. Drug 
resistance also requires more expensive detection and 
monitoring methods.44
HIV/AIDS
A major change in methods for estimating burden of HIV/
AIDS for GBD 2016 was the distribution of antiretroviral 
therapy coverage by age, sex, and CD4 count. We used 
two AIDS Indicator Surveys45,46 to predict the age-sex-CD4 
distribution of antiretroviral therapy coverage. This shifted 
the coverage distribution to groups with higher CD4 
counts and gave a better fit to the data. UNAIDS produces 
periodic updates to global, regional, and national estimates 
of HIV/AIDS incidence and prevalence. In their latest 
assessment there were 36·7 million (30·8 million to 42·9 
million) people living with HIV/AIDS in 2016, compared 
with 36·4 million (34·2 million to 39·1 million) estimated 
by GBD 2016.47 Comparisons of prevalence estimates at the 
country level in 2005 (the estimated peak of the HIV/AIDS 
epidemic globally) and 2016 show a high level of 
concordance between GBD 2016 and UNAIDS, with an 
average intra-class correlation coefficient of 0·992. For 
estimates of annual new infections, UNAIDS and GBD 
follow similar patterns, with UNAIDS having slightly 
lower estimates for years between 1996 and 2002. The 
estimates are similar between the two for most of the 
2000s, with UNAIDS estimates showing a slightly faster 
rate of decline in annual new infections from 2008 to 2016 
at the global level. GBD 2016 estimates about 1·9 million 
new infections globally in 2016, while UNAIDS estimates 
about 1.8 million for the same year.47
Cancer
Country-specific cancer statistics are published by the 
International Agency for Research on Cancer for their 
GLOBOCAN project.48 Their most recent estimate of 
incidence for all cancers combined is 14·1 million cases 
in 2012, compared with GBD estimates of 14·8 million 
cases in 2010 and 17·2 million cases in 2016. The appendix 
provides a comparison of incidence by cancer type 
between GBD and GLOBOCAN (appendix 1, p 255).
Zika virus disease
The large outbreak of Zika virus disease in Latin America 
in 2016 led WHO to declare it a public health emergency 
of international concern.49 There were 7·6 million new 
infections in 2016, 7·4 million of which occurred in Latin 
America and the Caribbean. Most of the health loss 
associated with Zika virus disease was from non-fatal 
outcomes, including fever and malaise during acute 
infection and congenital anomalies and Guillain-Barré 
syndrome as longer-term consequences.
Guinea worm
Guinea worm disease was included as a cause of non-fatal 
health loss because eradication of the disease is achievable 
in the near future.50Although not having received much 
attention in general global health policy debates, a 
remarkable reduction from an estimated 3·5 million 
cases in the mid-1980s to just 15 cases in 2016 has been 
achieved. Guinea worm eradication interventions include 
the distribution of filter cloths and pipe filters for drinking 
water, treatment of water sources with larvacide, case 
detection, containment to prevent further transmission, 
and health education.50
Limitations
The annual updates of GBD allow incremental 
improvements to methods. However, several 
measurement challenges in non-fatal estimation remain. 
The foremost concern is how best to disentangle 
measurement error from true variation in disease 
occurrence. We correct for known bias from non-
reference methods or case definitions, but often have to 
rely on sparse information to make those adjustments. 
Lack of consensus among researchers on how to measure 
a disease can make it difficult to define a manageable set 
of alternative methods for which we can make 
adjustments. An extreme example is dementia: among 
234 data sources we identified 228 different methods of 
screening, diagnostic tools, and diagnostic criteria. When 
possible, we use predictive covariates in our non-fatal 
models. For diseases with a lot of information on what 
drives differences in disease, covariates help to estimate 
true variation and minimise residual measurement error. 
However, many of the leading causes of YLDs lack strong 
predictors as indicated by our risk assessment, which 
assigned less than 20% of YLDs from mental, 
musculoskeletal, sense organ, and neurological disorders 
to the 79 risks evaluated in the GBD study.51
Second, many non-fatal models continue to rely on 
sparse data in some regions or super-regions despite the 
steady increase in data sources. With the addition of some 
Global Health Metrics
1248 www.thelancet.com   Vol 390   September 16, 2017
new data sources, this can lead to large variation with 
previous GBD estimates. Alcohol dependence is a good 
example. Our estimate of the global prevalence of alcohol 
dependence increased by 70% after adding nine new data 
sources for Brazil, 12 for India, seven for sub-Saharan 
Africa, and four in eastern and central Europe. Until 
there is better coverage of data, non-fatal disease models 
will continue to be prone to estimates varying between 
GBD iterations.
Third, the adjustments to our hospital admission data 
for multiple admissions and secondary diagnosis fields 
reflect all health-care episodes rather than inpatient 
episodes only. Adjustments derived from a large, though 
non-representative, source of medical claims data in 
the USA are assumed to be generalisable. The general-
isability of claims data, the validity of assuming diagnoses 
based on primary diagnosis alone or all diagnostic fields, 
and the validity of trends in claims data have been 
challenged.52–56 Also, there may be considerable inter-
country variation in how diseases are treated between 
inpatient and outpatient settings. Our models attempt to 
adjust for such potential biases by using a covariate on 
claims and hospital admission data to correct for systematic 
error, although in a relatively crude manner, this assumes 
no geographical variation in the error. Gaining access to 
claims data from other countries, particularly in low-
income and middle-income countries, is a crucial 
endeavour for future GBD iterations.
Fourth, our estimates of severity distributions for most 
diseases are based on sparse studies from the literature 
for diseases with a more established consensus on a 
measure of severity, or our analyses of three high-income 
surveys which combine diagnostic information with 
a general health status measure, the Short Form-12 
(SF-12).40,57,58 Disease-specific researchers can provide 
better data with more routine use of a single established 
measure of severity in surveys and patient populations. 
Another potential improvement can be expected from 
countries that are able to link survey data with a general 
health assessment instrument like SF-12 and admin-
istrative diagnostic information. The latter approach has 
the advantage that it would allow adjustments for 
comorbidity, which can affect measures aiming to capture 
the severity of a single disease.
Fifth, apart from COPD, stroke, and epilepsy, where we 
have epidemiological data to estimate the geographical 
variation in the distribution of sequelae, for most diseases 
we are unable to capture differences in severity that occur 
due to treatment. As almost all our data sources on severity 
are from high-income countries, this would underestimate 
YLDs in low-income and middle-income countries with 
poorer access to and quality of treatment. If greater 
geographical information on severity of disease becomes 
available, we can incorporate a more explicit gradient 
based on our health-system access and quality index.58
Sixth, we have not yet been able to incorporate depen-
dent comorbidity into our simulation methods. We aim 
for this to  take place in GBD 2017 and will require 
substantial developmental work to make the com-
putational code more efficient.
Seventh, most of the uncertainty in our YLD estimates 
comes from the disability weights. We have not con ducted 
any new surveys since GBD 2013. With further data 
collection, we may be able to reduce some of the 
uncertainty by increasing the volume of data and by 
removing some of the ambiguities in lay descriptions, but 
large uncertainty is inherent to health state valuations that 
rely on perceptions by respondents of brief descriptions of 
complex health problems.
Eighth, the separate estimation of non-fatal models in 
DisMod-MR 2.1 for 1990, 1995, 2000, 2006, 2010, and 2016 
implies uncertainty of estimates over time is independent. 
Also, compositional bias can lead to spurious time trends 
being estimated. DisMod-AT will allow for the more 
appealing simultaneous estimation over age and time 
and thus resolve the current limitations. However, as it is 
a more complex modelling tool, extensive testing and 
understanding what sensible settings are will need 
to take place before we can replace the current DisMod-
MR approach.
Ninth, scrutiny of the multitude of results generated by 
GBD is a challenge. Increasingly, we generate visual-
isation tools to query results and intermediate steps in 
our analyses to better vet our results. We share our data 
and modelling tools with our expanding network of over 
2500 collaborators who frequently query data sources 
and our measurements for particular diseases or 
locations. Also, by publishing all code and describing the 
methods used disease-by-disease we encourage scrutiny 
of every aspect of the GBD study.
Tenth, as our GBD collaborators have raised, the 
argument of including Guinea worm disease to docu-
ment pending eradication can be used to justify the 
inclusion of poliomyelitis in the next round of GBD. 
There are also a number of large residual categories, 
particularly other musculoskeletal disorders and other 
cardiovascular disease, where we could make more 
detailed estimates in future rounds of GBD.
Eleventh, despite adding estimates of the prevalence of 
several asymptomatic states of disease that are precursors 
of disease that can be targeted with preventive inter-
ventions (such as latent tuberculosis infection, chronic 
hepatitis, or stage III chronic kidney disease without 
anaemia), we are not comprehensive in doing so. As 
diagnostic capacity increases, more asymptomatic pre-
cursor states can be identified and, in GBD, we will aim 
to include these if they can be measured at the population 
level and become relevant to policy.
Future directions
We have introduced a quality grading system for cause of 
death sources for GBD 2016. We want to introduce a 
similar grading system of non-fatal data sources for GBD 
2017. Important elements to capture in a grading system 
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of non-fatal data sources will include the proportion of 
data sources using the reference method and case 
definition for a cause, the proportion of data sources 
representative of a location, and the amount of detail in 
reporting of age groups, sex, locations, and time periods 
covered. Unlike the location-specific grading of cause of 
death data sources, a grading system of non-fatal data 
sources will need to be location-specific and cause-
specific, making it a much larger endeavour that will 
likely take several years to complete.
A prototype of a new version of a new analytical tool, 
DisMod-AT, is currently being tested. It has the advantage 
over DisMod-MR 2.1 in that it solves for the differential 
equations that govern the relationship between incidence, 
prevalence, remission, and mortality simultaneously 
over age and time. This is of great relevance for causes 
that vary substantially over time, and overcomes the 
assumption of a steady disease state that underlies prev-
ious versions of DisMod. We expect for GBD 2017 to run 
both the current tool and DisMod-AT in parallel for a 
number of time-sensitive causes with a view of DisMod-
AT becoming the tool of choice from GBD 2018 onward.
We plan to reinstate a web survey facility that will allow 
derivation of disability weights for new health states; 
examination of the effect of changes in the wording of lay 
descriptions of health states on valuations provided by 
respondents; and creation of health states for combined 
impairments for which we currently estimate disability 
weights multiplicatively. 
Conclusion
Diverging trends in YLLs and YLDs raise the importance 
of non-fatal health outcomes as contributing to the 
burden of disease. Even if changes in trends for many 
causes are not large, more attention should be paid to 
assessing the burden of non-fatal health outcomes, as 
populations age and countries progress through the 
epidemiological transition, causing growing numbers of 
people to be in need of chronic care. More research is 
needed to identify risks of major disabling diseases, 
better methods of intervening by prevention, and 
treatment or improving severity of disability. As countries 
progress through the epidemiological transition, more 
attention should be paid to assessing the burden of non-
fatal health out comes, particularly in light of growing 
numbers of people in need of chronic care as populations 
age. More research is needed to identify risks of 
major disabling diseases, better methods of intervening 
by prevention, and treatment or improving severity 
of disability.
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators
Theo Vos, Amanuel Alemu Abajobir, Cristiana Abbafati, Kaja M Abbas, 
Kalkidan Hassen Abate, Foad Abd-Allah, Abdishakur M Abdulle, Teshome 
Abuka Abebo, Semaw Ferede Abera, Victor Aboyans, Laith J Abu-Raddad, 
Ilana N Ackerman, Abdu Abdullahi Adamu, Olatunji Adetokunboh, 
Mohsen Afarideh, Ashkan Afshin, Sanjay Kumar Agarwal, 
Rakesh Aggarwal, Anurag Agrawal, Sutapa Agrawal, 
Aliasghar Ahmad Kiadaliri, Hamid Ahmadieh, Muktar Beshir Ahmed, 
Amani Nidhal Aichour, Ibtihel Aichour, Miloud Taki Eddine Aichour, 
Sneha Aiyar, Rufus Olusola Akinyemi, Nadia Akseer, Faris Hasan Al Lami, 
Fares Alahdab, Ziyad Al-Aly, Khurshid Alam, Noore Alam, Tahiya Alam, 
Deena Alasfoor, Kefyalew Addis Alene, Raghib Ali, Reza Alizadeh-Navaei, 
Ala’a Alkerwi, François Alla, Peter Allebeck, Christine Allen, 
Fatma Al-Maskari, Rajaa Al-Raddadi, Ubai Alsharif, Shirina Alsowaidi, 
Khalid A Altirkawi, Azmeraw T Amare, Erfan Amini, Walid Ammar, 
Yaw Ampem Amoako, Hjalte H Andersen, Carl Abelardo T Antonio, 
Palwasha Anwari, Johan Ärnlöv, Al Artaman, Krishna Kumar Aryal, 
Hamid Asayesh, Solomon W Asgedom, Reza Assadi, Tesfay Mehari Atey, 
Niguse Tadele Atnafu, Sachin R Atre, Leticia Avila-Burgos, 
Euripide Frinel G Arthur Avokpaho, Ashish Awasthi, 
Beatriz Paulina Ayala Quintanilla, Huda Omer Ba Saleem, Umar Bacha, 
Alaa Badawi, Kalpana Balakrishnan, Amitava Banerjee, Marlena S Bannick, 
Aleksandra Barac, Ryan M Barber, Suzanne L Barker-Collo, 
Till Bärnighausen, Simon Barquera, Lars Barregard, Lope H Barrero, 
Sanjay Basu, Bob Battista, Katherine E Battle, Bernhard T Baune, 
Shahrzad Bazargan-Hejazi, Justin Beardsley, Neeraj Bedi, Ettore Beghi, 
Yannick Béjot, Bayu Begashaw Bekele, Michelle L Bell, Derrick A Bennett, 
Isabela M Bensenor, Jennifer Benson, Adugnaw Berhane, 
Derbew Fikadu Berhe, Eduardo Bernabé, Balem Demtsu Betsu, 
Mircea Beuran, Addisu Shunu Beyene, Neeraj Bhala, Anil Bhansali, 
Samir Bhatt, Zulfiqar A Bhutta, Sibhatu Biadgilign, Kelly Bienhoff, 
Boris Bikbov, Charles Birungi, Stan Biryukov, Donal Bisanzio, 
Habtamu Mellie Bizuayehu, Dube Jara Boneya, Soufiane Boufous, 
Rupert R A Bourne, Alexandra Brazinova, Traolach S Brugha, 
Rachelle Buchbinder, Lemma Negesa Bulto Bulto, Blair R Bumgarner, 
Zahid A Butt, Lucero Cahuana-Hurtado, Ewan Cameron, Mate Car, 
Hélène Carabin, Jonathan R Carapetis, Rosario Cárdenas, 
David O Carpenter, Juan Jesus Carrero, Austin Carter, Felix Carvalho, 
Daniel C Casey, Valeria Caso, Carlos A Castañeda-Orjuela, Chris D Castle, 
Ferrán Catalá-López, Hsing-Yi Chang, Jung-Chen Chang, Fiona J Charlson, 
Honglei Chen, Mirriam Chibalabala, Chioma Ezinne Chibueze, 
Vesper Hichilombwe Chisumpa, Abdulaal A Chitheer, 
Devasahayam Jesudas Christopher, Liliana G Ciobanu, Massimo Cirillo, 
Danny Colombara, Cyrus Cooper, Paolo Angelo Cortesi, Michael H Criqui, 
John A Crump, Abel Fekadu Dadi, Koustuv Dalal, Lalit Dandona, 
Rakhi Dandona, José das Neves, Dragos V Davitoiu, Barbora de Courten, 
Diego De Leo, Louisa Degenhardt, Selina Deiparine, Robert P Dellavalle, 
Kebede Deribe, Don C Des Jarlais, Subhojit Dey, Samath D Dharmaratne, 
Preet Kaur Dhillon, Daniel Dicker, Eric L Ding, Shirin Djalalinia, 
Huyen Phuc Do, E Ray Dorsey, Kadine Priscila Bender dos Santos, 
Dirk Douwes-Schultz, Kerrie E Doyle, Tim R Driscoll, Manisha Dubey, 
Bruce Bartholow Duncan, Ziad Ziad El-Khatib, Jerisha Ellerstrand, 
Ahmadali Enayati, Aman Yesuf Endries, Sergey Petrovich Ermakov, 
Holly E Erskine, Babak Eshrati, Sharareh Eskandarieh, 
Alireza Esteghamati, Kara Estep, Fanuel Belayneh Bekele Fanuel, 
Carla Sofia e Sa Farinha, André Faro, Farshad Farzadfar, Mir Sohail Fazeli, 
Valery L Feigin, Seyed-Mohammad Fereshtehnejad, João C Fernandes, 
Alize J Ferrari, Tesfaye Regassa Feyissa, Irina Filip, Florian Fischer, 
Christina Fitzmaurice, Abraham D Flaxman, Luisa Sorio Flor, 
Nataliya Foigt, Kyle J Foreman, Richard C Franklin, Nancy Fullman, 
Thomas Fürst, Joao M Furtado, Neal D Futran, Emmanuela Gakidou, 
Morsaleh Ganji, Alberto L Garcia-Basteiro, Teshome Gebre, 
Tsegaye Tewelde Gebrehiwot, Ayele Geleto, 
Bikila Lencha Gemechu, Hailay Abrha Gesesew, Peter W Gething, 
Alireza Ghajar, Katherine B Gibney, Paramjit Singh Gill, Richard F Gillum, 
Ibrahim Abdelmageem Mohamed Ginawi, Ababi Zergay Giref, 
Melkamu Dedefo Gishu, Giorgia Giussani, William W Godwin, 
Audra L Gold, Ellen M Goldberg, Philimon N Gona, Amador Goodridge, 
Sameer Vali Gopalani, Atsushi Goto, Alessandra Carvalho Goulart, 
Max Griswold, Harish Chander Gugnani, Rahul Gupta, Rajeev Gupta, 
Tanush Gupta, Vipin Gupta, Nima Hafezi-Nejad, 
Alemayehu Desalegne Hailu, Gessessew Bugssa Hailu, 
Randah Ribhi Hamadeh, Samer Hamidi, Alexis J Handal, 
Graeme J Hankey, Yuantao Hao, Hilda L Harb, Habtamu Abera Hareri, 
Josep Maria Haro, James Harvey, Mohammad Sadegh Hassanvand, 
Rasmus Havmoeller, Caitlin Hawley, Roderick J Hay, Simon I Hay, 
Nathaniel J Henry, Ileana Beatriz Heredia-Pi, Pouria Heydarpour, 
Hans W Hoek, Howard J Hoffman, Nobuyuki Horita, H Dean Hosgood, 
Sorin Hostiuc, Peter J Hotez, Damian G Hoy, Aung Soe Htet, Guoqing Hu, 
Global Health Metrics
1250 www.thelancet.com   Vol 390   September 16, 2017
Hsiang Huang, Chantal Huynh, Kim Moesgaard Iburg, 
Ehimario Uche Igumbor, Chad Ikeda, Caleb Mackay Salpeter Irvine, 
Kathryn H Jacobsen, Nader Jahanmehr, Mihajlo B Jakovljevic, 
Simerjot K Jassal, Mehdi Javanbakht, Sudha P Jayaraman, 
Panniyammakal Jeemon, Paul N Jensen, Vivekanand Jha, Guohong Jiang, 
Denny John, Catherine O Johnson, Sarah Charlotte Johnson, Jost B Jonas, 
Mikk Jürisson, Zubair Kabir, Rajendra Kadel, Amaha Kahsay, Ritul Kamal, 
Haidong Kan, Nadim E Karam, André Karch, Corine Kakizi Karema, 
Amir Kasaeian, Getachew Mullu Kassa, Nigussie Assefa Kassaw, 
Nicholas J Kassebaum, Anshul Kastor, Srinivasa Vittal Katikireddi, 
Anil Kaul, Norito Kawakami, Peter Njenga Keiyoro, Andre Pascal Kengne, 
Andre Keren, Yousef Saleh Khader, Ibrahim A Khalil, Ejaz Ahmad Khan, 
Young-Ho Khang, Ardeshir Khosravi, Jagdish Khubchandani, 
Christian Kieling, Daniel Kim, Pauline Kim, Yun Jin Kim, 
Ruth W Kimokoti, Yohannes Kinfu, Adnan Kisa, 
Katarzyna A Kissimova-Skarbek, Mika Kivimaki, Ann Kristin Knudsen, 
Yoshihiro Kokubo, Dhaval Kolte, Jacek A Kopec, 
Soewarta Kosen, Parvaiz A Koul, Ai Koyanagi, Michael Kravchenko, 
Sanjay Krishnaswami, Kristopher J Krohn, Barthelemy Kuate Defo, 
Burcu Kucuk Bicer, G Anil Kumar, Pushpendra Kumar, Sanjiv Kumar, 
Hmwe H Kyu, Dharmesh Kumar Lal, Ratilal Lalloo, 
Nkurunziza Lambert, Qing Lan, Anders Larsson, Pablo M Lavados, 
Janet L Leasher, Jong-Tae Lee, Paul H Lee, James Leigh, 
Cheru Tesema Leshargie, Janni Leung, Ricky Leung, Miriam Levi, 
Yichong Li, Yongmei Li, Darya Li Kappe, Xiaofeng Liang, 
Misgan Legesse Liben, Stephen S Lim, Shai Linn, Angela Liu, 
Patrick Y Liu, Shiwei Liu, Yang Liu, Rakesh Lodha, Giancarlo Logroscino, 
Stephanie J London, Katharine J Looker, Alan D Lopez, Stefan Lorkowski, 
Paulo A Lotufo, Nicola Low, Rafael Lozano, Timothy C D Lucas, 
Erlyn Rachelle King Macarayan, Hassan Magdy Abd El Razek, 
Mohammed Magdy Abd El Razek, Mahdi Mahdavi, Marek Majdan, 
Reza Majdzadeh, Azeem Majeed, Reza Malekzadeh, Rajesh Malhotra, 
Deborah Carvalho Malta, Abdullah A Mamun, Helena Manguerra, 
Treh Manhertz, Ana Mantilla, Lorenzo G Mantovani, Chabila C Mapoma, 
Laurie B Marczak, Jose Martinez-Raga, 
Francisco Rogerlândio Martins-Melo, Ira Martopullo, Winfried März, 
Manu Raj Mathur, Mohsen Mazidi, Colm McAlinden, 
Madeline McGaughey, John J McGrath, Martin McKee, Claire McNellan, 
Suresh Mehata, Man Mohan Mehndiratta, Tefera Chane Mekonnen, 
Peter Memiah, Ziad A Memish, Walter Mendoza, 
Mubarek Abera Mengistie, Desalegn Tadese Mengistu, George A Mensah, 
Atte Meretoja, Tuomo J Meretoja, Haftay Berhane Mezgebe, Renata Micha, 
Anoushka Millear, Ted R Miller, Edward J Mills, Mojde Mirarefin, 
Erkin M Mirrakhimov, Awoke Misganaw, Shiva Raj Mishra, 
Philip B Mitchell, Karzan Abdulmuhsin Mohammad, Alireza Mohammadi, 
Kedir Endris Mohammed, Shafiu Mohammed, Sanjay K Mohanty, 
Ali H Mokdad, Sarah K Mollenkopf, Lorenzo Monasta, Julio Montañez 
Hernandez, Marcella Montico, Maziar Moradi-Lakeh, Paula Moraga, 
Rintaro Mori, Chloe Morozoff, Shane D Morrison, Mark Moses, Cliff 
Mountjoy-Venning, Kalayu Birhane Mruts, Ulrich O Mueller, Kate Muller, 
Michele E Murdoch, Gudlavalleti Venkata Satyanarayana Murthy, 
Kamarul Imran Musa, Jean B Nachega, Gabriele Nagel, Mohsen Naghavi, 
Aliya Naheed, Kovin S Naidoo, Luigi Naldi, Vinay Nangia, 
Gopalakrishnan Natarajan, Dumessa Edessa Negasa, Ionut Negoi, 
Ruxandra Irina Negoi, Charles R Newton, Josephine Wanjiku Ngunjiri, 
Cuong Tat Nguyen, Grant Nguyen, Minh Nguyen, Quyen Le Nguyen, 
Trang Huyen Nguyen, Emma Nichols, Dina Nur Anggraini Ningrum, 
Sandra Nolte, Vuong Minh Nong, Bo Norrving, Jean Jacques N Noubiap, 
Martin J O’Donnell, Felix Akpojene Ogbo, In-Hwan Oh, Anselm Okoro, 
Olanrewaju Oladimeji, Andrew Toyin Olagunju, 
Tinuke Oluwasefunmi Olagunju, Helen E Olsen, Bolajoko Olubukunola 
Olusanya, Jacob Olusegun Olusanya, Kanyin Ong, John Nelson Opio, 
Eyal Oren, Alberto Ortiz, Aaron Osgood-Zimmerman, Majdi Osman, 
Mayowa O Owolabi, Mahesh PA, Rosana E Pacella, Adrian Pana, 
Basant Kumar Panda, Christina Papachristou, Eun-Kee Park, 
Charles D Parry, Mahboubeh Parsaeian, Scott B Patten, George C Patton, 
Katherine Paulson, Neil Pearce, David M Pereira, Norberto Perico, 
Konrad Pesudovs, Carrie Beth Peterson, Max Petzold, 
Michael Robert Phillips, David M Pigott, Julian David Pillay, 
Christine Pinho, Dietrich Plass, Martin A Pletcher, Svetlana Popova, 
Richie G Poulton, Farshad Pourmalek, Dorairaj Prabhakaran, 
Narayan Prasad, Noela M Prasad, Carrie Purcell, Mostafa Qorbani, 
Reginald Quansah, Rynaz H S Rabiee, Amir Radfar, Anwar Rafay, 
Kazem Rahimi, Afarin Rahimi-Movaghar, Vafa Rahimi-Movaghar, 
Mahfuzar Rahman, Mohammad Hifz Ur Rahman, Rajesh Kumar Rai, 
Sasa Rajsic, Usha Ram, Chhabi Lal Ranabhat, Zane Rankin, 
Paturi Vishnupriya Rao, Puja C Rao, Salman Rawaf, Sarah E Ray, 
Robert C Reiner, Nikolas Reinig, Marissa B Reitsma, Giuseppe Remuzzi, 
Andre M N Renzaho, Serge Resnikoff, Satar Rezaei, Antonio L Ribeiro, 
Luca Ronfani, Gholamreza Roshandel, Gregory A Roth, Ambuj Roy, 
Enrico Rubagotti, George Mugambage Ruhago, Soheil Saadat, Nafis Sadat, 
Mahdi Safdarian, Sare Safi, Saeid Safiri, Rajesh Sagar, Ramesh Sahathevan, 
Joseph Salama, Joshua A Salomon, Sundeep Santosh Salvi, 
Abdallah M Samy, Juan R Sanabria, Damian Santomauro, Itamar S Santos, 
João Vasco Santos, Milena M Santric Milicevic, Benn Sartorius, 
Maheswar Satpathy, Monika Sawhney, Sonia Saxena, Maria Inês Schmidt, 
Ione J C Schneider, Ben Schöttker, David C Schwebel, Falk Schwendicke, 
Soraya Seedat, Sadaf G Sepanlou, Edson E Servan-Mori, Tesfaye Setegn, 
Katya Anne Shackelford, Amira Shaheen, Masood Ali Shaikh, 
Mansour Shamsipour, Sheikh Mohammed Shariful Islam, 
Jayendra Sharma, Rajesh Sharma, Jun She, Peilin Shi, Chloe Shields, 
Mika Shigematsu, Yukito Shinohara, Rahman Shiri, Reza Shirkoohi, 
Shreya Shirude, Kawkab Shishani, Mark G Shrime, Abla Mehio Sibai, 
Inga Dora Sigfusdottir, Diego Augusto Santos Silva, João Pedro Silva, 
Dayane Gabriele Alves Silveira, Jasvinder A Singh, Narinder Pal Singh, 
Dhirendra Narain Sinha, Eirini Skiadaresi, Vegard Skirbekk, 
Erica Leigh Slepak, Amber Sligar, David L Smith, Mari Smith, 
Badr H A Sobaih, Eugene Sobngwi, Reed J D Sorensen, 
Tatiane Cristina Moraes Sousa, Luciano A Sposato, 
Chandrashekhar T Sreeramareddy, Vinay Srinivasan, Jeffrey D Stanaway, 
Vasiliki Stathopoulou, Nicholas Steel, Dan J Stein, Murray B Stein, 
Caitlyn Steiner, Timothy J Steiner, Sabine Steinke, Mark Andrew Stokes, 
Lars Jacob Stovner, Bryan Strub, Michelle Subart, 
Muawiyyah Babale Sufiyan, Rizwan Suliankatchi Abdulkader, 
Bruno F Sunguya, Patrick J Sur, Soumya Swaminathan, Bryan L Sykes, 
Dillon O Sylte, Rafael Tabarés-Seisdedos, Getachew Redae Taffere, 
Jukka S Takala, Nikhil Tandon, Mohammad Tavakkoli, Nuno Taveira, 
Hugh R Taylor, Arash Tehrani-Banihashemi, Tesfalidet Tekelab, 
Girma Temam Shifa, Abdullah Sulieman Terkawi, Dawit Jember Tesfaye, 
Belay Tesssema, Ornwipa Thamsuwan, Katie E Thomas, Amanda G Thrift, 
Tenaw Yimer Tiruye, Ruoyan Tobe-Gai, Mette C Tollanes, Marcello Tonelli, 
Roman Topor-Madry, Miguel Tortajada, Mathilde Touvier, Bach Xuan Tran, 
Suryakant Tripathi, Christopher Troeger, Thomas Truelsen, Derrick Tsoi, 
Kald Beshir Tuem, Emin Murat Tuzcu, Stefanos Tyrovolas, Kingsley N 
Ukwaja, Eduardo A Undurraga, Chigozie Jesse Uneke, Rachel Updike, 
Olalekan A Uthman, Benjamin S Chudi Uzochukwu, Job F M van Boven, 
Santosh Varughese, Tommi Vasankari, S Venkatesh, 
Narayanaswamy Venketasubramanian, Ramesh Vidavalur, 
Francesco S Violante, Sergey K Vladimirov, Vasiliy Victorovich Vlassov, 
Stein Emil Vollset, Fiseha Wadilo, Tolassa Wakayo, Yuan-Pang Wang, 
Marcia Weaver, Scott Weichenthal, Elisabete Weiderpass, 
Robert G Weintraub, Andrea Werdecker, Ronny Westerman, 
Harvey A Whiteford, Tissa Wijeratne, Charles Shey Wiysonge, 
Charles D A Wolfe, Rachel Woodbrook, Anthony D Woolf, 
Abdulhalik Workicho, Sarah Wulf Hanson, Denis Xavier, Gelin Xu, 
Simon Yadgir, Mohsen Yaghoubi, Bereket Yakob, Lijing L Yan, 
Yuichiro Yano, Pengpeng Ye, Hassen Hamid Yimam, Paul Yip, 
Naohiro Yonemoto, Seok-Jun Yoon, Marcel Yotebieng, Mustafa Z Younis, 
Zoubida Zaidi, Maysaa El Sayed Zaki, Elias Asfaw Zegeye, 
Zerihun Menlkalew Zenebe, Xueying Zhang, Maigeng Zhou, Ben Zipkin, 
Sanjay Zodpey, Liesl Joanna Zuhlke, Christopher J L Murray
Affiliations
Institute for Health Metrics and Evaluation (Prof T Vos PhD, 
A Afshin MD, S Aiyar, T Alam MPH, C Allen BA, M S Bannick BS, 
R M Barber BS, J Benson BA, K Bienhoff MA, S Biryukov BS, 
B R Bumgarner MBA, A Carter BS, D C Casey MPH, C D Castle BA, 
F J Charlson PhD, D Colombara PhD, Prof L Dandona MD, 
Prof R Dandona PhD, Prof L Degenhardt PhD, S Deiparine, D Dicker BS, 
D Douwes-Schultz BS, H E Erskine PhD, K Estep MPA, A J Ferrari PhD, 
C Fitzmaurice MD, A D Flaxman PhD, K J Foreman PhD, N Fullman 
MPH, Prof E Gakidou PhD, W W Godwin BS, A L Gold MSc, 
Global Health Metrics
www.thelancet.com   Vol 390   September 16, 2017 1251
E M Goldberg BS, M Griswold MA, J Harvey BS, C Hawley MS, 
Prof S I Hay DSc, N J Henry BS/BA, C Huynh BA, C Ikeda BS, 
C M S Irvine BA, C O Johnson PhD, S C Johnson MSc, 
N J Kassebaum MD, I A Khalil MD, P Kim BA, K J Krohn BA, 
H H Kyu PhD, D Li Kappe MBA, Prof S S Lim PhD, A Liu BS, 
P Y Liu MPH, R Lozano MD, H Manguerra BS, T Manhertz BA, 
L B Marczak PhD, I Martopullo MPH, M McGaughey BA, C McNellan BA, 
A Millear BA, M Mirarefin MPH, A Misganaw PhD, 
Prof A H Mokdad PhD, S Mollenkopf MPH, C Morozoff MPH, 
M Moses MHS, C Mountjoy-Venning BA, K Muller MPH, M Naghavi 
PhD, G Nguyen MPH, M Nguyen BS, E Nichols BA, H E Olsen MA, 
K Ong PhD, A Osgood-Zimmerman MS, K Paulson BS, D M Pigott DPhil, 
C Pinho BA, M A Pletcher BS, C Purcell BS, Z Rankin MPH, 
P C Rao MPH, S E Ray BS, R C Reiner PhD, N Reinig BS, M B Reitsma BS, 
G A Roth MD, N Sadat MA, J Salama MSc, D Santomauro PhD, 
K A Shackelford BA, C Shields BS, S Shirude MPH, E L Slepak MLIS, 
A Sligar MPH, Prof D L Smith PhD, M Smith MPA, 
R J D Sorensen MPH, V Srinivasan BA, J D Stanaway PhD, 
C Steiner MPH, B Strub BS, M Subart BA, P J Sur BA, D O Sylte BA, 
O Thamsuwan PhD, K E Thomas PhD, C Troeger MPH, D Tsoi BS, 
R Updike AB, Prof S E Vollset DrPH, M Weaver PhD, 
Prof H A Whiteford PhD, R Woodbrook MLIS, S Wulf Hanson MPH, 
S Yadgir BS, Prof M Zhou PhD, B Zipkin BS, Prof C J L Murray DPhil), 
Division of Hematology, Department of Medicine (C Fitzmaurice MD), 
Center for Health Trends and Forecasts, Institute for Health Metrics and 
Evaluation (Prof M B Jakovljevic PhD), University of Washington, Seattle, 
WA, USA (N D Futran MD, P N Jensen PhD, J Leung PhD, 
S D Morrison MD); School of Public Health (A A Abajobir MPH, 
F J Charlson PhD, J Ellerstrand MD, H E Erskine PhD, A J Ferrari PhD, 
J Leung PhD, A Mantilla MHEcon, D Santomauro PhD, 
Prof H A Whiteford PhD), School of Dentistry (Prof R Lalloo PhD), 
Queensland Brain Institute (Prof J J McGrath PhD), University of 
Queensland, Brisbane, QLD, Australia (S R Mishra MPH); La Sapienza 
University, Rome, Italy (C Abbafati PhD); Virginia Tech, Blacksburg, VA, 
USA (Prof K M Abbas PhD); Department of Neurology, Cairo University, 
Cairo, Egypt (Prof F Abd-Allah MD); New York University Abu Dhabi, 
Abu Dhabi, United Arab Emirates (A M Abdulle PhD); Hawassa 
University College of Medicine and Health Sciences, Hawassa, Ethiopia 
(T A Abebo MPH, D J Tesfaye MPH); School of Public Health, College of 
Health Sciences (S F Abera MSc), School of Pharmacy (D F Berhe MS), 
College of Health Sciences (D T Mengistu MS, K E Mohammed MPH), 
School of Public Health (G R Taffere PhD), Mekelle University, Mekelle, 
Ethiopia (S W Asgedom MS, T M Atey MS, B D Betsu MS, 
G B Hailu MSc, A Kahsay MPH, H B Mezgebe MS, K B Tuem MS, 
Z M Zenebe MS); Food Security and Institute for Biological Chemistry and 
Nutrition, University of Hohenheim, Stuttgart, Germany (S F Abera MSc); 
Dupuytren University Hospital, Limoges, France (Prof V Aboyans PhD); 
Infectious Disease Epidemiology Group, Weill Cornell Medical College in 
Qatar, Doha, Qatar (L J Abu-Raddad PhD); Department of Epidemiology 
and Preventive Medicine, School of Public Health and Preventive Medicine 
(I N Ackerman PhD, Prof R Buchbinder PhD), Department of Medicine, 
School of Clinical Sciences at Monash Health (Prof A G Thrift PhD), 
Monash University, Melbourne, VIC, Australia (Prof B de Courten PhD); 
Center for Infectious Diseases Research, Kano, Nigeria (A A Adamu MS); 
Department of Psychiatry (Prof C D Parry PhD), Stellenbosch University, 
Cape Town, South Africa (O Adetokunboh MD, Prof J B Nachega PhD, 
Prof S Seedat PhD, Prof C S Wiysonge PhD); All India Institute of Medical 
Sciences, New Delhi, India (Prof S K Agarwal MD, R Lodha MD, 
Prof R Malhotra MS, A Roy DM, R Sagar MD, Prof N Tandon PhD); 
Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India 
(Prof R Aggarwal MD); CSIR - Institute of Genomics and Integrative 
Biology, Delhi, India (A Agrawal PhD); Department of Internal Medicine, 
Baylor College of Medicine, Houston, TX, USA (A Agrawal PhD); Indian 
Institute of Public Health (S Dey PhD, Prof G V S Murthy MD), Centre for 
Control of Chronic Conditions (P Jeemon PhD), Public Health Foundation 
of India, Gurugram, India (S Agrawal PhD, Prof L Dandona MD, 
Prof R Dandona PhD, P K Dhillon PhD, G A Kumar PhD, D K Lal MD, 
M R Mathur PhD, Prof S Zodpey PhD); Department of Clinical Sciences 
Lund, Orthopedics, Clinical Epidemiology Unit (A Ahmad Kiadaliri PhD), 
Skane University Hospital, Department of Clinical Sciences Lund, 
Neurology (Prof B Norrving PhD), Lund University, Lund, Sweden; 
Ophthalmic Research Center (H Ahmadieh MD), School of Public Health 
(N Jahanmehr PhD), Ophthalmic Epidemiology Research Center 
(S Safi MS), Shahid Beheshti University of Medical Sciences, Tehran, Iran; 
Department of Ophthalmology, Labbafinejad Medical Center, Tehran, Iran 
(H Ahmadieh MD); Department of Epidemiology, College of Health 
Sciences (M B Ahmed MPH), Jimma University, Jimma, Ethiopia 
(T T Gebrehiwot MPH, H A Gesesew MPH, M A Mengistie MS, 
T Wakayo MS, A Workicho MPH); University Ferhat Abbas of Setif, Setif, 
Algeria (A N Aichour BS); National Institute of Nursing Education, Setif, 
Algeria (I Aichour MS); High National School of Veterinary Medicine, 
Algiers, Algeria (M T Aichour MD); University of Ibadan, Ibadan, Nigeria 
(R O Akinyemi PhD); Newcastle University, Newcastle upon Tyne, UK 
(R O Akinyemi PhD); Centre for Global Child Health, The Hospital for 
Sick Children, Toronto, ON, Canada (N Akseer MSc, Z A Bhutta PhD); 
Dalla Lana School of Public Health (N Akseer MSc), Department of 
Nutritional Sciences, Faculty of Medicine (A Badawi PhD), Centre for 
Addiction and Mental Health (S Popova PhD), University of Toronto, 
Toronto, ON, Canada; Baghdad College of Medicine, Baghdad, Iraq 
(F H Al Lami PhD); Mayo Clinic Foundation for Medical Education and 
Research, Rochester, MN, USA (F Alahdab MD); Syrian American Medical 
Society, Washington, DC, USA (F Alahdab MD); Washington University in 
St Louis, St Louis, MO, USA (Z Al-Aly MD); Murdoch Childrens Research 
Institute (K Alam PhD), Melbourne School of Population and Global 
Health (Prof A D Lopez PhD), Department of Medicine (A Meretoja PhD), 
Murdoch Childrens Research Institute, Department of Paediatrics 
(Prof G C Patton MD), The University of Melbourne, Melbourne, VIC, 
Australia (K Alam PhD, Prof H R Taylor AC, R G Weintraub MBBS, 
Prof T Wijeratne MD); Sydney School of Public Health 
(Prof T R Driscoll PhD), The University of Sydney, Sydney, NSW, Australia 
(K Alam PhD, J Leigh PhD); Department of Health, Queensland, 
Brisbane, QLD, Australia (N Alam MAppEpid); Ministry of Health, 
Al Khuwair, Oman (D Alasfoor MSc); Department of Epidemiology and 
Biostatistics, Institute of Public Health (K A Alene MPH), College of 
Medical and Health Sciences (B B Bekele PhD), University of Gondar, 
Gondar, Ethiopia (Prof A F Dadi MPH, B Tesssema PhD); Department of 
Global Health, Research School of Population Health (K A Alene MPH), 
Australian National University, Canberra, ACT, Australia 
(Prof K E Doyle PhD); Malaria Atlas Project (K E Battle DPhil), Oxford Big 
Data Institute, Li Ka Shing Centre for Health Information and Discovery 
(E Cameron PhD, Prof S I Hay DSc, T C D Lucas PhD), Nuffield 
Department of Population Health (D A Bennett PhD), Nuffield 
Department of Medicine (D Bisanzio PhD), NIHR Musculoskeletal 
Biomedical Research Centre (Prof C Cooper FMedSci), Department of 
Zoology (P W Gething PhD), University of Oxford, Oxford, UK (R Ali MSc, 
Prof V Jha DM, K Rahimi DM); Gastrointestinal Cancer Research Center, 
Mazandaran University of Medical Sciences, Sari, Iran 
(R Alizadeh-Navaei PhD); Luxembourg Institute of Health, Strassen, 
Luxembourg (A Alkerwi PhD); School of Public Health, University of 
Lorraine, Nancy, France (Prof F Alla PhD); College of Medicine and Health 
Sciences, United Arab Emirates University, Al Ain, United Arab Emirates 
(Prof F Al-Maskari PhD, S Alsowaidi MD); Joint Program of Family and 
Community Medicine, Jeddah, Saudi Arabia (R Al-Raddadi PhD); 
Department of Psychosomatic Medicine, Center for Internal Medicine and 
Dermatology (S Nolte PhD), Charité Universitätsmedizin, Berlin, 
Germany (U Alsharif MPH); King Saud University, Riyadh, Saudi Arabia 
(K A Altirkawi MD, B H A Sobaih MD); School of Medicine 
(A T Amare MPH, Prof B T Baune PhD, L G Ciobanu MS), Discipline of 
Psychiatry (A T Olagunju MS), University of Adelaide, Adelaide, SA, 
Australia; College of Medicine and Health Sciences (A T Amare MPH), 
Bahir Dar University, Bahir Dar, Ethiopia (T Setegn MPH); Uro-Oncology 
Research Center (E Amini MD), Non-Communicable Diseases Research 
Center (E Amini MD, F Farzadfar MD, A Khosravi PhD, 
M Parsaeian PhD), Endocrinology and Metabolism Research Center 
(M Afarideh MD, A Kasaeian PhD, Prof A Esteghamati MD, 
N Hafezi-Nejad MD), Department of Internal Medicine (A Ghajar MD), 
Center for Air Pollution Research, Institute for Environmental Research 
(M S Hassanvand PhD), Multiple Sclerosis Research Center, Neuroscience 
Institute (P Heydarpour MD), Hematology-Oncology and Stem Cell 
Transplantation Research Center (A Kasaeian PhD), Institute of Health 
Policy and Management (M Mahdavi PhD), Knowledge Utilization 
Research Center (Prof R Majdzadeh PhD), Digestive Diseases Research 
Global Health Metrics
1252 www.thelancet.com   Vol 390   September 16, 2017
Institute (Prof R Malekzadeh MD, G Roshandel PhD, S G Sepanlou PhD), 
Department of Epidemiology and Biostatistics, School of Public Health 
(M Parsaeian PhD), Iranian National Center for Addiction Studies 
(INCAS) (A Rahimi-Movaghar MD), Sina Trauma and Surgery Research 
Center (Prof V Rahimi-Movaghar MD, S Saadat PhD, M Safdarian MD), 
Institute for Environmental Research (M Shamsipour PhD), Cancer 
Research Center (Prof R Shirkoohi PhD), Tehran University of Medical 
Sciences, Tehran, Iran (M Ganji MD); Ministry of Public Health, Beirut, 
Lebanon (W Ammar PhD, H L Harb MPH); Department of Medicine, 
Komfo Anokye Teaching Hospital, Kumasi, Ghana (Y A Amoako MD); 
Center for Sensory-Motor Interaction, Department of Health Science and 
Technology, Faculty of Medicine (H H Andersen MSc), Aalborg University, 
Aalborg Esst, Denmark (C B Peterson PhD); Department of Health Policy 
and Administration, College of Public Health, University of the 
Philippines Manila, Manila, Philippines (C A T Antonio MD); 
Self-employed, Kabul, Afghanistan (P Anwari MS); Department of 
Neurobiology, Care Sciences and Society Division of Family Medicine and 
Primary Care (Prof J Ärnlöv PhD, S Fereshtehnejad PhD), Department of 
Medical Epidemiology and Biostatistics (Prof J J Carrero PhD, 
E Weiderpass PhD), Department of Public Health Sciences (Prof P 
Allebeck PhD, Z Z El-Khatib PhD, R H S Rabiee MPH), Karolinska 
Institutet, Stockholm, Sweden (R Havmoeller PhD); School of Health and 
Social Studies, Dalarna University, Falun, Sweden (Prof J Ärnlöv PhD); 
University of Manitoba, Winnipeg, MB, Canada (A Artaman PhD); Nepal 
Health Research Council, Kathmandu, Nepal (K K Aryal MPH); University 
of Oslo, Oslo, Norway (K K Aryal MPH, A S Htet MPhil); Department of 
Medical Emergency, School of Paramedic, Qom University of Medical 
Sciences, Qom, Iran (H Asayesh MS); Mashhad University of Medical 
Sciences, Mashhad, Iran (R Assadi PhD); Mizan Tepi University, Mizan 
Teferi, Ethiopia (N T Atnafu MS, H H Yimam MPH); Centre for Clinical 
Global Health Education (CCGHE) (S R Atre PhD), Johns Hopkins 
University, Baltimore, MD, USA (B X Tran PhD); Dr D Y Patil Vidyapeeth 
Pune, Pune, India (S R Atre PhD); National Institute of Public Health, 
Cuernavaca, Mexico (L Avila-Burgos PhD, S Barquera PhD, 
L Cahuana-Hurtado PhD, I B Heredia-Pi PhD, R Lozano MD, 
J Montañez Hernandez MSc, Prof E E Servan-Mori MSc); Institut de 
Recherche Clinique du Bénin (IRCB), Cotonou, Benin 
(E F G A Avokpaho MPH); Laboratoire d’Etudes et de Recherche-Action en 
Santé (LERAS Afrique), Parakou, Benin (E F G A Avokpaho MPH); Indian 
Institute of Public Health, Gandhinagar, India (A Awasthi PhD); The 
Judith Lumley Centre for Mother, Infant and Family Health Research, La 
Trobe University, Melbourne, VIC, Australia (B P Ayala Quintanilla PhD); 
Peruvian National Institute of Health, Lima, Peru 
(B P Ayala Quintanilla PhD); Faculty of Medicine and Health Sciences, 
Aden University, Aden, Yemen (Prof H O Ba Saleem PhD); School of 
Health Sciences, University of Management and Technology, Lahore, 
Pakistan (U Bacha PhD); Public Health Agency of Canada, Toronto, ON, 
Canada (A Badawi PhD); Department of Environmental Health 
Engineering, Sri Ramachandra University, Chennai, India 
(K Balakrishnan PhD); Farr Institute of Health Informatics Research 
(A Banerjee DPhil), Department of Epidemiology and Public Health 
(Prof M Kivimaki PhD), University College London, London, UK 
(C Birungi MS, M R Mathur PhD); Faculty of Medicine (A Barac PhD), 
Institute of Social Medicine and Centre School of Public Health and 
Health Management, Faculty of Medicine (M M Santric Milicevic PhD), 
University of Belgrade, Belgrade, Serbia; School of Psychology, University 
of Auckland, Auckland, New Zealand (S L Barker-Collo PhD); Department 
of Global Health and Population, Harvard T H Chan School of Public 
Health (Prof T Bärnighausen MD, E L Ding ScD, J A Salomon PhD), 
Ariadne Labs (E R K Macarayan PhD), Harvard University, Boston, MA, 
USA; Africa Health Research Institute, Mtubatuba, South Africa 
(Prof T Bärnighausen MD); Institute of Public Health, Heidelberg 
University, Heidelberg, Germany (Prof T Bärnighausen MD, 
S Mohammed PhD); Department of Occupational and Environmental 
Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, 
Sweden (Prof L Barregard MD); Department of Industrial Engineering, 
School of Engineering, Pontificia Universidad Javeriana, Bogota, Colombia 
(L H Barrero ScD); Stanford University, Stanford, CA, USA (S Basu PhD); 
Doctor Evidence, Santa Monica, CA, USA (B Battista MA, M S Fazeli MD); 
College of Medicine, Charles R Drew University of Medicine and Science, 
Los Angeles, CA, USA (Prof S Bazargan-Hejazi PhD); David Geffen 
School of Medicine, University of California at Los Angeles, Los Angeles, 
CA, USA (Prof S Bazargan-Hejazi PhD); Oxford University, Ho Chi Minh 
City, Vietnam (J Beardsley MBCHB); College of Public Health and Tropical 
Medicine, Jazan, Saudi Arabia (N Bedi MD); IRCCS - Istituto di Ricerche 
Farmacologiche Mario Negri, Milan, Italy (E Beghi MD, G Giussani BiolD); 
University Hospital and Medical School of Dijon, University of Burgundy, 
Dijon, France (Prof Y Béjot PhD); Mizan Tepi University, Mizan Aman, 
Ethiopia (B B Bekele PhD); Yale University, New Haven, CT, USA 
(Prof M L Bell PhD); Center for Clinical and Epidemiological Research 
Center, Hospital Universitario (A C Goulart PhD), Internal Medicine 
Department (Prof I S Santos PhD), University of São Paulo, São Paulo, 
Brazil (I M Bensenor PhD, Prof P A Lotufo DrPh); College of Health 
Sciences (A Berhane PhD), Public Health Department, College of Health 
(K B Mruts MPH), Debre Berhan University, Debre Berhan, Ethiopia; 
University Medical Center Groningen (D F Berhe MS), Department of 
Psychiatry, University Medical Center Groningen (Prof H W Hoek MD), 
University of Groningen, Groningen, Netherlands (J F M van Boven PhD); 
Division of Health and Social Care Research (Prof C D Wolfe MD), King’s 
College London, London, UK (E Bernabé PhD, Prof R J Hay DM); Carol 
Davila University of Medicine and Pharmacy, Bucharest, Romania 
(Prof M Beuran PhD, D V Davitoiu PhD, S Hostiuc PhD, I Negoi PhD, 
R I Negoi PhD); Emergency Hospital of Bucharest, Bucharest, Romania 
(Prof M Beuran PhD, I Negoi PhD); College of Health and Medical 
Sciences (A S Beyene MPH), Haramaya University, Harar, Ethiopia 
(L N B Bulto MS, A Geleto MPH, M D Gishu MS, D E Negasa MS); 
Queen Elizabeth Hospital Birmingham, Birmingham, UK 
(N Bhala DPhil); University of Otago Medical School, Wellington, New 
Zealand (N Bhala DPhil); Postgraduate Institute of Medical Education and 
Research, Chandigarh, India (A Bhansali DM); Department of Infectious 
Disease Epidemiology (S Bhatt DPhil, T Fürst PhD), Department of 
Primary Care & Public Health (Prof A Majeed MD), Division of Brain 
Sciences (Prof T J Steiner PhD), Imperial College London, London, UK 
(M Car PhD, Prof S Rawaf MD, S Saxena MD); Centre of Excellence in 
Women and Child Health, Aga Khan University, Karachi, Pakistan 
(Z A Bhutta PhD); Independent Public Health Consultants, Addis Ababa, 
Ethiopia (S Biadgilign MPH); IRCCS - Istituto di Ricerche Farmacologiche 
Mario Negri, Bergamo, Italy (B Bikbov MD, N Perico MD, 
Prof G Remuzzi MD); Department of Public Health (D J Boneya MPH), 
Debre Markos University, Debre Markos, Ethiopia (H M Bizuayehu MPH, 
G M Kassa MS, C T Leshargie MPH, T Y Tiruye MPH); Transport and 
Road Safety (TARS) Research (S Boufous PhD), National Drug and Alcohol 
Research Centre (Prof L Degenhardt PhD), Brien Holden Vision Institute 
and School of Optometry and Vision Science (Prof S Resnikoff MD), 
University of New South Wales, Kensington, NSW, Australia 
(Prof P B Mitchell MD); Vision & Eye Research Unit, Anglia Ruskin 
University, Cambridge, UK (Prof R R A Bourne MD); Faculty of Health 
Sciences and Social Work, Department of Public Health, Faculty of 
Medicine, Comenius University, Bratislava, Slovakia (A Brazinova MD); 
University of Leicester, Leicester, UK (Prof T S Brugha MD); Monash 
Department of Clinical Epidemiology, Cabrini Institute, Melbourne, VIC, 
Australia (Prof R Buchbinder PhD); Al Shifa Trust Eye Hospital, 
Rawalpindi, Pakistan (Z A Butt PhD); Ministry of Health of the Republic of 
Croatia, Zagreb, Croatia (M Car PhD); Department of Biostatistics and 
Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma 
City, OK, USA (H Carabin PhD); Telethon Kids Institute, Princess 
Margaret Hospital for Children, The University of Western Australia, 
Subiaco, WA, Australia (Prof J R Carapetis PhD); Metropolitan 
Autonomous University, Mexico City, Mexico (R Cárdenas ScD); University 
at Albany, Rensselaer, NY, USA (Prof D O Carpenter MD); Faculty of 
Pharmacy (Prof F Carvalho PhD), i3S - Instituto de Investigação e 
Inovação em Saúde and INEB - Instituto de Engenharia Biomédica 
(J das Neves PhD), Faculty of Medicine (J V Santos MD), UCIBIO@
REQUIMTE, Toxicology Group, Faculty of Pharmacy (J P Silva PhD), 
University of Porto, Porto, Portugal; Stroke Unit, University of Perugia, 
Perugia, Italy (V Caso MD); Colombian National Health Observatory, 
Instituto Nacional de Salud, Bogota, Colombia 
(C A Castañeda-Orjuela MSc); Epidemiology and Public Health Evaluation 
Group, Public Health Department, Universidad Nacional de Colombia, 
Bogota, Colombia (C A Castañeda-Orjuela MSc); Department of Medicine, 
University of Valencia, INCLIVA Health Research Institute and 
CIBERSAM, Valencia, Spain (F Catalá-López PhD, 
Global Health Metrics
www.thelancet.com   Vol 390   September 16, 2017 1253
Prof R Tabarés-Seisdedos PhD); Clinical Epidemiology Program, Ottawa 
Hospital Research Institute, Ottawa, ON, Canada (F Catalá-López PhD); 
National Health Research Institutes, Zgunan Town, Taiwan 
(H Chang DrPH); National Yang-Ming University, Taipei, Taiwan 
(H Chang DrPH); School of Nursing, College of Medicine, National 
Taiwan University, Taipei, Taiwan (Prof J Chang PhD); The Park Centre for 
Mental Health (Prof J J McGrath PhD), Queensland Centre for Mental 
Health Research, Brisbane, QLD, Australia (F J Charlson PhD, 
H E Erskine PhD, A J Ferrari PhD, D Santomauro PhD, 
Prof H A Whiteford PhD); Michigan State University, East Lansing, MI, 
USA (H Chen PhD); Crowd Watch Africa, Lusaka, Zambia 
(M Chibalabala BS); National Center for Child Health and Development, 
Setagaya ku, Japan (C E Chibueze PhD); University of Zambia, Lusaka, 
Zambia (V H Chisumpa MPhil, C C Mapoma PhD); University of 
Witwatersrand, Johannesburg, South Africa (V H Chisumpa MPhil); 
Ministry of Health, Baghdad, Iraq (A A Chitheer MD); Christian Medical 
College, Vellore, India (Prof D J Christopher MD, Prof S Varughese DM); 
University of Salerno, Baronissi, Italy (Prof M Cirillo MD); MRC 
Lifecourse Epidemiology Unit, University of Southampton, Southampton, 
UK (Prof C Cooper FMedSci); NIHR Biomedical Research Centre, 
University of Southampton and University Hospital Southampton NHS 
Foundation Trust, Southampton, UK (Prof C Cooper FMedSci); Research 
Centre on Public Health (CESP), University of Milan-Bicocca, Monza, Italy 
(P A Cortesi PhD); VA San Diego (S K Jassal MD), University of California, 
San Diego, La Jolla, CA, USA (M H Criqui MD, M B Stein MD); Centre for 
International Health, Dunedin School of Medicine (Prof J A Crump MD), 
University of Otago, Dunedin, New Zealand (Prof R G Poulton PhD); 
Flinders University, Adelaide, SA, Australia (Prof A F Dadi MPH, 
H A Gesesew MPH, Prof K Pesudovs PhD); Centre for Injury Prevention 
and Safety Promotion, School of Health and Medical Sciences, Orebro 
University, Orebro, Sweden (Prof K Dalal PhD); Griffith University, 
Brisbane, QLD, Australia (Prof D De Leo DSc); University of Colorado 
School of Medicine and the Colorado School of Public Health, Aurora, CO, 
USA (R P Dellavalle MD); Brighton and Sussex Medical School, Brighton, 
UK (K Deribe MPH); School of Public Health (K Deribe MPH, 
A D Hailu MPH), Addis Ababa University, Addis Ababa, Ethiopia 
(A Z Giref PhD, H A Hareri MS, N A Kassaw MPH, G Temam Shifa 
MPH); Mount Sinai Beth Israel, New York, NY, USA 
(Prof D C Des Jarlais PhD); Icahn School of Medicine at Mount Sinai, New 
York, NY, USA (Prof D C Des Jarlais PhD); Department of Community 
Medicine, Faculty of Medicine, University of Peradeniya, Peradeniya, Sri 
Lanka (S D Dharmaratne MD); Undersecretary for Research & Technology, 
Ministry of Health & Medical Education, Tehran, Iran (S Djalalinia PhD); 
Institute for Global Health Innovations, Duy Tan University, Da Nang, 
Vietnam (H P Do MSc, C T Nguyen MSc, Q L Nguyen MD, 
T H Nguyen MSc, V M Nong MSc); University of Rochester Medical 
Center, Rochester, NY, USA (E R Dorsey MD); Universidade do Estado de 
Santa Catarina, Florianópolis, Brazil (Prof K P B dos Santos MA); RMIT 
University, Bundoora, VIC, Australia (Prof K E Doyle PhD); International 
Institute for Population Sciences, Mumbai, India (M Dubey MPhil, 
A Kastor MPhil, P Kumar MPhil, Prof S K Mohanty PhD, 
B K Panda MPhil, M H U Rahman MPhil, Prof U Ram PhD); Federal 
University of Rio Grande do Sul, Porto Alegre, Brazil (B B Duncan PhD, 
C Kieling MD, Prof M I Schmidt MD); University of North Carolina, 
Chapel Hill, NC, USA (B B Duncan PhD); Department of Global Health 
and Social Medicine, Harvard Medical School, Kigali, Rwanda 
(Z Z El-Khatib PhD); School of Public Health and Health Sciences 
Research Center, Sari, Iran (Prof A Enayati PhD); Arba Minch University, 
Arba Minch, Ethiopia (A Y Endries MPH, G Temam Shifa MPH); The 
Institute of Social and Economic Studies of Population, Russian Academy 
of Sciences, Moscow, Russia (Prof S P Ermakov DSc); Federal Research 
Institute for Health Organization and Informatics, Ministry of Health of 
the Russian Federation, Moscow, Russia (Prof S P Ermakov DSc); Ministry 
of Health and Medical Education, Tehran, Iran (B Eshrati PhD); Arak 
University of Medical Sciences, Arak, Iran (B Eshrati PhD); Multiple 
Sclerosis Research Center, Tehran, Iran (S Eskandarieh PhD); Hawassa 
University, Hawassa, Ethiopia (F B B Fanuel MPH); Wolaita Sodo 
University, Wolaita Sodo, Ethiopia (F B B Fanuel MPH, F Wadilo MS); 
DGS Directorate General of Health, Lisboa, Portugal 
(C S E S Farinha MSc); Universidade Aberta, Lisboa, Portugal 
(C S E S Farinha MSc); Federal University of Sergipe, Aracaju, Brazil 
(Prof A Faro PhD); National Institute for Stroke and Applied 
Neurosciences, Auckland University of Technology, Auckland, New 
Zealand (V L Feigin PhD); CBQF - Center for Biotechnology and Fine 
Chemistry - Associate Laboratory, Faculty of Biotechnology, Catholic 
University of Portugal, Porto, Portugal (J C Fernandes PhD); Wollega 
University, Nekemte, Ethiopia (T R Feyissa MPH, T Tekelab MS); Kaiser 
Permanente, Fontana, CA, USA (I Filip MD); School of Public Health, 
Bielefeld University, Bielefeld, Germany (F Fischer PhD); Fred Hutchinson 
Cancer Research Center, Seattle, WA, USA (C Fitzmaurice MD); Escola 
Nacional de Saúde Pública Sergio Arouca (ENSP/Fiocruz), Rio de Janeiro, 
Brazil (L S Flor MPH); Universidade Federal do Espírito Santo, Vitoria, 
Brazil (L S Flor MPH); Institute of Gerontology, Academy of Medical 
Science, Kyiv, Ukraine (N Foigt PhD); James Cook University, Townsville, 
QLD, Australia (R C Franklin PhD); Department of Epidemiology and 
Public Health (T Fürst PhD), Swiss Tropical and Public Health Institute, 
Basel, Switzerland (C K Karema MSc); University of Basel, Basel, 
Switzerland (T Fürst PhD); Faculdade de Medicina de Ribeirão Preto, 
Universidade de São Paulo, Ribeirão Preto, Brazil (J M Furtado MD); 
Manhiça Health Research Center, Manhiça, Mozambique 
(A L Garcia-Basteiro MSc); Barcelona Institute for Global Health, 
Barcelona, Spain (A L Garcia-Basteiro MSc); The Task Force for Global 
Health, Decatur, GA, USA (T Gebre PhD); University of Newcastle, 
Newcastle, NSW, Australia (A Geleto MPH, T Tekelab MS); Madda Walabu 
University, Bale Goba, Ethiopia (B L Gemechu MPH); The Peter Doherty 
Institute for Infection and Immunity, The University of Melbourne & 
The Royal Melbourne Hospital, Melbourne, VIC, Australia 
(K B Gibney MBBS); Warwick Medical School, University of Birmingham, 
Birmingham, UK (Prof P S Gill DM); Howard University, Washington, 
DC, USA (R F Gillum MD); College of Medicine, University of Hail, Hail, 
Saudi Arabia (I A Ginawi MD); Kersa Health and Demographic 
Surveillance System, Harar, Ethiopia (M D Gishu MS); University of 
Massachusetts Boston, Boston, MA, USA (Prof P N Gona PhD); Instituto 
de Investigaciones Cientificas y Servicios de Alta Tecnologia - 
INDICASAT-AIP, Cuidad del Saber, Panama (A Goodridge PhD); 
Department of Health and Social Affairs, Government of the Federated 
States of Micronesia, Palikir, Federated States of Micronesia 
(S V Gopalani MPH); Division of Epidemiology, Center for Public Health 
Sciences, National Cancer Center, Tokyo, Japan (A Goto PhD); Center of 
Check of Hospital Sirio Libanes, São Paulo, Brazil (A C Goulart PhD); 
Departments of Microbiology and Epidemiology & Biostatistics, Saint 
James School of Medicine, The Quarter, Anguilla 
(Prof H C Gugnani PhD); West Virginia Bureau for Public Health, 
Charleston, WV, USA (R Gupta MD); Eternal Heart Care Centre and 
Research Institute, Jaipur, India (R Gupta PhD); Montefiore Medical 
Center, Bronx, NY, USA (T Gupta MD); Albert Einstein College of 
Medicine, Bronx, NY, USA (T Gupta MD, Prof H D Hosgood PhD); 
Department of Anthropology, University of Delhi, Delhi, India 
(V Gupta PhD); Department of Psychosocial Science (A K Knudsen PhD), 
Department of Global Public Health and Primary Care 
(Prof S E Vollset DrPH), University of Bergen, Bergen, Norway 
(A D Hailu MPH, M C Tollanes PhD); Kilte Awlaelo Health and 
Demographic Surveillance System, Mekelle, Ethiopia (G B Hailu MSc); 
Arabian Gulf University, Manama, Bahrain (Prof R R Hamadeh DPhil); 
Hamdan Bin Mohammed Smart University, Dubai, United Arab Emirates 
(S Hamidi DrPH); University of New Mexico, Albuquerque, NM, USA 
(A J Handal PhD); School of Medicine and Pharmacology, University of 
Western Australia, Perth, WA, Australia (Prof G J Hankey MD); 
Harry Perkins Institute of Medical Research, Nedlands, WA, Australia 
(Prof G J Hankey MD); Western Australian Neuroscience Research 
Institute, Nedlands, WA, Australia (Prof G J Hankey MD); School of Public 
Health, Sun Yat-sen University, Guangzhou, China (Prof Y Hao PhD); Parc 
Sanitari Sant Joan de Déu - CIBERSAM, Sant Boi de Llobregat (Barcelona), 
Spain (J M Haro MD); International Foundation for Dermatology, London, 
UK (Prof R J Hay DM); Department of Epidemiology, Mailman School of 
Public Health (Prof H W Hoek MD), Columbia University, New York, NY, 
USA (Prof V Skirbekk PhD); Epidemiology and Statistics Program, 
National Institute on Deafness and Other Communication Disorders 
(H J Hoffman MA), Center for Translation Research and Implementation 
Science, National Heart, Lung, and Blood Institute (G A Mensah MD), 
National Institutes of Health, Bethesda, MD, USA; Department of 
Pulmonology, Yokohama City University Graduate School of Medicine, 
Global Health Metrics
1254 www.thelancet.com   Vol 390   September 16, 2017
Yokohama, Japan (N Horita MD); College of Medicine, Baylor University, 
Houston, TX, USA (P J Hotez PhD); Public Health Division, The Pacific 
Community, Noumea, New Caledonia (D G Hoy PhD); International 
Relations Division, Ministry of Health, Nay Pyi Taw, Myanmar 
(A S Htet MPhil); Department of Epidemiology and Health Statistics, 
School of Public Health, Central South University, Changsha, China 
(G Hu PhD); Cambridge Health Alliance, Cambridge, MA, USA 
(H Huang MD); National Centre for Register-Based Research, Aarhus 
School of Business and Social Sciences (Prof J J McGrath PhD), Aarhus 
University, Aarhus, Denmark (K M Iburg PhD); US Centers for Disease 
Control and Prevention, Pretoria, South Africa (Prof E U Igumbor PhD); 
School of Public Health, University of the Western Cape, Cape Town, 
South Africa (Prof E U Igumbor PhD); Department of Global and 
Community Health, George Mason University, Fairfax, VA, USA 
(K H Jacobsen PhD); Faculty of Medical Sciences, University of 
Kragujevac, Kragujevac, Serbia (Prof M B Jakovljevic PhD); University of 
Aberdeen, Aberdeen, UK (M Javanbakht PhD); Department of Surgery, 
Virginia Commonwealth University, Richmond, VA, USA 
(S P Jayaraman MD); Centre for Chronic Disease Control, New Delhi, 
India (P Jeemon PhD, D Prabhakaran DM); The George Institute for 
Global Health, New Delhi, India (Prof V Jha DM); Tianjin Centers for 
Disease Control and Prevention, Tianjin, China (G Jiang MD); 
International Center for Research on Women, New Delhi, India 
(D John MPH); Department of Ophthalmology, Medical Faculty 
Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim, Germany 
(Prof J B Jonas MD); Institute of Family Medicine and Public Health, 
University of Tartu, Tartu, Estonia (M Jürisson MD); University College 
Cork, Cork, Ireland (Z Kabir PhD); London School of Economics and 
Political Science, London, UK (R Kadel MPH); CSIR - Indian Institute of 
Toxicology Research, Lucknow, India (R Kamal MSc); Department of 
Pulmonary Medicine, Zhongshan Hospital (J She MD), Fudan University, 
Shanghai, China (H Kan MD); University of Balamand, Beirut, Lebanon 
(N E Karam MD); Epidemiological and Statistical Methods Research 
Group, Helmholtz Centre for Infection Research, Braunschweig, Germany 
(A Karch MD); Hannover-Braunschweig Site, German Center for Infection 
Research, Braunschweig, Germany (A Karch MD); Quality and Equity 
Health Care, Kigali, Rwanda (C K Karema MSc); Department of 
Anesthesiology & Pain Medicine, Seattle Children’s Hospital, Seattle, WA, 
USA (N J Kassebaum MD); MRC/CSO Social & Public Health Sciences 
Unit, University of Glasgow, Glasgow, UK (S V Katikireddi PhD); 
Oklahoma State University, Tulsa, OK, USA (A Kaul MD); School of Public 
Health, University of Tokyo, Tokyo, Japan (Prof N Kawakami MD); 
Institute of Tropical and Infectious Diseases, Nairobi, Kenya 
(P N Keiyoro PhD); School of Continuing and Distance Education, Nairobi, 
Kenya (P N Keiyoro PhD); UKZN Gastrointestinal Cancer Research Centre 
(Prof B Sartorius PhD), South African Medical Research Council, Cape 
Town, South Africa (A P Kengne PhD); Department of Psychiatry 
(Prof D J Stein PhD), University of Cape Town, Cape Town, South Africa 
(A P Kengne PhD, J J N Noubiap MD); Assuta Hospitals, Assuta 
Hashalom, Tel Aviv, Israel (Prof A Keren MD); Department of Community 
Medicine, Public Health and Family Medicine, Jordan University of 
Science and Technology, Irbid, Jordan (Prof Y S Khader ScD); Health 
Services Academy, Islamabad, Pakistan (E A Khan MD); Department of 
Health Policy and Management, Seoul National University College of 
Medicine, Seoul, South Korea (Prof Y Khang MD); Institute of Health 
Policy and Management, Seoul National University Medical Center, Seoul, 
South Korea (Prof Y Khang MD); Iranian Ministry of Health and Medical 
Education, Tehran, Iran (A Khosravi PhD); Department of Nutrition and 
Health Science, Ball State University, Muncie, IN, USA 
(J Khubchandani PhD); Hospital de Clinicas de Porto Alegre, Porto Alegre, 
Brazil (C Kieling MD); Department of Health Sciences, Northeastern 
University, Boston, MA, USA (Prof D Kim DrPH); School of Medicine, 
Xiamen University Malaysia Campus, Sepang, Malaysia (Y J Kim PhD); 
Simmons College, Boston, MA, USA (R W Kimokoti MD); Centre for 
Research and Action in Public Health, University of Canberra, Canberra, 
ACT, Australia (Y Kinfu PhD); Oslo University, Oslo, Norway 
(Prof A Kisa PhD); Institute of Public Health, Faculty of Health Sciences 
(R Topor-Madry PhD), Jagiellonian University Medical College, Krakow, 
Poland (K A Kissimova-Skarbek PhD); Clinicum (Prof M Kivimaki PhD), 
Finnish Institute of Occupational Health, Work Organizations, Work 
Disability Program, Department of Public Health (R Shiri PhD), Faculty of 
Medicine, University of Helsinki, Helsinki, Finland (T J Meretoja PhD); 
Center for Disease Burden (A K Knudsen PhD, Prof S E Vollset DrPH), 
Norwegian Institute of Public Health, Oslo, Norway 
(Prof V Skirbekk PhD); Department of Preventive Cardiology, National 
Cerebral and Cardiovascular Center, Suita, Japan (Y Kokubo PhD); 
Division of Cardiology, Brown University, Providence, RI, USA 
(D Kolte MD); University of British Columbia, Vancouver, BC, Canada 
(J A Kopec PhD, F Pourmalek PhD); Center for Community 
Empowerment, Health Policy and Humanities, National Institute of 
Health Research & Development, Jakarta, Indonesia (S Kosen MD); 
Sher-i-Kashmir Institute of Medical Sciences, Srinagar, India 
(Prof P A Koul MD); Research and Development Unit, Parc Sanitari Sant 
Joan de Deu (CIBERSAM), Barcelona, Spain (A Koyanagi MD); Research 
Center of Neurology, Moscow, Russia (M Kravchenko PhD); Oregon 
Health and Science University, Portland, OR, USA (S Krishnaswami MD); 
Department of Social and Preventive Medicine, School of Public Health, 
and Department of Demography and Public Health Research Institute, 
University of Montreal, Montreal, QC, Canada (Prof B Kuate Defo PhD); 
Institute of Public Health, Hacettepe University, Ankara, Turkey 
(B Kucuk Bicer PhD); National Health Systems Resource Centre, New 
Delhi, India (S Kumar MD); Ministry of Public Health and Fight Against 
AIDS, Mukaza, Burundi (N Lambert MD); National Cancer Institute, 
Rockville, MD, USA (Q Lan PhD); Department of Medical Sciences, 
Uppsala University, Uppsala, Sweden (Prof A Larsson PhD); Servicio de 
Neurologia, Clinica Alemana, Universidad del Desarrollo, Santiago, Chile 
(P M Lavados MD); College of Optometry, Nova Southeastern University, 
Fort Lauderdale, FL, USA (J L Leasher OD); Department of Preventive 
Medicine, College of Medicine (S Yoon PhD), Korea University, Seoul, 
South Korea (Prof J Lee PhD); Hong Kong Polytechnic University, Hong 
Kong, China (P H Lee PhD); State University of New York, Albany, 
Rensselaer, NY, USA (R Leung PhD); Tuscany Regional Centre for 
Occupational Injuries and Diseases, Florence, Italy (M Levi PhD); 
Department of Data Management, Peking University Clinical Research 
Institute, Beijing, China (Y Li PhD); National Center for Chronic and 
Noncommunicable Disease Control and Prevention (Y Li PhD, S Liu PhD, 
P Ye MPH, Prof M Zhou PhD), Chinese Center for Disease Control and 
Prevention, Beijing, China (Prof X Liang MD); San Francisco VA Medical 
Center, San Francisco, CA, USA (Y Li PhD); Samara University, Samara, 
Ethiopia (M L Liben MPH); University of Haifa, Haifa, Israel 
(Prof S Linn MD); Emory University, Atlanta, GA, USA (Prof Y Liu PhD, 
Prof M R Phillips MD); University of Bari, Bari, Italy 
(Prof G Logroscino PhD); Division of Intramural Research, National 
Institute of Environmental Health Sciences (S J London MD), National 
Institutes of Health, Research Triangle Park, NC, USA; University of 
Bristol, Bristol, UK (K J Looker PhD); Institute of Nutrition, Friedrich 
Schiller University Jena, Jena, Germany (Prof S Lorkowski PhD); 
Competence Cluster for Nutrition and Cardiovascular Health (nutriCARD) 
Halle-Jena-Leipzig, Jena, Germany (Prof S Lorkowski PhD); Institute of 
Social and Preventive Medicine, University of Bern, Bern, Switzerland 
(Prof N Low MD); Ateneo de Manila University, Manila, Philippines 
(E R K Macarayan PhD); Mansoura Faculty of Medicine, Mansoura, Egypt 
(H Magdy Abd El Razek MBBCH); Aswan University Hospital, Aswan 
Faculty of Medicine, Aswan, Egypt (M Magdy Abd El Razek MBBCH); 
Erasmus University Rotterdam, Rotterdam, Netherlands 
(M Mahdavi PhD); Faculty of Health Sciences and Social Work, 
Department of Public Health, Trnava University, Trnava, Slovakia 
(M Majdan PhD); National Institute of Health Research, Tehran, Iran 
(Prof R Majdzadeh PhD); Universidade Federal de Minas Gerais, Belo 
Horizonte, Brazil (Prof D C Malta PhD); The University of Queensland, 
Brisbane, QLD, Australia (Prof A A Mamun PhD); University of Milano 
Bicocca, Monza, Italy (Prof L G Mantovani DSc); Hospital Universitario 
Doctor Peset, Valencia, Spain (J Martinez-Raga PhD, M Tortajada PhD); 
CEU Cardinal Herrera University, Moncada, Spain (J Martinez-Raga PhD); 
Federal Institute of Education, Science and Technology of Ceará, Caucaia, 
Brazil (F R Martins-Melo PhD); Synlab Academy, Mannheim, Germany 
(Prof W März MD); Clinical Institute of Medical and Chemical Laboratory 
Diagnostics, Medical University of Graz, Graz, Austria (Prof W März MD); 
Key State Laboratory of Molecular Developmental Biology, Institute of 
Genetics and Developmental Biology, Chinese Academy of Sciences, 
Beijing, China (M Mazidi PhD); University Hospitals Bristol NHS 
Foundation Trust, Bristol, UK (C McAlinden PhD); Public Health Wales, 
Global Health Metrics
www.thelancet.com   Vol 390   September 16, 2017 1255
Swansea, UK (C McAlinden PhD); London School of Hygiene and Tropical 
Medicine, London, UK (Prof M McKee DSc, Prof G V S Murthy MD, 
Prof N Pearce PhD); Ipas Nepal, Kathmandu, Nepal (S Mehata PhD); 
Janakpuri Superspecialty Hospital, New Delhi, India 
(Prof M M Mehndiratta DM); Wollo University, Dessie, Ethiopia 
(T C Mekonnen MPH); University of West Florida, Pensacola, FL, USA 
(P Memiah PhD); Saudi Ministry of Health, Riyadh, Saudi Arabia 
(Prof Z A Memish MD); College of Medicine, Alfaisal University, Riyadh, 
Saudi Arabia (Prof Z A Memish MD); United Nations Population Fund, 
Lima, Peru (W Mendoza MD); Department of Neurology 
(A Meretoja PhD), Comprehensive Cancer Center, Breast Surgery Unit 
(T J Meretoja PhD), Helsinki University Hospital, Helsinki, Finland; 
Friedman School of Nutrition Science and Policy (R Micha PhD), Tufts 
University, Boston, MA, USA (P Shi PhD); Pacific Institute for Research & 
Evaluation, Calverton, MD, USA (T R Miller PhD); Centre for Population 
Health, Curtin University, Perth, WA, Australia (T R Miller PhD); 
University of Ottawa, Ottawa, ON, Canada (E J Mills PhD); Hunger Action 
Los Angeles, Los Angeles, CA, USA (M Mirarefin MPH); Kyrgyz State 
Medical Academy, Bishkek, Kyrgyzstan (Prof E M Mirrakhimov PhD); 
National Center of Cardiology and Internal Disease, Bishkek, Kyrgyzstan 
(Prof E M Mirrakhimov PhD); Nepal Development Society, Chitwan, Nepal 
(S R Mishra MPH); University of Salahaddin, Erbil, Iraq 
(K A Mohammad PhD); ISHIK University, Erbil, Iraq 
(K A Mohammad PhD); Neuroscience Research Center, Baqiyatallah 
University of Medical Sciences, Tehran, Iran (A Mohammadi PhD); Health 
Systems and Policy Research Unit (S Mohammed PhD), Ahmadu Bello 
University, Zaria, Nigeria (M B Sufiyan MBA); Institute for Maternal and 
Child Health, IRCCS “Burlo Garofolo”, Trieste, Italy (L Monasta DSc, 
M Montico MSc, L Ronfani PhD); Department of Community Medicine 
(A Tehrani-Banihashemi PhD), Preventive Medicine and Public Health 
Research Center, Gastrointestinal and Liver Disease Research Center 
(GILDRC) (M Moradi-Lakeh MD), Preventive Medicine and Public Health 
Research Center (A Tehrani-Banihashemi PhD), Iran University of 
Medical Sciences, Tehran, Iran (M Yaghoubi MSc); Lancaster Medical 
School, Lancaster University, Lancaster, UK (P Moraga PhD); National 
Center for Child Health and Development, Setagaya, Japan (R Mori PhD); 
Competence Center Mortality-Follow-Up of the German National Cohort 
(A Werdecker PhD), Federal Institute for Population Research, Wiesbaden, 
Germany (Prof U O Mueller PhD, R Westerman PhD); West Herts 
Hospitals NHS Trust, Watford, United Kingdom (M E Murdoch MD); 
School of Medical Sciences, University of Science Malaysia, Kubang 
Kerian, Malaysia (K I Musa MD); Graduate School of Public Health, 
University of Pittsburgh, Pittsburgh, PA, USA (Prof J B Nachega PhD); 
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA 
(Prof J B Nachega PhD); Ulm University, Ulm, Germany 
(Prof G Nagel PhD); International Centre for Diarrhoeal Disease Research, 
Bangladesh (icddr,b), Dhaka, Bangladesh (A Naheed PhD, 
S M Shariful Islam PhD); Public Health Medicine, School of Nursing and 
Public Health (Prof B Sartorius PhD), Discipline of Public Health 
Medicine, School of Nursing and Public Health (B Yakob PhD), University 
of KwaZulu-Natal, Durban, South Africa (Prof K S Naidoo PhD, 
E A Zegeye MS); Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, 
Italy (Prof L Naldi MD); Suraj Eye Institute, Nagpur, India (V Nangia MD); 
Madras Medical College, Chennai, India, India (Prof G Natarajan DM); 
KEMRI Wellcome Trust, Kilifi, Kenya (Prof C R Newton MD); University 
of Nairobi, Nairobi, Kenya (J W Ngunjiri PhD); Department of Public 
Health, Semarang State University, Semarang City, Indonesia 
(D N A Ningrum MPH); Graduate Institute of Biomedical Informatics, 
College of Medical Science and Technology, Taipei Medical University, 
Taipei City, Taiwan (D N A Ningrum MPH); Population Health Strategic 
Research Centre, School of Health and Social Development (S Nolte PhD), 
Deakin University, Burwood, VIC, Australia (Prof M A Stokes PhD); 
Medical Diagnostic Centre, Yaounde, Cameroon (J J N Noubiap MD); 
National University of Ireland Galway, Galway, Ireland 
(M J O’Donnell PhD); Centre for Health Research (F A Ogbo MPH), 
Western Sydney University, Penrith, NSW, Australia 
(Prof A M N Renzaho PhD); Department of Preventive Medicine, School 
of Medicine, Kyung Hee University, Seoul, South Korea (Prof I Oh PhD); 
Society for Family Health, Abuja, Nigeria (A Okoro MPH); Human 
Sciences Research Council (HSRC), South Africa and University of 
KwaZulu-Natal, Durban, South Africa (O Oladimeji MS); Department of 
Psychiatry, College of Medicine, University of Lagos, Lagos, Nigeria 
(A T Olagunju MS); Department of Psychiatry, Lagos University Teaching 
Hospital, Lagos, Nigeria (A T Olagunju MS); McMaster University, 
Hamilton, ON, Canada (T O Olagunju MD); Department of Clinical 
Neurological Sciences (L A Sposato MD), Western University, London, 
ON, Canada (T O Olagunju MD); Center for Healthy Start Initiative, Lagos, 
Nigeria (B O Olusanya PhD, J O Olusanya MBA); Lira District Local 
Government, Lira Municipal Council, Uganda (J N Opio MPH); University 
of Arizona, Tucson, AZ, USA (Prof E Oren PhD); IIS-Fundacion Jimenez 
Diaz-UAM, Madrid, Spain (Prof A Ortiz PhD); YBank, Cambridge, MA, 
USA (M Osman MD); Department of Medicine, Ibadan, Nigeria 
(M O Owolabi DrMed); Blossom Specialist Medical Center, Ibadan, Nigeria 
(M O Owolabi DrMed); JSS Medical College, JSS University, Mysore, India 
(Prof M PA DNB); Institute of Health and Biomedical Innovation, 
Queensland University of Technology, Brisbane, QLD, Australia 
(R E Pacella PhD); Bucharest University of Economic Studies, Bucharest, 
Romania (A Pana MPH); Charité University Medicine Berlin, Berlin, 
Germany (C Papachristou PhD); Department of Medical Humanities and 
Social Medicine, College of Medicine, Kosin University, Busan, South 
Korea (E Park PhD); Alcohol, Tobacco & Other Drug Research Unit 
(Prof C D Parry PhD), South African Medical Research Council, Cape 
Town, South Africa (A P Kengne PhD); Department of Community Health 
Sciences (Prof S B Patten PhD), University of Calgary, Calgary, AB, Canada 
(Prof M Tonelli MD); REQUIMTE/LAQV, Laboratório de Farmacognosia, 
Departamento de Química, Faculdade de Farmácia, Universidade do Porto, 
Porto, Portugal (Prof D M Pereira PhD); Health Metrics Unit, University of 
Gothenburg, Gothenburg, Sweden (Prof M Petzold PhD); University of the 
Witwatersrand, Johannesburg, South Africa (Prof M Petzold PhD); 
Shanghai Jiao Tong University School of Medicine, Shanghai, China 
(Prof M R Phillips MD); Durban University of Technology, Durban, South 
Africa (J D Pillay PhD); Exposure Assessment and Environmental Health 
Indicators, German Environment Agency, Berlin, Germany 
(D Plass DrPH); Sanjay Gandhi Post Graduate Institute of Medical 
Sciences, Lucknow, India (Prof N Prasad DM); The Fred Hollows 
Foundation, Sydney, NSW, Australia (N M Prasad DO); Centre for Eye 
Research Australia, Melbourne, VIC, Australia (N M Prasad DO); Non-
Communicable Diseases Research Center, Alborz University of Medical 
Sciences, Karaj, Iran (M Qorbani PhD); University of Ghana, Accra, Ghana 
(R Quansah PhD); Noguchi Memorial Institute of Medical Research, 
Accra, Ghana (R Quansah PhD); A T Still University, Kirksville, MO, USA 
(A Radfar MD); Contech International Health Consultants, Lahore, 
Pakistan (A Rafay MS); Contech School of Public Health, Lahore, Pakistan 
(A Rafay MS); Research and Evaluation Division, BRAC, Dhaka, 
Bangladesh (M Rahman PhD); Society for Health and Demographic 
Surveillance, Suri, India (R K Rai MPH); ERAWEB Program, University 
for Health Sciences, Medical Informatics and Technology, Hall in Tirol, 
Austria (S Rajsic MD); Department of Preventive Medicine, Wonju College 
of Medicine, Yonsei University, Wonju, South Korea (C L Ranabhat PhD); 
Health Science Foundation and Study Center, Kathmandu, Nepal 
(C L Ranabhat PhD); Diabetes Research Society, Hyderabad, India 
(Prof P V Rao MD); Diabetes Research Center, Hyderabad, India 
(Prof P V Rao MD); Azienda Socio-Sanitaria Territoriale, Papa Giovanni 
XXIII, Bergamo, Italy (Prof G Remuzzi MD); Department of Biomedical 
and Clinical Sciences “L Sacco”, University of Milan, Milan, Italy 
(Prof G Remuzzi MD); Research Center for Environmental Determinants 
of Health, School of Public Health, Kermanshah University of Medical 
Sciences, Kermanshah, Iran (S Rezaei PhD); Hospital das Clínicas da 
Universidade Federal de Minas Gerais, Belo Horizonte, Brazil 
(Prof A L Ribeiro MD); Golestan Research Center of Gastroenterology and 
Hepatology, Golestan University of Medical Sciences, Gorgan, Iran 
(G Roshandel PhD); Universidad Tecnica del Norte, Ibarra, Ecuador 
(E Rubagotti PhD); Muhimbili University of Health and Allied Sciences, 
Dar es Salaam, Tanzania (G M Ruhago PhD, B F Sunguya PhD); 
Managerial Epidemiology Research Center, Department of Public Health, 
School of Nursing and Midwifery, Maragheh University of Medical 
Sciences, Maragheh, Iran (S Safiri PhD); Universiti Kebangsaan Malaysia 
Medical Centre, Kuala Lumpur, Malaysia (R Sahathevan PhD); Ballarat 
Health Service, Ballarat, VIC, Australia (R Sahathevan PhD); Chest 
Research Foundation, Pune, India (S S Salvi MD); Faculty of Science, 
Ain Shams University, Cairo, Egypt (A M Samy PhD); J Edwards School of 
Medicine, Marshall University, Huntington, WV, USA (J R Sanabria MD, 
Global Health Metrics
1256 www.thelancet.com   Vol 390   September 16, 2017
M Sawhney PhD); Case Western Reserve University, Cleveland, OH, USA 
(J R Sanabria MD); Department of Community Medicine, Information and 
Health Decision Sciences, Center for Health Technology and Services 
Research - CINTESIS, Porto, Portugal (J V Santos MD); Centre of 
Advanced Study in Psychology, Utkal University, Bhubaneswar, India 
(M Satpathy PhD); Federal University of Santa Catarina, Florianópolis, 
Brazil (I J C Schneider PhD); Division of Clinical Epidemiology and 
Ageing Research, German Cancer Research Center, Heidelberg, Germany 
(B Schöttker MPH); Institute of Health Care and Social Sciences, FOM 
University, Essen, Germany (B Schöttker MPH); University of Alabama at 
Birmingham, Birmingham, AL, USA (D C Schwebel PhD, J A Singh MD); 
Charité Berlin, Berlin, Germany (F Schwendicke PhD); Department of 
Public Health, An-Najah University, Nablus, Palestine (A Shaheen PhD); 
Independent Consultant, Karachi, Pakistan (M A Shaikh MD); The George 
Institute for Global Health, Sydney, NSW, Australia 
(S M Shariful Islam PhD); Ministry of Health, Thimphu, Bhutan 
(J Sharma MPH); Indian Institute of Technology Ropar, Rupnagar, India 
(R Sharma MA); National Institute of Infectious Diseases, Tokyo, Japan 
(M Shigematsu PhD); Sandia National Laboratories, Albuquerque, NM, 
USA (M Shigematsu PhD); Tachikawa Hospital, Tokyo, Japan 
(Y Shinohara PhD); Washington State University, Spokane, WA, USA 
(K Shishani PhD); Harvard Medical School, Boston, MA, USA 
(M Osman MD, M G Shrime MD); American University of Beirut, Beirut, 
Lebanon (Prof A M Sibai PhD); Reykjavik University, Reykjavik, Iceland 
(I D Sigfusdottir PhD); Federal University of Santa Catarina, Florianopolis, 
Brazil (D A S Silva PhD); Brasília University, Brasília, Brazil 
(D G A Silveira MD); Max Hospital, Ghaziabad, India 
(Prof N P Singh MD); School of Preventive Oncology, Patna, India 
(D N Sinha PhD); WHO FCTC Global Knowledge Hub on Smokeless 
Tobacco, National Institute of Cancer Prevention, Noida, India 
(D N Sinha PhD); Hywel Dda University Health Board, Carmarthen, UK 
(E Skiadaresi MD); Bristol Eye Hospital, Bristol, UK (E Skiadaresi MD); 
King Khalid University Hospital, Riyadh, Saudi Arabia 
(B H A Sobaih MD); University of Yaoundé, Yaoundé, Cameroon 
(Prof E Sobngwi PhD); Yaoundé Central Hospital, Yaoundé, Cameroon 
(Prof E Sobngwi PhD); National School of Public Health/Oswaldo Cruz 
Foundation, Rio de Janeiro, Brazil (Prof T C M Sousa MPH); Department 
of Community Medicine, International Medical University, Kuala Lumpur, 
Malaysia (C T Sreeramareddy MD); Attikon University Hospital, Athens, 
Greece (V Stathopoulou PhD); University of East Anglia, Norwich, UK 
(Prof N Steel PhD); Public Health England, London, UK 
(Prof N Steel PhD); South African Medical Research Council Unit on 
Anxiety & Stress Disorders, Cape Town, South Africa (Prof D J Stein PhD); 
Department of Neuroscience, Norwegian University of Science and 
Technology, Trondheim, Norway (Prof T J Steiner PhD, 
Prof L J Stovner PhD); Department of Dermatology, University Hospital 
Muenster, Muenster, Germany (S Steinke DrMed); Norwegian Advisory 
Unit on Headache, St Olavs Hospital, Trondheim, Norway 
(Prof L J Stovner PhD); Ministry of Health, Kingdom of Saudi Arabia, 
Riyadh, Saudi Arabia (R Suliankatchi Abdulkader MD); Indian Council of 
Medical Research, New Delhi, India (S Swaminathan MD); Departments 
of Criminology, Law & Society, Sociology, and Public Health, University of 
California, Irvine, Irvine, CA, USA (Prof B L Sykes PhD); WSH Institute, 
Ministry of Manpower, Singapore, Singapore (J S Takala DSc); Tampere 
University of Technology, Tampere, Finland (J S Takala DSc); New York 
Medical Center, Valhalla, NY, USA (M Tavakkoli MD); Instituto Superior 
de Ciências da Saúde Egas Moniz, Almada, Portugal (Prof N Taveira PhD); 
Faculty of Pharmacy, Universidade de Lisboa, Lisboa, Portugal 
(Prof N Taveira PhD); Department of Anesthesiology, University of 
Virginia, Charlottesville, VA, USA (A S Terkawi MD); Department of 
Anesthesiology, King Fahad Medical City, Riyadh, Saudi Arabia 
(A S Terkawi MD); Outcomes Research Consortium (A S Terkawi MD), 
Cleveland Clinic, Cleveland, OH, USA (Prof E M Tuzcu MD); National 
Center for Child Health and Development, Tokyo, Japan (R Tobe-Gai PhD); 
National Institute of Public Health, Bergen, Norway (M C Tollanes PhD); 
Faculty of Health Sciences, Wroclaw Medical University, Wroclaw, Poland 
(R Topor-Madry PhD); School of Medicine, University of Valencia, 
Valencia, Spain (M Tortajada PhD); INSERM (French National Institute for 
Health and Medical Research), Paris, France (M Touvier PhD); Hanoi 
Medical University, Hanoi, Vietnam (B X Tran PhD); Department of 
Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, 
Denmark (T Truelsen DMSc); Parc Sanitari Sant Joan de Déu, Fundació 
Sant Joan de Déu, Universitat de Barcelona, CIBERSAM, Barcelona, Spain 
(S Tyrovolas PhD); Department of Internal Medicine, Federal Teaching 
Hospital, Abakaliki, Nigeria (K N Ukwaja MD); School of Government, 
Pontificia Universidad Catolica de Chile, Santiago, Chile 
(E A Undurraga PhD); Ebonyi State University, Abakaliki, Nigeria 
(C J Uneke PhD); Warwick Medical School, University of Warwick, 
Coventry, UK (O A Uthman PhD); University of Nigeria, Nsukka, Enugu 
Campus, Enugu, Nigeria (Prof B S C Uzochukwu MD); UKK Institute for 
Health Promotion Research, Tampere, Finland (Prof T Vasankari PhD); 
National Centre for Disease Control, Delhi, India (S Venkatesh MD); 
Raffles Neuroscience Centre, Raffles Hospital, Singapore, Singapore 
(N Venketasubramanian MBBS); Weill Cornell Medical College, New York, 
NY, USA (R Vidavalur MD); University of Bologna, Bologna, Italy 
(Prof F S Violante MD); Federal Research Institute for Health 
Organization and Informatics, Moscow, Russia (S K Vladimirov PhD); 
National Research University Higher School of Economics, Moscow, 
Russia (Prof V V Vlassov MD); University of São Paulo Medical School, 
São Paulo, Brazil (Y Wang PhD); McGill University, Ottawa, ON, Canada 
(S Weichenthal PhD); Department of Research, Cancer Registry of Norway, 
Institute of Population-Based Cancer Research, Oslo, Norway 
(E Weiderpass PhD); Department of Community Medicine, Faculty of 
Health Sciences, University of Tromsø, The Arctic University of Norway, 
Tromsø, Norway (E Weiderpass PhD); Genetic Epidemiology Group, 
Folkhälsan Research Center, Helsinki, Finland (E Weiderpass PhD); 
Royal Children’s Hospital, Melbourne, VIC, Australia 
(R G Weintraub MBBS); Murdoch Childrens Research Institute, 
Melbourne, VIC, Australia (R G Weintraub MBBS); German National 
Cohort Consortium, Heidelberg, Germany (R Westerman PhD); Western 
Health, Footscray, VIC, Australia (Prof T Wijeratne MD); South African 
Medical Research Council, Cochrane South Africa, Cape Town, South 
Africa (Prof C S Wiysonge PhD); National Institute for Health Research 
Comprehensive Biomedical Research Centre, Guy’s & St Thomas’ NHS 
Foundation Trust and King’s College London, London, UK 
(Prof C D Wolfe MD); Royal Cornwall Hospital, Truro, UK 
(Prof A D Woolf MBBS); Ghent University, Ghent, Belgium 
(A Workicho MPH); St John’s Medical College and Research Institute, 
Bangalore, India (Prof D Xavier MD); Department of Neurology, Jinling 
Hospital, Nanjing University School of Medicine, Nanjing, China 
(Prof G Xu PhD); School of Public Health, University of Saskatchewan, 
Saskatoon, SK, Canada (M Yaghoubi MSc); Global Health Research 
Center, Duke Kunshan University, Kunshan, China (Prof L L Yan PhD); 
Department of Preventive Medicine, Northwestern University, Chicago, 
IL, USA (Y Yano MD); Social Work and Social Administration 
Department (Prof P Yip PhD), The Hong Kong Jockey Club Centre for 
Suicide Research and Prevention (Prof P Yip PhD), University of Hong 
Kong, Hong Kong, China; Department of Biostatistics, School of Public 
Health, Kyoto University, Kyoto, Japan (N Yonemoto MPH); The Ohio 
State University, Columbus, OH, USA (M Yotebieng PhD); School of 
Public Health, University of Kinshasa, Kinshasa, Democratic Republic of 
the Congo (M Yotebieng PhD); Jackson State University, Jackson, MS, 
USA (Prof M Z Younis DrPH); University Hospital of Setif, Setif, Algeria 
(Prof Z Zaidi DSc); Faculty of Medicine, Mansoura University, 
Mansoura, Egypt (Prof M E Zaki PhD); Ethiopian Public Health 
Institute, Addis Ababa, Ethiopia (E A Zegeye MS); University of Texas 
School of Public Health, Houston, TX, USA (X Zhang MS); MD 
Anderson Cancer Center, Houston, TX, USA (X Zhang MS); and Red 
Cross War Memorial Children’s Hospital, Cape Town, South Africa 
(L J Zuhlke PhD).
Contributors 
Please see the appendix for more detailed information about individual 
authors’ contributions to the research, divided into the following 
categories: managing the estimation process; writing the first draft of the 
manuscript; providing data or critical feedback on data sources; 
developing methods or computational machinery; applying analytical 
methods to produce estimates; providing critical feedback on methods or 
results; drafting the work or revising it critically for important 
intellectual content; extracting, cleaning, or cataloging data; designing or 
coding figures and tables; and managing the overall research enterprise.
Global Health Metrics
www.thelancet.com   Vol 390   September 16, 2017 1257
Declaration of interests 
Laith J Abu-Raddad acknowledges the support of Qatar National Research 
Fund (NPRP 9-040-3-008) who provided the main funding for generating 
the data provided to the GBD-IHME effort. Johan Ärnlöv reports personal 
fees from AstraZeneca, outside the submitted work. Anurag Agrawal 
acknowledges support from the Wellcome Trust DBT India Alliance Senior 
Fellowship. Ashish Awasthi has received funding from DST, Government 
of India through INSPIRE Faculty scheme. Scientific work of 
Dr Aleksandra Barac is part of the Project No. III45005 granted by Ministry 
of Education, Science and Technological Development of the Republic of 
Serbia. Till Bärnighausen was supported by the Alexander von Humboldt 
Foundation through the Alexander von Humboldt Professor award, funded 
by the Federal Ministry of Education and Research; the Wellcome Trust; the 
European Commission; the Clinton Health Access Initiative; and from 
NICHD of NIH (R01-HD084233), NIA of NIH (P01-AG041710), NIAID of 
NIH (R01-AI124389 and R01-AI112339) as well as FIC of NIH 
(D43-TW009775). Lars Barregard acknowledges support from Sahlgrenska 
University Hospital, Gothenburg, Sweden. Shahrzad Bazargan-Hejazi 
acknowledges that this research was supported by NIH National Center for 
Advancing Translational Science (NCATS) UCLA CTSI Grant Number 
UL1TR001881. Yannick Béjot reports personal fees from Daiichi-Sankyo, 
Pfizer-BMS, MSD, Bayer, and Covidiem, and grants and personal fees from 
AstraZeneca and Boehringer-Ingelheim, outside the submitted work. 
Boris Bikbov has received funding from the European Union’s Horizon 
2020 research and innovation programme under Marie Sklodowska-Curie 
grant agreement No. 703226. Boris Bikbov acknowledges that work related 
to this paper has been done on the behalf of the GBD Genitourinary 
Disease Expert Group supported by the International Society of Nephrology 
(ISN). Rachelle Buchbinder is funded by an Australian National Health and 
Medical Research Council (NHMRC) Senior Principal Research Fellowship. 
Juan-Jesus Carrero acknowledges support from the Stockholm County 
Council Swedish Heart and Lung Foundation. Cyrus Cooper reports 
personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, 
Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB. 
José das Neves was supported in his contribution to this work by a 
Fellowship from Fundação para a Ciência e a Tecnologia, Portugal 
(SFRH/BPD/92934/2013). Barbora de Courten is supported by National 
Heart Foundation Future Leader Fellowship (100864). Louisa Degenhardt is 
supported by an Australian National Health and Medical Research Council 
Principal Research Fellowship. Kebede Deribe is funded by a Wellcome 
Trust Intermediate Fellowship in Public Health and Tropical Medicine 
[grant number 201900]. Mir Sohail Fazeli reports personal fees from Doctor 
Evidence LLC, outside the submitted work. João Fernandes gratefully 
acknowledges funding from FCT - Fundação para a Ciência e a Tecnologia 
(grant number UID/Multi/50016/2013). Katherine B Gibney is supported 
by an NHMRC Early Career Fellowship. Amador Goodridge acknowledges 
support from Sistema Nacional de Investigación (SNI) de Panamá, 
Secretaría Nacional de Ciencia, Tecnología e Innovación (SENACYT).  
Simon I Hay is funded by grants from the Bill & Melinda Gates Foundation 
(OPP1106023, OPP1119467, OPP1093011, and OPP1132415). 
Dr. Shariful Islam received a postdoctoral research fellowship from the 
George Institute for Global Health and career transition grants from High 
Blood Pressure Research Foundation of Australia. Mihajlo Jakovljevic 
acknowledges support from the Ministry of Education Science and 
Technological Development of the Republic of Serbia financially supported 
Serbian part of this GBD Project related contribution through Grant OI 175 
014. Publication of results was not contingent upon Ministry’s approval or 
censorship. Panniyammakal Jeemon acknowledges support from the 
Clinical and public health intermediate fellowship from the Wellcome Trust 
and Department of Biotechnology, India Alliance (2015-2020). 
Srinivasa Vittal Katikireddi reports grants from Medical Research Council 
and Chief Scientist Office during the conduct of the study. 
Dr Christian Kieling has received support from Brazilian governmental 
research funding agencies Conselho Nacional de Desenvolvimento 
Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de 
Pessoal de Nível Superior (CAPES), Fundação de Amparo à Pesquisa do 
Estado do Rio Grande do Sul (Fapergs), and Hospital de Clínicas de Porto 
Alegre (FIPE/HCPA). Ai Koyanagi’s work was supported by the 
Miguel Servet contract financed by the CP13/00150 and PI15/00862 
projects, integrated into the National R + D + I and funded by the 
ISCIII - General Branch Evaluation and Promotion of Health 
Research - and the European Regional Development Fund (ERDF-FEDER). 
Cheru Leshargie would like to thank Debremarkos University for the 
arrangement of internet service to communicate with GBD organizer and 
to download the manuscript and send the comment. Stephanie J London is 
supported by the Intramural Research Program of the NIH, National 
Institute of Environmental Health Sciences. Katherine J Looker thanks the 
National Institute for Health Research Health Protection Research Unit 
(NIHR HPRU) in Evaluation of Interventions at the University of Bristol, 
in partnership with Public Health England (PHE), for research support; she 
received separate funding from the World Health Organization and Sexual 
Health 24 during the course of this study. These funders had no role in the 
writing of the manuscript nor the decision to submit it for publication. 
The views expressed are those of the authors and not necessarily those of 
the National Health Service, the NIHR, the Department of Health or Public 
Health England. Azeem Majeed and Imperial College London are grateful 
for support from the NW London NIHR Collaboration for Leadership in 
Applied Health Research & Care. Francisco Rogerlândio Martins-Melo 
acknowledges support from the postdoctoral fellowship - Coordenação de 
Aperfeiçoamento de Pessoal de Nível Superior (CAPES) (Brazilian public 
agency); outside the submitted work. Winfried März acknowledges the 
Ludwigshafen Risk and Cardiovascular Health (LURIC) study, which has 
been supported by the 7th Framework Program (Project Athero Remo, 
grant number 201668 and RiskyCAD, project number 305739) of the 
European Union. Mohsen Mazidi was supported by The World Academy of 
Sciences studentship of the Chinese Academy of Sciences. John McGrath 
received John Cade Fellowship APP1056929 from the National Health and 
Medical Research Council, and Niels Bohr Professorship from the Danish 
National Research Foundation. Philip Mitchell’s research is supported by 
Australian NHMRC Program Grant number 1037196. Karzan Mohammad 
would like to acknowledge Salahaddin University, Iraq, which awarded him 
the best research and best researcher award due to his contribution to the 
GBD studies. Ulrich Mueller gratefully acknowledges funding by the 
German National Cohort (BMBF grant # 01ER1511D). 
Olanrewaju Oladimeji is a Senior Research Specialist at the Human 
Sciences Research Council (HSRC), South Africa and Doctoral Candidate at 
the University of KwaZulu-Natal (UKZN), South Africa. We appreciate the 
institutional support for him to use the existing organisational research 
facilities at HSRC and UKZN. Alberto Ortiz was supported by 
Intensificacion ISCIII and RETIC REDINREN FEDER funds. 
Charles Parry acknowledges support from the South African Medical 
Research Council. Norberto Perico acknowledges that work related to this 
paper has been done on the behalf of the GBD Genitourinary Disease 
Expert Group supported by the International Society of Nephrology (ISN). 
Konrad Pesudovs acknowledges support from Flinders University. 
Kazem Rahimi is funded by a NIHR Career Development Fellowship and 
is supported by a National Institute for Health Research (NIHR) 
Biomedical Research Centre (BRC) and the Oxford Martin School. 
Giuseppe Remuzzi acknowledges that the work related to this paper has 
been done on behalf of the GBD Genitourinary Disease Expert Group 
supported by the International Society of Nephrology (ISN). Mark Shrime 
acknowledges support from GE Safe Surgery 2020 Project; Damon Runyon 
Cancer Research Foundation. Jasvinder Singh received consultancy fees 
from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon, 
Allergan, UBM LLC, WebMD, and the American College of Rheumatology, 
and grants from Takeda and Savient; he serves as the principal investigator 
for an investigator-initiated study funded by Horizon pharmaceuticals 
through a grant to DINORA, Inc, a 501c3 entity, and is on the steering 
committee of OMERACT, an international organisation that develops 
measures for clinical trials and receives arms length funding from 
36 pharmaceutical companies. Jeffrey Stanaway reports grants from Merck 
outside the submitted work. Rafael Tabarés-Seisdedos was supported in 
part by grant PROMETEOII/2015/021 from Generalitat Valenciana and the 
national grands PI14/00894 and PIE14/00031 from ISCIII-FEDER. Amanda 
G Thrift received fellowship funding from the National Health & Medical 
Research Council (NHMRC; 1042600). Stefano Tyrovola’s work was 
supported by the Foundation for Education and European Culture (IPEP), 
the Sara Borrell postdoctoral programme (reference no. CD15/00019 from 
the Instituto de Salud Carlos III (ISCIII - Spain) and the Fondos Europeo 
de Desarrollo Regional (FEDER). Dr Job FM van Boven’s work was 
supported by the University Medical Center Groningen, University of 
Groningen, The Netherlands. Prof Marcia Weaver received salary support 
Global Health Metrics
1258 www.thelancet.com   Vol 390   September 16, 2017
from the Disease Control Priorities Network (DCPN) funded by the Bill & 
Melinda Gates Foundation. Ronny Westerman acknowledges efforts on 
behalf of the German National Cohort funded by the German Ministry of 
Education and Research. Lijing Yan is partially supported by the National 
Natural Sciences Foundation of China grants (71233001 and 71490732). No 
ICMJE Conflicts of Interest. Marcel Yotebieng is partially supported by the 
NIAID U01AI096299 and the NICHD R01HD087993.
Acknowledgments 
Research reported in this publication was supported by the Bill & 
Melinda Gates Foundation, the National Institute on Aging of the 
National Institutes of Health (award P30AG047845), and the National 
Institute of Mental Health of the National Institutes of Health (award 
R01MH110163). The content is solely the responsibility of the authors and 
does not necessarily represent the official views of the Bill & Melinda 
Gates Foundation or the National Institutes of Health. The Palestinian 
Central Bureau of Statistics granted the researchers access to relevant 
data in accordance with license no. SLN2014-3-170, after subjecting data 
to processing aiming to preserve the confidentiality of individual data in 
accordance with the General Statistics Law - 2000. The researchers are 
solely responsible for the conclusions and inferences drawn upon 
available data. We thank the Russia Longitudinal Monitoring Survey, 
RLMS-HSE, conducted by the National Research University Higher 
School of Economics and ZAO “Demoscope” together with Carolina 
Population Center, University of North Carolina at Chapel Hill and the 
Institute of Sociology RAS for making these data available. This study has 
been realized using the data collected by the Swiss Household Panel 
(SHP), which is based at the Swiss Centre of Expertise in the Social 
Sciences FORS. The project is financed by the Swiss National Science 
Foundation. From the Framingham Heart Study of the National Heart 
Lung and Blood Institute of the National Institutes of Health and Boston 
University School of Medicine. This work was supported by the National 
Heart, Lung and Blood Institute’s Framingham Heart Study (Contract 
No.N01-HC-25195). The HRS (Health and Retirement Study) is 
sponsored by the National Institute on Aging (grant number NIA 
U01AG009740) and is conducted by the University of Michigan. This 
research used data from the National Health Survey 2003 and the 
National Health Survey 2009-2010. The authors are grateful to the 
Ministry of Health, Survey copyright owner, allowing them to have the 
database. All results of the study are those of the author and in no way 
committed to the Ministry. This research uses data from Add Health, a 
program project designed by J. Richard Udry, Peter S. Bearman, and 
Kathleen Mullan Harris, and funded by a grant P01-HD31921 from the 
Eunice Kennedy Shriver National Institute of Child Health and Human 
Development, with cooperative funding from 17 other agencies. Special 
acknowledgment is due Ronald R. Rindfuss and Barbara Entwisle for 
assistance in the original design. Persons interested in obtaining data 
files from Add Health should contact Add Health, Carolina Population 
Center, 123 W. Franklin Street, Chapel Hill, NC 27516-2524 (addhealth@
unc.edu). No direct support was received from grant P01-HD31921 for 
this analysis. The data reported here have been supplied by the United 
States Renal Data System (USRDS). The interpretation and reporting of 
these data are the responsibility of the author(s) and in no way should be 
seen as an official policy or interpretation of the U.S. government. 
HBSC is an international study carried out in collaboration with WHO/
EURO. The International Coordinator of the 1997/98, 2001/02, 2005/06 
and 2009/10 surveys was Prof. Candace Currie and the Data Bank 
Manager for the 1997/98 survey was Prof. Bente Wold, whereas for the 
following survey Prof. Oddrun Samdal was the Databank Manager. A list 
of principal investigator in each country can be found at http://www.
hbsc.org. Data used in the preparation of this article were obtained from 
the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) 
Database. In 2011, Prize4Life, in collaboration with the Northeast ALS 
Consortium, and with funding from the ALS Therapy Alliance, formed 
the Pooled Resource Open-Access ALS Clinical Trials (PRO-ACT) 
Consortium. The data available in the PRO-ACT Database has been 
volunteered by PRO-ACT Consortium members. This paper uses data 
from SHARE Waves 1, 2, 3 (SHARELIFE), 4, 5 and 6 (DOIs: 10.6103/
SHARE.w1.600, 10.6103/SHARE.w2.600, 10.6103/SHARE.w3.600, 
10.6103/SHARE.w4.600, 10.6103/SHARE.w5.600, 10.6103/SHARE.
w6.600), see Börsch-Supan et al. (2013) for methodological details. (1) 
The SHARE data collection has been primarily funded by the European 
Commission through FP5 (QLK6-CT-2001-00360), FP6 (SHARE-I3: 
RII-CT-2006-062193, COMPARE: CIT5-CT-2005-028857, SHARELIFE: 
CIT4-CT-2006-028812) and FP7 (SHARE-PREP: N°211909, SHARE-
LEAP: N°227822, SHARE M4: N°261982). Additional funding from the 
German Ministry of Education and Research, the Max Planck Society for 
the Advancement of Science, the U.S. National Institute on Aging 
(U01_AG09740-13S2, P01_AG005842, P01_AG08291, P30_AG12815, 
R21_AG025169, Y1-AG-4553-01, IAG_BSR06-11, OGHA_04-064, 
HHSN271201300071C) and from various national funding sources is 
gratefully acknowledged (see www.share-project.org). This manuscript is 
based on data collected and shared by the International Vaccine Institute 
(IVI). This manuscript was not prepared in collaboration with 
investigators of IVI and does not necessarily reflect the opinions or 
views of IVI. The data used in this paper come from the 2009-10 Ghana 
Socioeconomic Panel Study Survey which is a nationally representative 
survey of over 5,000 households in Ghana. The survey is a joint effort 
undertaken by the Institute of Statistical, Social and Economic Research 
(ISSER) at the University of Ghana, and the Economic Growth Centre 
(EGC) at Yale University. It was funded by the Economic Growth Center. 
At the same time, ISSER and the EGC are not responsible for the 
estimations reported by the analyst(s).
References
1 Nino F. United Nations Sustainable Development Goals. UNDP. 
http://www.undp.org/content/undp/en/home/sustainable-
development-goals.html (accessed March 10, 2017).
2 Lim SS, Allen K, Bhutta ZA, et al. Measuring the health-related 
Sustainable Development Goals in 188 countries: a baseline analysis 
from the Global Burden of Disease Study 2015. Lancet 2016; 
388: 1813–50.
3 Vos T, Allen C, Arora M, et al. Global, regional, and national 
incidence, prevalence, and years lived with disability for 
310 diseases and injuries, 1990–2015: a systematic analysis for the 
Global Burden of Disease Study 2015. Lancet 2016; 388: 1545–602.
4 Kassebaum NJ, Arora M, Barber RM, et al. Global, regional, and 
national disability-adjusted life-years (DALYs) for 315 diseases and 
injuries and healthy life expectancy (HALE), 1990–2015: 
a systematic analysis for the Global Burden of Disease Study 2015. 
Lancet 2016; 388: 1603–58.
5 Kissoon N, Uyeki TM. Sepsis and the Global Burden of Disease in 
Children. JAMA Pediatr 2016; 170: 107–08.
6 Limmathurotsakul D, Golding N, Dance DAB, et al. 
Predicted global distribution of Burkholderia pseudomallei and 
burden of melioidosis. Nature Microbiology 2016; 
1: nmicrobiol20158.
7 Vallabhaneni S, Mody RK, Walker T, Chiller T. The Global Burden 
of Fungal Diseases. Infect Dis Clin North Am 2016; 30: 1–11.
8 Vigo D, Thornicroft G, Atun R. Estimating the true global burden of 
mental illness. Lancet Psychiatry 2016; 3: 171–78.
9 Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of 
Myopia and High Myopia and Temporal Trends from 2000 
through 2050. Ophthalmology 2016; 123: 1036–42.
10 Jackson T, Thomas S, Stabile V, Shotwell M, Han X, McQueen K. 
A Systematic Review and Meta-Analysis of the Global Burden of 
Chronic Pain Without Clear Etiology in Low- and Middle-Income 
Countries: Trends in Heterogeneous Data and a Proposal for New 
Assessment Methods. Anesth Analg 2016; 123: 739–48.
11 Chavan BS, Aneja J. Global mental health movement has not 
helped in reducing global burden of psychiatric disorders. 
Indian JSoc Psychiatry 2016; 32: 261–66.
12 Neethling I, Jelsma J, Ramma L, Schneider H, Bradshaw D. 
Disability weights from a household survey in a low socio-economic 
setting: how does it compare to the global burden of disease 2010 
study? Global Health Action 2016; 9: 31754.
13 Jager KJ, Fraser SDS. The ascending rank of chronic kidney disease 
in the global burden of disease study. Nephrol Dial Transplant 2017; 
32: ii121-ii128.
14 Jin LJ, Lamster IB, Greenspan JS, Pitts NB, Scully C, 
Warnakulasuriya S. Global burden of oral diseases: emerging 
concepts, management and interplay with systemic health. 
Oral Diseases 2016; 22: 609–19.
15 Kwan GF, Mayosi BM, Mocumbi AO, et al. Endemic 
Cardiovascular Diseases of the Poorest Billion. Circulation 2016; 
133: 2561–75.
Global Health Metrics
www.thelancet.com   Vol 390   September 16, 2017 1259
16 Flaxman AD, Vos T, Murray CJL, eds. An Integrative 
Metaregression Framework for Descriptive Epidemiology, 1st edn. 
Seattle: University of Washington Press, 2015.
17 Stevens GA, Alkema L, Black RE, et al. Guidelines for Accurate and 
Transparent Health Estimates Reporting: the GATHER statement. 
Lancet 2016; 388: e19–23.
18 GBD 2016 Causes of Death Collaborators. Global, regional, and 
national age-sex specific mortality for 264 causes of death, 
1980–2016: a systematic analysis for the Global Burden of Disease 
Study 2016. Lancet 2017; 390: 1151–210.
19 National Tuberculosis Institute. Tuberculosis in a rural population 
of South India: a five-year epidemiological study. 
Bull World Health Organ 1974; 51: 473–88.
20 Mesfin YM, Hailemariam D, Biadglign S, Kibret KT. 
Association between HIV/AIDS and Multi-Drug Resistance 
Tuberculosis: A Systematic Review and Meta-Analysis. PLoS One 
2014; 9: e82235.
21 Banks JL, Marotta CA. Outcomes validity and reliability of the 
modified Rankin scale: implications for stroke clinical trials: 
a literature review and synthesis. Stroke 2007; 38: 1091–96.
22 GBD 2016 Mortality Collaborators. Global, regional, and national 
under-5 mortality, adult mortality, age-specific mortality, and life 
expectancy, 1970–2016: a systematic analysis for the Global Burden 
of Disease Study 2016. Lancet 2017; 390: 1084–150.
23 Agency for Healthcare Research and Quality. United States Medical 
Expenditure Panel Survey. Rockville, USA: Agency for Health Care 
Research and Quality.
24 McKee S. Rethinking Development and Health: Findings from the 
Global Burden of Disease Study. Seattle, Washington, USA: 
Institute for Health Metrics and Evaluation, 2016 
http://www.healthdata.org/sites/default/files/files/policy_report/
GBD/2016/IHME_GBD2015_report.pdf (accessed June 1, 2017).
25 Tsang A, Von Korff M, Lee S, et al. Common Chronic Pain 
Conditions in Developed and Developing Countries: Gender and 
Age Differences and Comorbidity With Depression-Anxiety 
Disorders. J Pain 2008; 9: 883–91.
26 Parker G, Cheah Y-C, Roy K. Do the Chinese somatize depression? 
A cross-cultural study. Soc Psychiatry Psychiatr Epidemiol 2001; 
36: 287–93.
27 Tung W-C, Li Z. Pain Beliefs and Behaviors Among Chinese. 
Home Health Care Management & Practice 2015; 27: 95–97.
28 Anand A. Understanding Depression among Older Adults in 
Six Low-Middle Income Countries using WHO-SAGE Survey. 
http://jghcs.info/index.php/bh/article/view/363 (accessed 
July 17, 2017).
29 Phillips MR, Zhang J, Shi Q, et al. Prevalence, treatment, and associated 
disability of mental disorders in four provinces in China during 2001–05: 
an epidemiological survey. Lancet 2009; 373: 2041–53.
30 WHO. Antimicrobial resistance: global report on surveillance, 2014. 
Geneva, Switzerland: World Health Organization, 2014.
31 Spellberg B, Bartlett JG, Gilbert DN. The Future of Antibiotics and 
Resistance. N Engl J Med 2013; 368: 299–302.
32 Burnham G, Doocy S, Dzeng E, Lafta R, Roberts L. The Human Cost 
of the War in Iraq. A Mortality Study, 2002–2006. Baltimore, MD; 
Baghdad, Iraq; Cambridge, MA: Bloomberg School of Public Health, 
Johns Hopkins University; School of Medicine, Al Mustansiriya 
University; Center for International Studies, Massachusetts Institute 
of Technology, 2016.
33 McMichael AJ, Woodruff RE, Hales S. Climate change and human 
health: present and future risks. Lancet 2006; 367: 859–69.
34 Patz JA, Campbell-Lendrum D, Holloway T, Foley JA. Impact of 
regional climate change on human health. Nature 2005; 438: 310–17.
35 Ramsey R, Giskes K, Turrell G, Gallegos D. Food insecurity among 
adults residing in disadvantaged urban areas: potential health and 
dietary consequences. Public Health Nutr 2012; 15: 227–37.
36 Hassan G, Ventevogel P, Jefee-Bahloul H, Barkil-Oteo A, 
Kirmayer LJ. Mental health and psychosocial wellbeing of Syrians 
affected by armed conflict. Epidemiol Psychiatr Sci 2016; 25: 129–41.
37 Rapid Assessment of Avoidable Blideness Repository. RAAB 
Repository. http://raabdata.info/repository/ (accessed July 17, 2017).
38 Brooker S, Hotez PJ, Bundy DAP. The Global Atlas of Helminth 
Infection: Mapping the Way Forward in Neglected Tropical Disease 
Control. PLOS Neglected Tropical Diseases 2010; 4: e779.
39 WHO. Guidelines on the management of latent tuberculosis infection. 
Geneva, Switzerland: World Health Organization, 2015 
http://www.who.int/tb/publications/latent-tuberculosis-infection/en/ 
(accessed May 3, 2017).
40 Patel V, Chisholm D, Parikh R, et al. Addressing the burden of mental, 
neurological, and substance use disorders: key messages from Disease 
Control Priorities, 3rd edition.  Lancet 2016; 387: 1672–85.
41 Afshin A, Forouzanfar MH, Reitsma M, Sur P, Estep K, Murray CJ. 
Obesity and overweight and their health impact 1990-2015 in 
195 countries. N Engl J Med 2017; 377: 13–27.
42 Dieleman JL, Baral R, Birger M, et al. US Spending on Personal 
Health Care and Public Health, 1996-2013. JAMA 2016; 316: 2627–46.
43 WHO. Global Tuberculosis Report 2016. Geneva, Switzerland: World 
Health Organization, 2016.
44 WHO. Companion handbook to the WHO guidelines for the 
programmatic management of drug-resistant tuberculosis. Geneva, 
Switzerland: World Health Organization, 2014.
45 National AIDS and STI Control Programme (NASCOP). Kenya AIDS 
Indicator Survey 2012: Final Report. Nairobi, Kenya: NASCOP, 2014.
46 Ministry of Health, ICF International, Centers for Disease Control 
and Prevention, U.S. Agency for International Development, and 
WHO Uganda. Uganda AIDS Indicator Survey. Kampala, Uganda: 
Ministry of Health, 2012.
47 UNAIDS. Global AIDS update 2016. 2016; published online 
May 31. http://www.unaids.org/en/resources/documents/2016/
Global-AIDS-update-2016 (accessed March 10, 2017).
48 International Agency for Research on Cancer. Globocan 2012: 
Estimated Cancer Incidence, Mortality, and Prevlance Worldwide 
in 2012. Geneva: World Health Organization, 2017.
49 WHO. Fifth meeting of the Emergency Committee under the 
International Health Regulations (2005) regarding microcephaly, 
other neurological disorders and Zika virus. http://www.who.int/
mediacentre/news/statements/2016/zika-fifth-ec/en/ (accessed 
July 6, 2017).
50 Barry M. The tail end of guinea worm: global eradication without a 
drug or a vaccine. N Engl J Med 2007; 356: 2561–64.
51 GBD 2016 Risk Factors Collaborators. Global, regional, and 
national comparative risk assessment of 84 behavioural, 
environmental and occupational, and metabolic risks or clusters of 
risks, 1990–2016: a systematic analysis for the Global Burden of 
Disease Study 2016. Lancet 2017 390: 1345–59.
52 Jensen ET, Cook SF, Allen JK, et al. Enrollment factors and bias of 
disease prevalence estimates in administrative claims data. 
Ann Epidemiol 2015; 25: 519–525.e2.
53 Kottke TE, Baechler CJ, Parker ED. Accuracy of Heart Disease 
Prevalence Estimated from Claims Data Compared With an 
Electronic Health Record. Prev Chronic Dis 2012; 9. DOI:10.5888/
pcd9.120009.
54 Rothberg MB, Pekow PS, Priya A, Lindenauer PK. Variation in 
Diagnostic Coding of Patients With Pneumonia and Its Association 
With Hospital Risk-Standardized Mortality Rates: A Cross-sectional 
Analysis. Ann Intern Med 2014; 160: 380–88.
55 Yeom H, Kang DR, Cho SK, Lee SW, Shin D-H, Kim HC. Admission 
route and use of invasive procedures during hospitalization for acute 
myocardial infarction: analysis of 2007-2011 National Health 
Insurance database. Epidemiol Health 2015; 37: e2015022.
56 Ghosh A, McCarthy S, Halcomb E. Perceptions of primary care 
staff on a regional data quality intervention in Australian general 
practice: a qualitative study. BMC Fam Pract 2016; 17: 50.
57 Pooled Resource Open-Access ALS Clinical Trials Database. PRO-
ACT - Data Sets. https://nctu.partners.org/ProACT/Data/Index/ 
(accessed May 3, 2017).
58 Barber RM, Fullman N, Sorensen RJD, et al. Healthcare Access and 
Quality Index based on mortality from causes amenable to 
personal health care in 195 countries and territories, 1990–2015: 
a novel analysis from the Global Burden of Disease Study 2015. 
Lancet 2017; 390: 231–66.
